# CITATION REPORT List of articles citing

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

DOI: 10.1007/s00134-020-05991-x Intensive Care Medicine, 2020, 46, 846-848.

Source: https://exaly.com/paper-pdf/77337896/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2220	Novel 2019-coronavirus on new year's Eve. <b>2019</b> , 37, 459-477		12
2219	Acute Kidney Injury in Critically Ill Children: A Retrospective Analysis of Risk Factors. <b>2020</b> , 49, 1-7		6
2218	Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. <b>2020</b> , 7, ofaa320		
2217	Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. <b>2020</b> , 4, rkaa040		7
2216	Treatment of Critically Ill Coronavirus Disease 2019 Patients With Adjunct Therapeutic Plasma Exchange: A Single-Center Retrospective Case Series. <b>2020</b> , 2, e0223		4
2215	Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. <b>2020</b> , 54, 438-450		13
2214	Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review. <b>2020</b> , 60, 2131-2138		16
2213	Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrICCht). <b>2020</b> , 10, e040	)175	12
2212	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. <b>2020</b> , 76, 1350-1367		36
2211	The "Elderly" Lesson in a "Stressful" Life: Italian Holistic Approach to Increase COVID-19 Prevention and Awareness. <b>2020</b> , 11, 579401		4
2210	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <b>2020</b> , 7, 546		5
2209	Etiologic Subtypes of Ischemic Stroke in SARS-CoV-2 Patients in a Cohort of New York City Hospitals. <b>2020</b> , 11, 1004		25
2208	Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia. <b>2020</b> , 10, 562625		4
2207	Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. <b>2020</b> , 9,		57
2206	The Clinical Frailty Scale: Estimating the Prevalence of Frailty in Older Patients Hospitalised with COVID-19. The COPE Study. <b>2020</b> , 5,		8
2205	and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients?. 2020, 8,		14
2204	Cancer and COVID-19. <b>2020</b> , 396, 1066-1067		3

2203	Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City Cohort. <b>2020</b> , 31, 3086-3096	23
2202	Veno-Arterial-Venous Extracorporeal Membrane Oxygenation in a Critically Ill Patient with Coronavirus Disease 2019. <b>2020</b> , 56,	О
2201	Endothelial Cell Contributions to COVID-19. <b>2020</b> , 9,	12
2200	COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate. <b>2020</b> , 57, 827-833	10
2199	Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. <b>2020</b> , 23, 101631	39
2198	The low-harm score for predicting mortality in patients diagnosed with COVID-19: A multicentric validation study. <b>2020</b> , 1, 1436	11
2197	Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. <b>2021</b> , 46, 382-391	32
2196	Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents. <b>2020</b> , 131, 110643	7
2195	Tocilizumab for severe COVID-19 related illness - A community academic medical center experience. <b>2020</b> , 2, 100035	5
2194	The Scientific Foundation of Chinese Herbal Medicine against COVID-19. <b>2020</b> , 6, 1099-1107	12
2193	Implantation of Impella CP left ventricular assist device under the guidance of three-dimensional intracardiac echocardiography. <b>2020</b> , 10, 17485	4
2192	Deadly Companions: COVID-19 and Diabetes in Mexico. <b>2020</b> , 39, 660-665	12
2191	Extracorporeal Membrane Oxygenation Retrieval in Coronavirus Disease 2019: A Case-Series of 19 Patients Supported at a High-Volume Extracorporeal Membrane Oxygenation Center. <b>2020</b> , 2, e0228	9
2190	Computed Tomography Radiomics Can Predict Disease Severity and Outcome in Coronavirus Disease 2019 Pneumonia. <b>2020</b> , 44, 640-646	14
2189	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. <b>2020</b> , 2, e0207	8
2188	Teleophthalmology for age-related macular degeneration during the COVID-19 pandemic and beyond. <b>2020</b> , 1357633X20960636	5
2187	Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients. <b>2020</b> , 11, 437	28
2186	Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. <b>2020</b> , 31, 44-49	44

2185	The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications. <b>2020</b> , 16, 1007-1022	12
2184	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Nervous System: Implications of COVID-19 in Neurodegeneration. <b>2020</b> , 11, 583459	13
2183	Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome. <b>2020</b> , 11, 574703	1
2182	A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19. <b>2020</b> , 17,	30
2181	Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients. <b>2020</b> , 16, 3028-3036	8
2180	Coronavirus and Cardiometabolic´Syndrome: JACC Focus Seminar. <b>2020</b> , 76, 2024-2035	21
2179	Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. <b>2020</b> , 11, 2056	27
2178	Research Progress of Genetic Structure, Pathogenic Mechanism, Clinical Characteristics, and Potential Treatments of Coronavirus Disease 2019. <b>2020</b> , 11, 1327	3
2177	Swollen heart in COVID-19 patients who progress to critical illness: a perspective from echo-cardiologists. <b>2020</b> , 7, 3621	14
2176	Laboratory findings in COVID-19 diagnosis and prognosis. <b>2020</b> , 510, 475-482	71
2175	On the genetics and immunopathogenesis of COVID-19. <b>2020</b> , 220, 108591	22
2174	Repurposing anticancer drugs for the management of COVID-19. <b>2020</b> , 141, 40-61	30
2173	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. <b>2020</b> , 887, 173561	8
2172	History of coronary heart disease increased the mortality rate of patients with COVID-19: a nested case-control study. <b>2020</b> , 10, e038976	18
2171	A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study. <b>2020</b> , 8, 638-649	5
2170	Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States. <b>2020</b> , 76, 1947-1961	85
2169	Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. <b>2020</b> , 2, e516-e525	102
2168	Cardiac inflammation in COVID-19: Lessons from heart failure. <b>2020</b> , 260, 118482	40

2167	Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. <b>2020</b> , 20, 1087-1097	12
2166	Non-respiratory presentations of COVID-19, a clinical review. <b>2020</b> , 38, 2444-2454	27
2165	Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses. <b>2020</b> , 54, 102350	38
2164	Immune response in SARS-CoV-2 infection: the role of interferons type I and type III. <b>2020</b> , 24, 428-433	11
2163	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. <b>2021</b> , 8, 385-400	18
2162	The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?. <b>2020</b> , 148, 104452	23
2161	Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in". <b>2020</b> , 11, 2132	50
2160	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. <b>2020</b> , 2, e754-e763	135
2159	The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019. <b>2020</b> , 2, e0203	16
2158	COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?. <b>2020</b> , 131, 1324-1333	34
2157	Early management of critically ill patients with COVID-19. <b>2020</b> , 1, 1418-1426	О
2156	Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?. <b>2021</b> , 66, 2855-2864	6
2155	Emergence and Evolution of Olfactory and Gustatory Symptoms in Patients with COVID-19 in the Outpatient Setting. <b>2020</b> , 1-7	4
2154	Critically Ill Patients with COVID-19: A Narrative Review on Prone Position. <b>2020</b> , 6, 233-246	16
2153	Estimative of real number of infections by COVID-19 in Brazil and possible scenarios. <b>2020</b> , 5, 720-736	7
2152	Understand variability of COVID-19 through population and tissue variations in expression of SARS-CoV-2 host genes. <b>2020</b> , 21, 100443	12
2151	Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. <b>2020</b> , 116, 2197-2206	62
2150	Gamut of cardiac manifestations and complications of COVID-19: a contemporary review. <b>2020</b> , 68, 1334-134	0 9

2149	Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. <b>2020</b> , 13, 1178633720962935	16
2148	Risk factors for the critical illness in SARS-CoV-2 infection: a multicenter retrospective cohort study. <b>2020</b> , 21, 277	6
2147	Covid-19 Quarantine: Impact of Lifestyle Behaviors Changes on Endothelial Function and Possible Protective Effect of Beetroot Juice. <b>2020</b> , 7, 582210	5
2146	Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. <b>2020</b> , 89, 107088	79
2145	ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart. <b>2021</b> , 41, 542-544	14
2144	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <b>2020</b> , 383, 2030-2040	628
2143	Histopathologic and Autopsy Findings in Patients Diagnosed With Coronavirus Disease 2019 (COVID-19): What We Know So Far Based on Correlation With Clinical, Morphologic and Pathobiological Aspects. <b>2020</b> , 27, 363-370	15
2142	Immunomodulation Through Low-Dose Radiation for Severe COVID-19: Lessons From the Past and New Developments. <b>2020</b> , 18, 1559325820956800	5
2141	The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. <b>2020</b> , 43, 1478-1493	35
2140	[SARS-COV-2´myocarditis. An update]. <b>2020</b> , 69, 349-354	1
2139	Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism. <b>2020</b> , 89, 529-530	14
2138	COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. <b>2020</b> , 30, 100631	47
2137	Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. <b>2020</b> , 63, 101942	39
2136	SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. <b>2020</b> , 5, 235	122
2135	Preemptive interleukin-6 blockade in patients with COVID-19. <b>2020</b> , 10, 16826	22
2134	Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome. <b>2020</b> , 93, 132-133	4
2133	Elective cardiac surgery during the COVID-19 pandemic: Proceed or postpone?. <b>2020</b> , 34, 643-650	11
2132	Risk stratification of hospitalized COVID-19 patients through comparative studies of laboratory results with influenza. <b>2020</b> , 26, 100475	22

2131	Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. <b>2020</b> , 262, 118510	32
2130	Clinical characteristics and manifestations in older patients with COVID-19. <b>2020</b> , 20, 395	23
2129	Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia. <b>2020</b> , 15, e0239692	12
2128	Editorial commentary: Hitting a moving target: The challenge of creating consensus treatment protocols for cardiovascular care during the coronavirus pandemic. <b>2020</b> , 30, 326-327	
2127	Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform to Enhance Lung-Protective Ventilation in Hypercapnic Patients With Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome. <b>2020</b> , 7, 598379	9
2126	Identifying a Kidney Transplant Recipient COVID Phenotype to Aid Test Utilization in the Setting of Limited Testing Availability-Does One Exist?. <b>2020</b> , 52, 2584-2591	1
2125	Technology and cardiovascular diseases in the era of COVID-19. <b>2020</b> , 35, 3551-3554	4
2124	Outcomes and Laboratory and Clinical Findings of Asthma and Allergic Patients Admitted With Covid-19 in a Spanish University Hospital. <b>2020</b> , 11, 570721	2
2123	Tissue Proteases and Immune Responses: Influencing Factors of COVID-19 Severity and Mortality. <b>2020</b> , 9,	2
2122	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <b>2020</b> , 11, 585888	7
2121	Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study. <b>2020</b> , 20, e2000202	15
2120	A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. <b>2020</b> , 11, 5097	128
2119	Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome. <b>2020</b> , 54, 700-701	10
2118	The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. <b>2020</b> , 4, 4981-4989	68
2117	Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics. <b>2020</b> , 3, 7326-7343	63
2116	COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. <b>2020</b> , 16, 747-764	229
2115	Potential Therapeutic Effect of Traditional Chinese Medicine on Coronavirus Disease 2019: A Review. <b>2020</b> , 11, 570893	5
2114	Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. <b>2020</b> , 8, 1233-1244	395

2113	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. <b>2020</b> , 41, 1100-1115	345
2112	The fourth industrial revolution and the coronavirus: a new era catalyzed by a virus. <b>2020</b> , 2, 100024	13
2111	Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study. <b>2020</b> , 9,	15
2110	Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. <b>2020</b> , 22, 2248-2257	8
2109	COVID-19 and multiorgan failure: A narrative review on potential mechanisms. <b>2020</b> , 51, 613-628	141
2108	A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria based medicinal plants. <b>2020</b> , 6, e04897	31
2107	A case of corticosteroid-responsive SARS-CoV-2 related massive rhabdomyolysis. <b>2020</b> , 22, e00946	2
2106	Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?. <b>2020</b> , 34, 107723	27
2105	IL-17A and TNF-has potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19. <b>2020</b> , 144, 109935	18
2104	Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report. <b>2020</b> , 4, 1-6	13
2103	Case report: high-grade atrioventricular block in suspected COVID-19 myocarditis. 2020, 4, 1-6	10
2102	A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence. <b>2020</b> , 34, 165-171	6
<b>2</b> 101	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. <b>2020</b> , 17, 543-558	560
2100	[Cardiac complications in critically ill COVID-19 patients]. <b>2020</b> , 24, 212-217	1
2099	A brief-review of the risk factors for covid-19 severity. <b>2020</b> , 54, 60	79
2098	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. <b>2020</b> , 74, 109721	63
2097	Multimodality Imaging in Evaluation of Cardiovascular Complications in Patients With COVID-19: JACC Scientific Expert Panel. <b>2020</b> , 76, 1345-1357	28
2096	Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?. <b>2020</b> , 39, 685-693	31

2095	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. <b>2021</b> , 73, e445-e454	235
2094	The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. <b>2020</b> , 296, 205-219	99
2093	Comprehensive mapping of immune perturbations associated with severe COVID-19. <b>2020</b> , 5,	387
2092	Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations. <b>2020</b> , 202, 690-699	156
2091	Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?. <b>2020</b> , 18, 214	36
2090	Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: a review. <b>2020</b> , 14, 28	3
2089	Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis. <b>2020</b> , 8,	42
2088	COVID-19: Review and hematologic impact. <b>2020</b> , 510, 170-176	26
2087	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. <b>2020</b> , 5, 871-883	26
2086	High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction. <b>2020</b> , 76, 1168-1176	116
2085	Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. <b>2020</b> , 81, e11-e17	70
2084	Immune response in COVID-19: A review. <b>2020</b> , 13, 1619-1629	143
2083	Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. <b>2020</b> , 30, e2144	44
2082	Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage. <b>2020</b> , 2, 1-9	19
2081	Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. <b>2020</b> , 25, 100449	94
2080	Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review. <b>2020</b> , 42, 761-765	45
2079	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. <b>2020</b> , 24, 435	31
2078	Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications?. <b>2020</b> , 12, 63	14

2077	Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients. <b>2020</b> , 12, 1127-1132	6
2076	Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. 2020,	9
2075	Epidemiology, prognosis, and clinical manifestation of cardiovascular disease in COVID-19. <b>2020</b> , 18, 531-539	4
2074	Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. <b>2020</b> , 12, 851-855	37
2073	The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. <b>2020</b> , 510, 186-190	19
2072	Could Bordetella pertussis vaccine protect against coronavirus COVID-19?. <b>2020</b> , 22, 803-805	7
2071	Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis. <b>2020</b> , 147, 104390	41
2070	The importance of IL-6 blockade beyond the COVID-19 pandemic: Consideration for cancer care. <b>2020</b> , 151, 24-25	2
2069	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. <b>2020</b> , 68, 213-224	90
2068	Obstetric and intensive-care strategies in a high-risk pregnancy with critical respiratory failure due to COVID-19: A case report. <b>2020</b> , 27, e00240	9
2067	Emergency Nursing Care of Patients With Novel Coronavirus Disease 2019. <b>2020</b> , 46, 748-759	8
2066	Paper spray mass spectrometry utilizing Teslin substrate for rapid detection of lipid metabolite changes during COVID-19 infection. <b>2020</b> , 145, 5725-5732	19
2065	Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020. <b>2020</b> , 26, 1679-1685	58
2064	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <b>2020</b> , 12, 483-497	22
2063	Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study. <b>2020</b> , 20, 3051-3060	71
2062	Usefulness of echocardiography to detect cardiac involvement in COVID-19 patients. <b>2020</b> , 37, 1278-1286	23
2061	Cardiac manifestations in COVID-19 patients-A systematic review. <b>2020</b> , 35, 1988-2008	73
2060	Could Ergothioneine Aid in the Treatment of Coronavirus Patients?. <b>2020</b> , 9,	29

2059	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. <b>2020</b> , 9,	23
2058	Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. <b>2020</b> , 4, 1257	33
2057	Vascular Manifestations of COVID-19 - Thromboembolism and Microvascular Dysfunction. <b>2020</b> , 7, 598400	27
2056	Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease. <b>2020</b> , 11, 613170	16
2055	COVID-19 during Pregnancy and Postpartum. <b>2020</b> , 1-28	8
2054	Timing of Tracheostomy for Prolonged Respiratory Wean in Critically Ill Coronavirus Disease 2019 Patients: A Machine Learning Approach. <b>2020</b> , 2, e0279	7
2053	Outpatient Management of Oligosymptomatic Patients with respiratory infection in the era of SARS-CoV-2: Experience from rural German general practitioners. <b>2020</b> , 20, 811	3
2052	Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. <b>2021</b> , 110, 1029-1040	8
2051	The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. <b>2020</b> , 72, 1529-1537	6
2050	Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. <b>2020</b> , 20, 301	48
2049	Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?. <b>2020</b> , 7, 571597	5
2048	Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports. <b>2020</b> , 17, 2974-2986	9
2047	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <b>2020</b> , 12, 6054-6069	7
2046	Short-Term Outcomes of Patients With COVID-19 Undergoing Invasive Mechanical Ventilation: A Retrospective Observational Study From Wuhan, China. <b>2020</b> , 7, 571542	5
2045	Elevated interleukin levels are associated with higher severity and mortality in COVID 19 - A systematic review, meta-analysis, and meta-regression. <b>2020</b> , 14, 2219-2230	26
2044	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <b>2020</b> , 27, 434-441	2
2043	A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic. <b>2020</b> , 11, 569633	7
2042	An update on COVID-19: SARS-CoV-2 life cycle, immunopathology, and BCG vaccination. <b>2021</b> , 51, 650-658	6

2041	COVID-19 and cardiovascular diseases. <b>2021</b> , 13, 161-167	1
2040	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. <b>2020</b> , 8,	8
2039	Acute Ischemic Stroke in COVID-19: Putative Mechanisms, Clinical Characteristics, and Management. <b>2020</b> , 2020, 7397480	6
2038	Cardiovascular Manifestations of COVID-19 Infection. <b>2020</b> , 9,	49
2037	COVID-19 and cardiovascular disease: characteristic features in older patients. <b>2020</b> , 18, 141-148	1
2036	Hospital Resources May Be an Important Aspect of Mortality Rate among Critically Ill Patients with COVID-19: The Paradigm of Greece. <b>2020</b> , 9,	6
2035	[COVID-19 pneumonia]. <b>2020</b> , 15, 1-11	2
2034	Clinical Characteristics and Predictors of Mortality in Patients with COVID-19 Infection Outside Intensive Care. <b>2020</b> , 13, 1157-1165	7
2033	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. <b>2020</b> , 7, 2054358120967845	9
2032	Bacterial Superinfection in COVID-19 Patients Diagnosed With Dual-Energy CT Pulmonary Angiography. <b>2020</b> , 2, 295	
2031	Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates. <b>2020</b> , 11, 6078	45
2030	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. <b>2020</b> , 7, ofaa563	32
2029	Role of Inflammation in Virus Pathogenesis during Pregnancy. <b>2020</b> , 95,	7
2028	Lymphocyte percentage and hemoglobin as a joint parameter for the prediction of severe and nonsevere COVID-19: a preliminary study. <b>2020</b> , 8, 1231	3
2027	Residual Lung Injury in Patients Recovering From COVID-19 Critical Illness: A Prospective Longitudinal Point-of-Care Lung Ultrasound Study. <b>2021</b> , 40, 1823-1838	23
2026	Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019. <b>2020</b> , 99, e23186	9
2025	Management principles in patients with COVID-19: perspectives from a growing global experience with emphasis on cardiovascular surveillance. <b>2020</b> , 7,	2
2024	MIS-C and Cardiac Conduction Abnormalities. <b>2020</b> , 146,	28

Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. <b>2021</b> , 9, 835-844.e4	8
Acute Respiratory Distress Syndrome Treated With Awake Extracorporeal Membrane Oxyger in a Patient With COVID-19 Pneumonia. <b>2021</b> , 35, 2467-2470	nation 6
2021 COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <b>2020</b> , 11	, 588409 11
Development and Validation of a Prognostic Risk Score System for COVID-19 Inpatients: A Multi-Center Retrospective Study in China. <b>2020</b> ,	10
2019 Controlling Cytokine Storm Is Vital in COVID-19. <b>2020</b> , 11, 570993	43
Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review. <b>2020</b> , 7, 572115	10
2017 Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. <b>2020</b> , 142, 11114	7 32
2016 COVID-19 during Pregnancy and Postpartum. <b>2020</b> , 1-37	8
Reninangiotensin system blockers and the risk of critical or fatal coronavirus disease 2019 in African Americans. <b>2020</b> , 38, 2384-2386	1
Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the L Tract and Their Associations with Clinical Manifestations of COVID-19. <b>2020</b> , 13, 3977-3990	Jrinary 16
Diagnostic and prognostic utility of WBC counts and cell population data in patients with COV <b>2021</b> , 43 Suppl 1, 124-128	VID-19.
Coronavirus Disease 2019 (COVID-19): A Modeling Study of Factors Driving Variation in Case Fatality Rate by Country. <b>2020</b> , 17,	9
Fisiopatologa de la enfermedad cardiovascular en pacientes con COVID-19. Isquemia, trombo disfuncia cardiaca. <b>2020</b> , 20, 2-8	osis y
2010 Complicaciones cardiovasculares y pron\(\text{B}\)tico en pacientes con COVID-19. <b>2020</b> , 20, 9-13	0
2009 COVID-19 and sudden cardiac death: A new potential risk. <b>2020</b> , 72, 333-336	10
2008 Acute Fulminant Myocarditis in a Pediatric Patient With COVID-19 Infection. <b>2020</b> , 146,	16
2007 Modeling the viral dynamics of SARS-CoV-2 infection. <b>2020</b> , 328, 108438	52
2006 Imaging of COVID-19 pneumonia: Patterns, pathogenesis, and advances. <b>2020</b> , 93, 20200538	18

2005	Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?. <b>2020</b> , 8, 677		30
2004	The prevalence, risk factors and outcome of cardiac dysfunction in hospitalized patients with COVID-19. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 2096-2098	14.5	13
	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. <b>2020</b> , 1		13
2002	Cardiac Involvment in COVID-19-Related Acute Respiratory Distress Syndrome. <b>2020</b> , 132, 147-149		20
2001	Oxygen-ozone (O-O) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. <b>2020</b> , 88, 106879		25
	Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. <b>2020</b> , 287, 198108		48
1999	Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities. <b>2020</b> , 17, 533-535		22
1998	Antiplatelet/anticoagulant agents for preventing thrombosis events in patients with severe COVID-19: A protocol for systematic review and meta-analysis. <b>2020</b> , 99, e21380		2
	The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. <b>2020</b> , 177, 4921-4930		19
1996	Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience). <b>2020</b> , 59, 1287-1289		4
	Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease. <b>2020</b> , 81, 1-4		1
	Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City. <b>2020</b> , 21, 779-784		50
	Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China. <b>2020</b> , 10, 6113-6121		50
1992	Sympathetic activation: a potential link between comorbidities and COVID-19. 2020, 287, 3681-3688		51
1991	Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regressions. <b>2020</b> , 9,		20
1990	Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople). <b>2020</b> , 106, 376-384		97
1989	Pre-existing traits associated with Covid-19 illness severity. <b>2020</b> , 15, e0236240		69
1988	A Review on Currently Available Potential Therapeutic Options for COVID-19. <b>2020</b> , 13, 443-467		11

1987	response to SARS-CoV-2 infection. <b>2020</b> , 55, 2556-2564		25
1986	The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. <b>2020</b> , 9, 1287-1302		27
1985	Cardiac tamponade as a cause of cardiac arrest in severe COVID-19 pneumonia. <b>2020</b> , 155, 1-2		2
1984	Chronic Hemodialysis Patients Hospitalized with COVID-19: Short-term Outcomes in the Bronx, New York <b>2020</b> , 1, 755-762		31
1983	Efficacy of early prone position for COVID-19 patients with severe hypoxia: a single-center prospective cohort study. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1927-1929	14.5	35
1982	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. <b>2020</b> , 10, 12232		21
1981	Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. <b>2020</b> , 25, 616-625		39
1980	Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. <b>2020</b> , 24, 454		47
1979	COVID-19, State of the Adult and Pediatric Heart: From Myocardial Injury to Cardiac Effect of Potential Therapeutic Intervention. <b>2020</b> , 7, 140		7
1978	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. <b>2020</b> , 6, 1-13		10
1977	COVID-19 Pandemic: Global Impact and Potential Implications for Cardiovascular Disease in Canada. <b>2020</b> , 2, 265-272		7
1976	Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study. <b>2020</b> , 24, 100410		18
1975	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. <b>2020</b> , 99, 28-33		40
1974	Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. <b>2020</b> , 142, 1176-1189		252
1973	Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. <b>2020</b> , 11, 1625		64
1972	Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 5, 1265-1273		929
1971	Deciphering the TCR Repertoire to Solve the COVID-19 Mystery. <b>2020</b> , 41, 518-530		30
1970	Multiorgan Involvement in COVID-19 and Possible Therapies. <b>2020</b> , 04, 20-24		

1969	A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. <b>2020</b> , 52, 367-375	18
1968	Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases. <b>2020</b> , 7, 138	13
1967	Inpatient Neurology Consultations During the Onset of the SARS-CoV-2 New York City Pandemic: A Single Center Case Series. <b>2020</b> , 11, 805	13
1966	Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections. <b>2020</b> , 10, 9591-9600	17
1965	Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. <b>2020</b> , 9, e1159	12
1964	[COVID-19 pneumonia]. <b>2020</b> , 61, 793-803	5
1963	Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 2200-2211	166
1962	Organ-specific manifestations of COVID-19 infection. <b>2020</b> , 20, 493-506	194
1961	Appropriate use of tocilizumab in COVID-19 infection. <b>2020</b> , 99, 338-343	29
1960	COVID-19-Associated Collapsing Focal Segmental Glomerulosclerosis: A Report of 2 Cases. <b>2020</b> , 2, 493-497	31
1959	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. <b>2020</b> , 28, 745-764	9
1958	Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis. <b>2020</b> , 32, 1869-1878	57
1957	[COVID-19: a cardiological point-of-view]. <b>2020</b> , 145, 1063-1067	1
1956	Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. <b>2020</b> , 14, 1149-1163	84
1955	Hip Fracture Outcomes During the COVID-19 Pandemic: Early Results From New York. <b>2020</b> , 34, 403-410	63
1954	Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. <b>2020</b> , 39, 268-284	27
1953	Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. <b>2020</b> , 6, 2319-2336	27
1952	The Neurocritical Care Society of India (NCSI) and the Indian Society of Neuroanaesthesiology and Critical Care (ISNACC) Joint Position Statement and Advisory on the Practice of Neurocritical Care during the COVID-19 Pandemic. <b>2020</b> , 7, 128-139	3

-	1951	Thoracic Imaging Findings of Multisystem Inflammatory Syndrome in Children Associated with COVID-19: What Radiologists Need to Know Now. <b>2020</b> , 2, e200346	20
	1950	CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury. <b>2020</b> , 7, 2054358120941679	4
	1949	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <b>2020</b> , 11, 1991	56
	1948	Accounting for incomplete testing in the estimation of epidemic parameters. <b>2020</b> , 49, 1419-1426	4
	1947	The absorbing filter Oxiris in severe coronavirus disease 2019 patients: A case series. <b>2020</b> , 44, 1296-1302	18
	1946	COVID-19 and diabetes mellitus: how one pandemic worsens the other. <b>2020</b> , 21, 451-463	41
	1945	Role of computed tomography in predicting critical disease in patients with covid-19 pneumonia: A retrospective study using a semiautomatic quantitative method. <b>2020</b> , 130, 109202	22
:	1944	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. <b>2020</b> , 258, 118166	43
	1943	Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. <b>2020</b> , 258, 118202	22
	1942	The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. <b>2020</b> , 144, 110140	16
	1941	[Variables associated with mortality in a selected sample of patients older than 80 years and with some degree of functional dependence hospitalized for COVID-19 in a Geriatrics Service]. <b>2020</b> , 55, 317-325	8
:	1940	Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. <b>2020</b> , 12, 478-482	5
·	1939	Role of extracorporeal membrane oxygenation in COVID-19: A systematic review. <b>2020</b> , 35, 2679-2687	22
:	1938	Critical COVID-19 patient evacuation on an amphibious assault ship: feasibility and safety. A case series. <b>2021</b> , 167, 224-228	2
·	1937	Relevant Nutrition Therapy in COVID-19 and the Constraints on Its Delivery by a Unique Disease Process. <b>2020</b> , 35, 792-799	17
	1936	Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. <b>2020</b> , 42, 773-779	21
	1935	The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19. <b>2020</b> , 42, e270-e273	3
	1934	Acute transverse myelitis in COVID-19 infection. <b>2020</b> , 13,	53

1933	Is there a smoker's paradox in COVID-19?. <b>2021</b> , 26, 279-284		53
1932	Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1714-1722	14.5	40
1931	Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. <b>2020</b> , 40, 1593-1598		44
1930	Renal replacement therapy in critically ill patients with COVID-19: A retrospective study investigating mortality, renal recovery and filter lifetime. <b>2020</b> , 60, 103-105		24
1929	A Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Prediction Model From Standard Laboratory Tests. <b>2021</b> , 73, e2901-e2907		10
1928	Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase. <b>2020</b> , 4, e448		1
1927	Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia. <b>2020</b> , 25, 845-849		2
1926	Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis. <b>2020</b> , 7, 431		15
1925	COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis. <b>2020</b> , 7, 459		71
1924	Immunosuppressive Drugs and COVID-19: A Review. <b>2020</b> , 11, 1333		48
1923	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. <b>2020</b> , 38, 3538-3546		104
1922	Robustness during Aging-Molecular Biological and Physiological Aspects. <b>2020</b> , 9,		4
1921	Extremely Severe Case of COVID-19 Pneumonia Recovered Despite Bad Prognostic Indicators: a Didactic Report. <b>2020</b> , 2, 1-4		20
1920	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <b>2020</b> , 26, 1537-1544		50
1919	Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature. <b>2020</b> , 36, 1-5		4
1918	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. <b>2020</b> , 358, 10424	10	4
1917	Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era. <b>2020</b> , 18, 408		11
1916	The Perfect Storm: COVID-19 Health Disparities in US Blacks. <b>2021</b> , 8, 1153-1160		27

1915	Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt. <b>2020</b> , 13, 3409-3422	33
1914	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. <b>2020</b> , 7, 562142	11
1913	Risk Stratification of COVID-19 Patients Using Ambulatory Oxygen Saturation in the Emergency Department. <b>2020</b> , 21, 5-14	4
1912	Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 136, 1025-1029	30
1911	Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020. <b>2020</b> , 26, 2694-2696	120
1910	Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. <b>2020</b> , 8, 587866	6
1909	Guillain Barr yndrome and COVID-19: Possible role of the cytokine storm. <b>2020</b> , 19, 102681	11
1908	High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. <b>2020</b> , 128, 64-68	21
1907	Cardiovascular Manifestations and Mechanisms in Patients with COVID-19. <b>2020</b> , 31, 893-904	19
1906	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <b>2020</b> , 217,	795
1906 1905	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <b>2020</b> , 217,  Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. <b>2020</b> , 54, 633-637	795 46
	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus.	
1905	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. <b>2020</b> , 54, 633-637  A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive	46
1905 1904	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus.  2020, 54, 633-637  A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe Covide19 (PISCO) trial methods 2020, 20, 7765  Prognostic Value and Reproducibility of AI-assisted Analysis of Lung Involvement in COVID-19 on Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials. 2020, 2, e200441	46 6
1905 1904 1903	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. <b>2020</b> , 54, 633-637  A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe Covid-19 (PISCO) trial protocol 2020, 20, 765  Prognostic Value and Reproducibility of Al-assisted Analysis of Lung Involvement in COVID-19 on Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials. <b>2020</b> , 2, e200441	46 6 9
1905 1904 1903 1902	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. 2020, 54, 633-637  A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe Prognostic Value and Reproducibility of Al-assisted Analysis of Lung Involvement in COVID-19 on Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials. 2020, 2, e200441  Current Understanding of COVID-19 Clinical Course and Investigational Treatments. 2020, 7, 555301  Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response	46 6 9
1905 1904 1903 1902	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. 2020, 54, 633-637  A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe Condete (Place) trial actions 2000-2000 (Prognostic Value and Reproducibility of Al-assisted Analysis of Lung Involvement in COVID-19 on Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials. 2020, 2, e200441  Current Understanding of COVID-19 Clinical Course and Investigational Treatments. 2020, 7, 555301  Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. 2020, 11, 921	46 6 9 13 52

1897	COVID-19 multidisciplinary high dependency unit: the Milan model. <b>2020</b> , 21, 260	14
1896	Lung Secretoglobin Scgb1a1 Influences Alveolar Macrophage-Mediated Inflammation and Immunity. <b>2020</b> , 11, 584310	9
1895	Spatial variation in socio-ecological vulnerability to Covid-19 in the contiguous United States. <b>2020</b> , 66, 102471	28
1894	Coronavirus disease 2019 and the pancreas. <b>2020</b> , 20, 1567-1575	28
1893	Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study. <b>2020</b> , 25, 383-388	22
1892	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. <b>2020</b> , 56, 106208	15
1891	Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. <b>2020</b> , 5, 17	26
1890	Lack of tocilizumab effect on mortality in COVID19 patients. <b>2020</b> , 10, 17100	9
1889	A Case Report of COVID-19 in New Orleans, Louisiana: Highlighting the Complexities of Prognostication in a Critically Ill Patient. <b>2020</b> , 1, 227-231	1
1888	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. <b>2020</b> , 10, 200160	116
1888 1887	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. <b>2020</b> , 10, 200160  A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic. <b>2020</b> , 7, 200585	116 9
	A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress	
1887	A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic. <b>2020</b> , 7, 200585  Relationship between the history of cerebrovascular disease and mortality in COVID-19 patients: A	9
1887 1886	A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic. 2020, 7, 200585  Relationship between the history of cerebrovascular disease and mortality in COVID-19 patients: A systematic review and meta-analysis. 2020, 197, 106183  Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. 2020, 101, 59-64  Novel FCoronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments	9
1887 1886 1885	A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic. 2020, 7, 200585  Relationship between the history of cerebrovascular disease and mortality in COVID-19 patients: A systematic review and meta-analysis. 2020, 197, 106183  Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. 2020, 101, 59-64  Novel ECoronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. 2020, 28, 1243-1252	9 7 10 3
1887 1886 1885	A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic. 2020, 7, 200585  Relationship between the history of cerebrovascular disease and mortality in COVID-19 patients: A systematic review and meta-analysis. 2020, 197, 106183  Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. 2020, 101, 59-64  Novel & Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. 2020, 28, 1243-1252  Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. 2021, 73, e2932-e2	9 7 10 3
1887 1886 1885 1884 1883	A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic. 2020, 7, 200585  Relationship between the history of cerebrovascular disease and mortality in COVID-19 patients: A systematic review and meta-analysis. 2020, 197, 106183  Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. 2020, 101, 59-64  Novel Ecoronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. 2020, 28, 1243-1252  Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. 2021, 73, e2932-e2  Myocarditis in Multisystem Inflammatory Syndrome in Children Associated With Coronavirus	9 7 10 3 94 <b>2</b> 8

1879	A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). <b>2020</b> , 8, 37	66
1878	Correlation between immunity from BCG and the morbidity and mortality of COVID-19. <b>2020</b> , 6, 17	9
1877	Interleukin-6 in Covid-19: A systematic review and meta-analysis. <b>2020</b> , 30, 1-9	256
1876	Coronavirus-induced myocarditis: A meta-summary of cases. <b>2020</b> , 49, 681-685	60
1875	Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. <b>2020</b> , 12, 75	95
1874	Pulmonary and Extra-Pulmonary Clinical Manifestations of COVID-19. <b>2020</b> , 7, 526	76
1873	Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report. <b>2020</b> , 7, e569	2
1872	Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery. <b>2020</b> , 20, 511	13
1871	Immunomodulatory Drugs in the Management of SARS-CoV-2. <b>2020</b> , 11, 1844	37
1870	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. <b>2020</b> , 205, 2566-2575	9
1869	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. <b>2020</b> , 15, 1457-1465	21
1868	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends". <b>2020</b> , 11, 2059	11
1867	Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. <b>2020</b> , 9,	32
1866	Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses. 2020, 12,	5
1865	SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. <b>2020</b> , 34, 14103-14119	20
1864	Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study. <b>2020</b> , 10, e041983	5
1863	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. <b>2020</b> , 131, 110698	46
1862	Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. <b>2020</b> , 9, 2190-2199	79

1861	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. 2020, 5,	105
1860	Co-diagnoses of acute myeloid leukaemia and COVID-19: presentation and management implications. <b>2020</b> , 8, e00650	2
1859	Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. <b>2020</b> , 136, 149-155	96
1858	Coronavirus and Cardiovascular System. <b>2020</b> , 56, 099-101	
1857	Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. <b>2020</b> , 7, ofaa375	19
1856	T cell response in patients with COVID-19 <b>2020</b> , 2, 76-78	12
1855	Incidence and mortality risk in coronavirus disease 2019 patients complicated by acute cardiac injury: systematic review and meta-analysis. <b>2020</b> , 21, 759-764	14
1854	The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease. <b>2020</b> , 11, 1044	18
1853	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. <b>2020</b> , 21,	32
1852	Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. <b>2020</b> , 7, 466	32
1851	An inflammatory cytokine signature predicts COVID-19 severity and survival. <b>2020</b> , 26, 1636-1643	895
1850	Cytokines and COVID-19: friends or foes?. <b>2020</b> , 16, 2363-2365	38
1849	COVID-19 and the Cardiovascular System. <b>2020</b> , 43, 381-389	6
1848	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. <b>2020</b> , 21, 718	15
1847	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. <b>2020</b> , 12,	49
1846	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. <b>2020</b> , 148, 25-33	15
1845	Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. <b>2020</b> , 21, e13128	427
1844	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). <b>2020</b> , 43, 1055-1063	30

1843	Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. <b>2020</b> , 8, 1209-1218	98
1842	Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19). <b>2020</b> , 43, 349-368	2
1841	Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19. <b>2020</b> , 43, 2938-2944	48
1840	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. <b>2020</b> , 146, 518-534.e1	79
1839	COVID-19 infection and its deadly cytokine storm in a young obese adult. <b>2020</b> , 10, 295-298	1
1838	Immune responses during COVID-19 infection. <b>2020</b> , 9, 1807836	49
1837	Obesity: A critical risk factor in the COVID-19 pandemic. <b>2020</b> , 10, e12403	81
1836	Management of a Parkinson's disease patient with severe COVID-19 pneumonia. <b>2020</b> , 11, 204062232094942	236
1835	The Immune Response and Immunopathology of COVID-19. <b>2020</b> , 11, 2037	61
1834	Care for Critical Ill Patients With COVID-19: Establishment of a Temporary Intensive Care Unit in an Isolated Hospital. <b>2020</b> , 7, 519	4
1833	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. <b>2020</b> , 11, 1969	5
1832	Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study. <b>2020</b> , 34, e23527	16
1831	Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework. <b>2020</b> , 12,	69
1830	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <b>2020</b> , 120, 1597-1628	73
1829	Massive pulmonary embolism following recovery from COVID-19 infection: inflammation, thrombosis and the role of extended thromboprophylaxis. <b>2020</b> , 13,	14
1828	How to get rid of visceral fat: a randomised double-blind clinical trial. <b>2020</b> , 9, 268-275	
1827	Targeting the Linear Ubiquitin Assembly Complex to Modulate the Host Response and Improve Influenza A Virus Induced Lung Injury. <b>2020</b> , 56, 586-591	
1826	Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2. <b>2020</b> , 56,	18

1825	SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics. <b>2020</b> , 72, 2331-2354	16
1824	Retrospective Description of Pregnant Women Infected with Severe Acute Respiratory Syndrome Coronavirus 2, France. <b>2020</b> , 26, 2069-2076	23
1823	COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review. <b>2020</b> , 125, 912-925	15
1822	WITHDRAWN: Subsegmental Thrombus in COVID-19 Pneumonia: Immuno-Thrombosis or Pulmonary Embolism? Data Analysis of Hospitalized Patients with Coronavirus Disease. <b>2020</b> ,	2
1821	A Multicentered Study on Epidemiologic and Clinical Characteristics of 37 Neonates With Community-acquired COVID-19. <b>2020</b> , 39, e297-e302	18
1820	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <b>2020</b> , 54, 416-437	22
1819	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. <b>2020</b> , 72, 2313-2330	7
1818	Derivation and validation of the clinical prediction model for COVID-19. <b>2020</b> , 15, 1409-1414	5
1817	Bowel ulceration following tocilizumab administration in a COVID-19 patient. <b>2020</b> , 7,	10
1816	Intensive Care Unit Management of the Adult with Congenital Heart Disease. <b>2020</b> , 22, 136	2
1815	A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19. <b>2020</b> , 59, 102936	10
1814	The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. <b>2020</b> , 11, 2033	42
1813	Hypertension and Age-Related Cognitive Impairment: Common Risk Factors and a Role for Precision Aging. <b>2020</b> , 22, 80	11
1812	Cardiac Arrhythmias in Critically Ill Patients With COVID-19: A Brief Review. <b>2021</b> , 35, 3789-3796	6
1811	Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic. <b>2020</b> , 83, 809-811	1
1810	Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. <b>2020</b> , 19, 204	69
1809	Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. <b>2020</b> , 26, 1076029620955	5240
1808	Age-Adjusted Risk Factors Associated with Mortality and Mechanical Ventilation Utilization Amongst COVID-19 Hospitalizations-a Systematic Review and Meta-Analysis. <b>2020</b> , 2, 1-10	25

1807	syndrome. <b>2020</b> , 100, 327-332	107
1806	Covid-19: Perspectives on Innate Immune Evasion. <b>2020</b> , 11, 580641	64
1805	HIV infection and COVID-19: risk factors for severe disease. <b>2020</b> , 34, 1771-1774	31
1804	The potential role of microvascular pathology in the neurological manifestations of coronavirus infection. <b>2020</b> , 17, 55	13
1803	Pan-Echinocandin-Resistant Bloodstream Infection Complicating COVID-19: A Fatal Case Report. <b>2020</b> , 6,	29
1802	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. <b>2020</b> , 8,	53
1801	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. <b>2020</b> , 9, 716-737	22
1800	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. <b>2020</b> , 2, e0178	25
1799	COVID-19 Therapeutic Options Under Investigation. <b>2020</b> , 11, 1196	49
1798	Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. <b>2020</b> , 21,	49
1797	A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. <b>2020</b> , 28, 1141-1152	28
1796	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <b>2020</b> , 15, e0237831	62
1795	Treatment Options for COVID-19: A Review. <b>2020</b> , 7, 480	46
1794	Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. <b>2020</b> , 10, 020503	42
1793	Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1863-1842	86
1792	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. <b>2020</b> , 2, e594-e602	141
1791	Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. <b>2020</b> , 155, 143-151	17
1790	A prediction model of outcome of SARS-CoV-2 pneumonia based on laboratory findings. <b>2020</b> , 10, 14042	11

1789	Current effect of COVID-19 global pandemic on the professional and life profiles of the Egyptian spine surgeons. <b>2020</b> , 6, 31	3
1788	Echocardiographic characteristics of patients with SARS-CoV-2 infection. <b>2020</b> , 109, 1549-1566	30
1787	COVID-19: IFSO LAC Recommendations for the Resumption of Elective Bariatric Surgery. <b>2020</b> , 30, 4519-4528	4
1786	Characterization of Patients Who Return to Hospital Following Discharge from Hospitalization for COVID-19. <b>2020</b> , 35, 2838-2844	47
1785	Factors Affecting Mortality in 1022 COVID-19 Patients Referred to an Emergency Department in Bergamo during the Peak of the Pandemic. <b>2020</b> , 2, 1-6	3
1784	Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. <b>2020</b> , 147, 74-87	45
1783	Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic. <b>2020</b> , 33, e14204	2
1782	Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. <b>2020</b> , 21,	39
1781	Quantification of Death Risk in Relation to Sex, Pre-Existing Cardiovascular Diseases and Risk Factors in COVID-19 Patients: Let's Take Stock and See Where We Are. <b>2020</b> , 9,	7
1780	Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. <b>2020</b> , 120, 1668-1679	34
1779	Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients. <b>2020</b> , 23, 1030-1039	8
1778	Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19). <b>2020</b> , 56,	4
1777	Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review. <b>2020</b> , 40, 549-554	12
1776	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. <b>2020</b> , 11, 611275	12
1775	Collider bias undermines our understanding of COVID-19 disease risk and severity. <b>2020</b> , 11, 5749	274
1774	Blockage of interleukin-1@with canakinumab in patients with Covid-19. <b>2020</b> , 10, 21775	33
1773	Analyses of abdominal adiposity and metabolic syndrome as risk factors for respiratory distress in COVID-19. <b>2020</b> , 7,	12
1772	Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. <b>2020</b> , 13, 4427-4438	26

1771	COVID-19-related myocarditis and cholinergic anti-inflammatory pathways. <b>2021</b> , 62, 265-269	3
1770	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. <b>2020</b> , 21, 1470320320979097	3
1769	Clinical characteristics and outcomes of 85 intensive care patients with Covid-19 in South London: A single centre observational study. <b>2020</b> , 175114372097154	3
1768	Contemplating on the Etiology of COVID-19 Severity and Mortality Sex Differences. <b>2020</b> , 4, 2470289720970	20
1767	Cardiovascular implications of COVID-19 versus influenza infection: a review. <b>2020</b> , 18, 403	18
1766	Use of Venovenous Extracorporeal Membrane Oxygenation in Critically-Ill Patients With COVID-19. <b>2020</b> , 7, 614569	6
1765	COVID-19 and children with Down syndrome: is there any real reason to worry? Two case reports with severe course. <b>2020</b> , 20, 561	10
1764	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. <b>2020</b> , 7, 602183	13
1763	Some Questions to Our Chinese Colleagues Pioneering Research Into Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 7, 594623	
1762	Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment. <b>2020</b> , 11, 612347	8
1761	Table Organization Optimization in Schools for Preserving the Social Distance during the COVID-19 Pandemic. <b>2020</b> , 10, 8392	6
1760	Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection. <b>2020</b> , 1, 801-809	17
1759	COVID-19: from an acute to chronic disease? Potential long-term health consequences. <b>2021</b> , 58, 297-310	69
1758	Use of out-of-hospital cardiac arrest registries to assess COVID-19 home mortality. <b>2020</b> , 20, 305	5
1757	Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis. <b>2020</b> , 11, 607689	7
1756	Propofol-Associated Hypertriglyceridemia in Coronavirus Disease 2019 Versus Noncoronavirus Disease 2019 Acute Respiratory Distress Syndrome. <b>2020</b> , 2, e0303	3
1755	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. <b>2020</b> , 5,	134
1754	Clinical features and short-term outcomes of patients with COVID-19 due to different exposure history. <b>2020</b> , 99, e23319	2

1753	Positive role of continuous positive airway pressure for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-19 pneumonia: A single centre experience <b>2022</b> , 23, 27-33	1
1752	Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. <b>2020</b> , 17,	6
1751	Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. <b>2020</b> , 60, 417-424	10
1750	Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019. <b>2020</b> , 21, 100484	6
1749	Acute aortoiliac and infrainguinal arterial thrombotic events in four patients diagnosed with the novel coronavirus 2019. <b>2020</b> , 6, 698-702	9
1748	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. <b>2020</b> , 261, 118355	12
1747	Cardiovascular Disease in Hospitalized Patients With a Diagnosis of Coronavirus From the Pre-COVID-19 Era in United States: National Analysis From 2016-2017. <b>2020</b> , 95, 2674-2683	8
1746	High serum nitrates levels in non-survivor COVID-19 patients. <b>2020</b> ,	5
1745	COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight?. <b>2020</b> , 144, 110231	27
1744	Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. <b>2021</b> , 221, 529-535	1
1743	Alteration of lipid profile and value of lipids in the prediction of the length of hospital stay in COVID-19 pneumonia patients. <b>2020</b> , 8, 6144-6152	13
1742	Non-communicable Diseases and COVID-19; a double-edged sword A Special Communication from IRAN. <b>2020</b> , 19, 1-5	O
1741	A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019. <b>2020</b> , 2, e0283	14
1740	Nursing Home Residents Face Severe Functional Limitation or Death After Hospitalization for Pneumonia. <b>2020</b> , 21, 1879-1884	1
1739	Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome. <b>2020</b> , 144, 110242	16
1738	COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps. <b>2020</b> , 2020, 8829674	62
1737	Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. <b>2020</b> , 24, 688	56
1736	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. <b>2020</b> , 21, 1005	10

1735	Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. <b>2020</b> , 7, 594495	63
1734	Outcomes of COVID-19 Among Hospitalized Patients With Non-dialysis CKD. <b>2020</b> , 7, 615312	5
1733	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. <b>2020</b> , 11, 572168	8
1732	Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study. <b>2020</b> , 38, 117-123	14
1731	Predictive biomarkers of mortality in critically ill patients with COVID-19. <b>2020</b> , 46, 94-94	
1730	A Kidney Transplant Recipient With Coronavirus Disease 2019: Utility of a Prognostication Score. <b>2020</b> , 52, 2688-2692	4
1729	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. <b>2020</b> , 1, 100137	26
1728	Impact of tocilizumab administration on mortality in severe COVID-19. <b>2020</b> , 10, 19131	33
1727	Multisystem Imaging Manifestations of COVID-19, Part 2: From Cardiac Complications to Pediatric Manifestations. <b>2020</b> , 40, 1866-1892	45
1726	Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. <b>2020</b> , 21,	17
1725	NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. <b>2020</b> , 11, 570251	32
1724	COVID-19 and Cardiovascular Comorbidities. <b>2020</b> ,	2
1723	Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19. <b>2020</b> , 7, 588692	5
1722	COVID-19 and Cerebrovascular Diseases: A Systematic Review and Perspectives for Stroke Management. <b>2020</b> , 11, 574694	28
1721	COVID-19 in hemodialysis patients in Colombia: Report of seven cases. <b>2020</b> , 40, 50-67	O
1720	Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study. <b>2020</b> , 11, 581338	32
1719	Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. <b>2020</b> , 25,	17
1718	Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. <b>2020</b> , 1, 100144	39

1717	Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center in New York City. <b>2020</b> , 9, e017580	24
1716	Factors associated with increased mortality in hospitalized COVID-19 patients. <b>2020</b> , 60, 308-313	7
1715	Laboratory Findings Associated With Severe Illness and Mortality Among Hospitalized Individuals With Coronavirus Disease 2019 in Eastern Massachusetts. <b>2020</b> , 3, e2023934	27
1714	General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection: Management for Transplant Recipients. <b>2020</b> , 7, 1-13	4
1713	Explaining among-country variation in COVID-19 case fatality rate. <b>2020</b> , 10, 18909	99
1712	Dual-Energy CT Pulmonary Angiography (DECTPA) Quantifies Vasculopathy in Severe COVID-19 Pneumonia. <b>2020</b> , 2, e200428	21
1711	Tocilizumab and liver injury in patients with COVID-19. 2020, 13, 1756284820959183	13
1710	Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran. <b>2020</b> , 185, 607-611	67
1709	Cardiovascular manifestations and treatment considerations in COVID-19. <b>2020</b> , 106, 1132-1141	194
1708	Endovascular Therapy for Patients With Acute Ischemic Stroke During the COVID-19 Pandemic: A Proposed Algorithm. <b>2020</b> , 51, 1902-1909	33
1707	A current review of COVID-19 for the cardiovascular specialist. <b>2020</b> , 226, 29-44	66
1706	Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. <b>2020</b> , 53, 33-37	84
1705	A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001. <b>2020</b> , 2, 1331-1336	54
1704	Medical treatment options for COVID-19. <b>2020</b> , 9, 209-214	27
1703	The Ethics of Creating a Resource Allocation Strategy During the COVID-19 Pandemic. <b>2020</b> , 146,	27
1702	Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications. <b>2020</b> , 92, 1491-1494	65
1701	Immunomodulation in COVID-19. <b>2020</b> , 8, 544-546	107
1700	Stroke as a complication and prognostic factor of COVID-19. <b>2020</b> , 35, 318-322	39

1699	Down Syndrome and COVID-19: A Perfect Storm?. <b>2020</b> , 1, 100019	45
1698	Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas. <b>2020</b> ,	39
1697	Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression. <b>2020</b> , 189, e222-e224	20
1696	At the heart of COVID-19. <b>2020</b> , 35, 1287-1294	53
1695	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. <b>2020</b> , 7, 85	13
1694	The Rationale for Potential Pharmacotherapy of COVID-19. <b>2020</b> , 13,	27
1693	Three months of COVID-19: A systematic review and meta-analysis. <b>2020</b> , 30, e2113	25
1692	Unique Patterns of Cardiovascular Involvement in Coronavirus Disease-2019. <b>2020</b> , 26, 466-469	12
1691	Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology. <b>2020</b> , 73, 569-576	9
1690	Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. <b>2020</b> , 28, 1586-1589	46
1689	COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ). <b>2020</b> , 29, e94-e98	10
1688	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. <b>2020</b> , 96, 431-439	29
1687	Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. <b>2020</b> , 96, 531-537	71
1686	Association of inflammatory markers with the severity of COVID-19: A meta-analysis. <b>2020</b> , 96, 467-474	225
1685	p38 MAPK inhibition: A promising therapeutic approach for COVID-19. <b>2020</b> , 144, 63-65	105
1684	Orbital cellulitis, sinusitis and intracranial abnormalities in two adolescents with COVID-19. <b>2020</b> , 39, 305-310	42
1683	Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis. <b>2020</b> , 106, 1154-1159	107
1682	Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. <b>2020</b> , 6,	45

1681	Effect of coronavirus infection on the human heart: A scoping review. <b>2020</b> , 27, 1136-1148	15
1680	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <b>2020</b> , 8,	31
1679	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. <b>2020</b> , 42, 1021-1049	78
1678	COVID-19 in adults: test menu for hospital blood science laboratories. <b>2020</b> , 189, 1147-1152	6
1677	Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. <b>2020</b> , 395, 1763-1770	1167
1676	Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. <b>2020</b> , 48, 169-179	32
1675	COVID-19 and hypertension. <b>2020</b> , 21, 1470320320927851	14
1674	The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis. <b>2020</b> , 14, 21	11
1673	Clinical characteristics of COVID-19 in children: Are they similar to those of SARS?. <b>2020</b> , 55, 1592-1597	10
1672	Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. <b>2020</b> , 20, 355-362	1194
1672 1671		1194 80
	2020, 20, 355-362  Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic	
1671 1670	2020, 20, 355-362  Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. 2020, 50, 924-935  Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at	80
1671 1670 1669	Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. 2020, 50, 924-935  Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 2020, 57, 339-350	80
1671 1670 1669	Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. 2020, 50, 924-935  Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 2020, 57, 339-350  A SARS-Cov2-negative corona victim. 2020, 109, 1569-1572	80 18 5
1671 1670 1669 1668	Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. 2020, 50, 924-935  Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 2020, 57, 339-350  A SARS-Cov2-negative corona victim. 2020, 109, 1569-1572  COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?. 2020, 115, 31  Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in	80 18 5
1671 1670 1669 1668	Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. 2020, 50, 924-935  Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 2020, 57, 339-350  A SARS-Cov2-negative corona victim. 2020, 109, 1569-1572  COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?. 2020, 115, 31  Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?. 2020, 15, 845-852	80 18 5 123 157

1663	with COVID-19. <b>2020</b> , 96, 348-351	21
1662	Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study. <b>2020</b> , 68, E19-E23	115
1661	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. <b>2020</b> , 8,	56
1660	COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review. <b>2020</b> , 24, 205	90
1659	Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation. <b>2020</b> , 11, 1131	27
1658	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <b>2020</b> , 2, e325-e331	612
1657	The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. <b>2020</b> , 48, 107233	242
1656	Etoposide-based therapy for severe forms of COVID-19. <b>2020</b> , 142, 109826	11
1655	Exploration of strategies to reduce aerosol-spread during chest compressions: A simulation and cadaver model. <b>2020</b> , 152, 192-198	25
1654	Lessons From COVID-19 in Children: Key Hypotheses to Guide Preventative and Therapeutic Strategies. <b>2020</b> , 71, 2006-2013	22
1653	The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients. <b>2020</b> , 21, 709-714	44
1652	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. <b>2020</b> , 75, 1564-1581	496
1651	How Might AI and Chest Imaging Help Unravel COVID-19's Mysteries?. <b>2020</b> , 2, e200053	25
1650	Coronavirus Disease 2019 and the Cerebrovascular-Cardiovascular Systems: What Do We Know So Far?. <b>2020</b> , 9, e016793	25
1649	Cardiovascular disease and COVID-19: les liaisons dangereuses. <b>2020</b> , 27, 1017-1025	14
1648	Preparing your intensive care unit for the COVID-19 pandemic: practical considerations and strategies. <b>2020</b> , 24, 215	60
1647	Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?. 2020, 14, 100-102	26
1646	Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know. <b>2020</b> , 55, 24-29	11

1645	[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]. <b>2020</b> , 46 Suppl 1, 78-87	4
1644	Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. <b>2020</b> , 12, e12697	135
1643	Clinical characteristics and chest CT imaging features of critically ill COVID-19 patients. <b>2020</b> , 30, 6151-6160	28
1642	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. <b>2020</b> , 256, 117883	62
1641	Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. <b>2020</b> , 159, 104965	66
1640	Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2. <b>2020</b> , 20, 3191-3197	15
1639	Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia. <b>2020</b> , 190, e128-e130	3
1638	Related molecular mechanisms of COVID-19, hypertension, and diabetes. <b>2020</b> , 318, E881	1
1637	Cardiac dysfunction and thrombocytopenia-associated multiple organ failure inflammation phenotype in a severe paediatric case of COVID-19. <b>2020</b> , 4, 552-554	33
1636	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <b>2020</b> , 1, 100009	43
1635	SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. <b>2020</b> , 54, 62-75	447
1634	Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study. <b>2020</b> , 13, e007274	53
1633	Cancer and COVID-19: Unmasking their ties. 2020, 88, 102041	48
1632	Stroke as a complication and prognostic factor of COVID-19. <b>2020</b> , 35, 318-322	20
1631	Impact of COVID-19 on the Cardiovascular System: A Review. <b>2020</b> , 9,	31
1630	Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. <b>2020</b> , 16, 485-489	54
1629	Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?. <b>2020</b> , 99, 1675-1676	10
1628	Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe. <b>2020</b> , 42, 200-205	7

1627	COVID-19. <b>2020</b> , 117, 12526-12527	25
1626	Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c). <b>2020</b> , 39, 263-268	69
1625	Arterial hypertension and the risk of severity and mortality of COVID-19. 2020, 55,	23
1624	Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia. <b>2020</b> , 146,	25
1623	Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?. <b>2020</b> , 11, 1206	44
1622	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)The BRACE CORONA Trial. <b>2020</b> , 226, 49-59	87
1621	Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. <b>2020</b> , 128, 147-150	21
1620	A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. <b>2020</b> , 360, 5-34	56
1619	Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. <b>2020</b> , 14, 535-545	292
1618	Cardiological society of India position statement on COVID-19 and heart failure. <b>2020</b> , 72, 75-81	13
1617	The role of biomarkers in diagnosis of COVID-19 - A systematic review. <b>2020</b> , 254, 117788	289
1616	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. <b>2020</b> , 71, 2199-2206	145
1615	Targeting the Linear Ubiquitin Assembly Complex to Modulate the Host Response and Improve Influenza A Virus Induced Lung Injury. <b>2020</b> , 56, 586-591	
1614	Lymphopenia in COVID-19: Therapeutic opportunities. <b>2020</b> , 44, 1792-1797	139
1613	Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. <b>2020</b> , 9, 1007-1022	47
1612	Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19. <b>2020</b> , 13, 894-899	34
1611	Cardiovascular Implications of the COVID-19 Pandemic: A´Global Perspective. <b>2020</b> , 36, 1068-1080	87
1610	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. <b>2020</b> , 98, 115094	152

1609	Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. <b>2020</b> , 96, 683-687	54
1608	Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. <b>2020</b> , 159, 104946	17
1607	Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. <b>2020</b> , 31, 740-745	40
1606	Mechanistic inferences from clinical reports of SARS-CoV-2. <b>2020</b> , 52, 527-537	4
1605	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <b>2020</b> , 79, 859-866	575
1604	Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019. <b>2020</b> , 2020, 7413673	9
1603	COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients. <b>2020</b> , 24, 263	16
1602	Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel. <b>2020</b> , 17,	13
1601	Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302 patients from Italy. <b>2020</b> , 96, 291-293	68
1600	Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 158, 104939	112
1599	Understanding the COVID-19 coagulopathy spectrum. <b>2020</b> , 75, 1432-1436	29
1598	Nutrition, immunity and COVID-19. <b>2020</b> , 3, 74-92	185
1597	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. <b>2020</b> , 8,	2
1596	Potential specific therapies in COVID-19. <b>2020</b> , 14, 1753466620926853	13
1595	Use of anakinra in severe COVID-19: A case report. <b>2020</b> , 96, 607-609	50
1594	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <b>2020</b> , 22, 941-956	60
1593	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. <b>2020</b> , 109, 1446-1459	34
1592	Treatment algorithm for COVID-19: a multidisciplinary point of view. <b>2020</b> , 39, 2077-2084	25

1591	Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. <b>2020</b> , 38, 1722-1726	189
1590	Co-infections in people with COVID-19: a systematic review and meta-analysis. <b>2020</b> , 81, 266-275	598
1589	Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations. <b>2020</b> , 43, 102224	6
1588	Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary. <b>2020</b> , 10, 381-384	34
1587	Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. <b>2020</b> , 106, 1142-1147	78
1586	Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes. <b>2020</b> , 319, E105-E109	104
1585	Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. <b>2020</b> , 8, 36	265
1584	Presentation and Outcomes of Patients with ESKD and COVID-19. <b>2020</b> , 31, 1409-1415	159
1583	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. <b>2020</b> , 11, 1130	51
1582	Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. <b>2020</b> , 21,	34
1581	Considering how biological sex impacts immune responses and COVID-19 outcomes. <b>2020</b> , 20, 442-447	369
1580	Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. <b>2020</b> , 24, 331	29
1579	Neurovascular Complications in COVID-19 Infection: Case Series. <b>2020</b> , 41, 1632-1640	13
1578	Effect of the COVID-19 pandemic on anxiety among children with cystic fibrosis and their mothers. <b>2020</b> , 55, 2128-2134	35
1577	Personal View: Low-dose Lung Radiotherapy for COVID-19 Pneumonia - The Atypical Science and the Unknown Collateral Consequence. <b>2020</b> , 32, 497-500	5
1576	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. <b>2020</b> , 61, 381-395	29
1575	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?. <b>2020</b> , 104, 510-522	8
1574	Immune Parameters and COVID-19 Infection - Associations With Clinical Severity and Disease Prognosis. <b>2020</b> , 10, 364	55

1573	Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection. <b>2020</b> , 9, 293-305	3
1572	IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. <b>2020</b> , 34, 223-231	81
1571	From the trenches: inpatient management of coronavirus disease 2019 in pregnancy. <b>2020</b> , 2, 100154	6
1570	COVID-19 and Myocarditis: What Do We Know So Far?. <b>2020</b> , 2, 278-285	67
1569	Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years. <b>2020</b> , 98, 80-83	27
1568	High mortality in COVID-19 patients with mild respiratory disease. <b>2020</b> , 50, e13314	21
1567	Kawasaki Disease Features and Myocarditis in a Patient with COVID-19. <b>2020</b> , 41, 1526-1528	16
1566	Specific Considerations for Sonographers When Performing Echocardiography during the 2019 Novel Coronavirus Outbreak: Supplement to the American Society of Echocardiography Statement. <b>2020</b> , 33, 654-657	9
1565	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. <b>2020</b> , 114, 102506	150
1564	Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. <b>2020</b> , 155, 143-151	53
1563	SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. <b>2020</b> , 178, 114114	46
1562	Exportin 1 inhibition as antiviral therapy. <b>2020</b> , 25, 1775-1781	24
1561	Current and future therapeutical approaches for COVID-19. <b>2020</b> , 25, 1545-1552	12
1560	Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. <b>2020</b> , 24, 100418	113
1559	Targeting the NLRP3 Inflammasome in Severe COVID-19. <b>2020</b> , 11, 1518	185
1558	COVID-19 Pandemic: Cardiovascular Complications and Future Implications. <b>2020</b> , 20, 311-324	63
1557	COVID-19: 10 things I wished I'd known some months ago. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1449-1452 14.5	2
1556	COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?. <b>2020</b> , 106, 1127-1131	95

1555	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. <b>2020</b> , 100, 1455-1466	75
1554	Implications of COVID-19 in pediatric rheumatology. <b>2020</b> , 40, 1193-1213	26
1553	Anakinra for severe forms of COVID-19: a cohort study. <b>2020</b> , 2, e393-e400	377
1552	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. <b>2020</b> , 29, 973-987	68
1551	Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. <b>2020</b> , 7, 100052	31
1550	Diacerein: A potential multi-target therapeutic drug for COVID-19. <b>2020</b> , 144, 109920	13
1549	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). <b>2020</b> , 27, 72	25
1548	Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. <b>2020</b> , 17, 1281-1292	108
1547	Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. <b>2020</b> , 56, 106044	33
1546	Potential role of statins in COVID-19. <b>2020</b> , 96, 615-617	57
1545	Covid-19 in children: A brief overview after three months experience. <b>2020</b> , 35, 9-14	17
1544	Biomarkers associated with COVID-19 disease progression. <b>2020</b> , 57, 389-399	263
1543	Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019. <b>2020</b> , 15, 733-742	52
1542	Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis. <b>2020</b> , 165, 112361	59
1541	Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. <b>2020</b> , 41, 531-543	137
1540	Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?. <b>2020</b> , 123, 691-693	12
1539	Coronavirus disease 19 in minority populations of Newark, New Jersey. <b>2020</b> , 19, 93	37
1538	The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. <b>2020</b> , 24, 353	251

1537	The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases. <b>2020</b> , 2, e0145	8
1536	American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines. <b>2020</b> , 13, e006967	31
1535	COVID-19 in the Cancer Patient. <b>2020</b> , 131, 16-23	29
1534	Characteristics Associated With Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease 2019 Pandemic in New York City. <b>2020</b> , 5, 1154-1163	124
1533	A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. <b>2020</b> , 60, 1131-1146	36
1532	Severe COVID-19 and aging: are monocytes the key?. <b>2020</b> , 42, 1051-1061	70
1531	Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review. <b>2020</b> , 51, 608-612	37
1530	Doxycycline as a potential partner of COVID-19 therapies. <b>2020</b> , 21, e00864	51
1529	Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. <b>2020</b> , 19, e13168	236
1528	The unique characteristics of COVID-19 coagulopathy. <b>2020</b> , 24, 360	225
1527	Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. <b>2020</b> , 98, 84-89	68
1526	Modelling insights into the COVID-19 pandemic. <b>2020</b> , 35, 64-69	22
1525	The laboratory's role in combating COVID-19. <b>2020</b> , 57, 400-414	26
1524	Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. <b>2020</b> , 18, 997-1003	13
1523	COVID-19: Some clinical questions after the first 4′months. <b>2020</b> , 50, e13326	3
1522	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. <b>2020</b> , 8,	12
1521	Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19. <b>2020</b> , 99, 521-542	33
1520	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. <b>2020</b> , 63, 682-689	126

1519 Approaching COVID-19-Bedside strategies for intensive care. **2020**, 50, e13310

Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis?. <b>2020</b> , 40, 1818-1829	41
ECMO use in COVID-19: lessons from past respiratory virus outbreaks-a narrative review. <b>2020</b> , 24, 301	35
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. <b>2020</b> , 34, 1567-1588	57
1515 Myocarditis in the era of SARS-CoV-2: one piece of a complex puzzle?. <b>2020</b> , 45, 458-460	2
Cardiac imaging procedures and the COVID-19 pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR). <b>2020</b> , 36, 1801-1810	11
1513 COVID-19 infection: the China and Italy perspectives. <b>2020</b> , 11, 438	49
Additive treatment considerations in COVID-19-The clinician's perspective on extracorporeal adjunctive purification techniques. <b>2020</b> , 44, 918-925	14
Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. <b>2020</b> , 12,	96
1510 COVID-19 infection may increase the risk of parkinsonism - Remember the Spanish flu?. <b>2020</b> , 54, 6-7	7
Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients. <b>2020</b> , 41, 1335-1337	7
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. <b>2020</b> , 34, 1805-1815	132
1507 Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019. <b>2020</b> , 9, e017529	17
1506 COVID 19: a clue from innate immunity. <b>2020</b> , 68, 161-168	82
Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. <b>2020</b> , 20, 427	74
Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. <b>2020</b> , 11, 1648	201
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. <b>2020</b> , 28, 507-516	7
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <b>2020</b> , 2, e465-e473	130

1501	COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. <b>2020</b> , 226, 174-187		8
1500	Approaching COVID-19: Bedside strategies for intensive care. <b>2020</b> , 50, e13327		
1499	Acute myocarditis as the main clinical manifestation of SARS-CoV 2 infection. <b>2020</b> , 12, 8609		4
1498	COVID-19 and rationally layered social distancing. <b>2020</b> , 74, e13501		38
1497	SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. <b>2020</b> , 97, 340-343		66
1496	[Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March´2020]. <b>2020</b> , 69, 225-235		40
1495	Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. <b>2020</b> , 75, 2352-2371		1109
1494	Clinical considerations for patients with diabetes in times of COVID-19 epidemic. <b>2020</b> , 14, 211-212		299
1493	Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. <b>2020</b> , 63, 390-391		403
1492	Where are we now with COVID-19?. <b>2020</b> , 74, e13497		6
1491	Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. <b>2020</b> , 1		41
1490	Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. <b>2020</b> , 222, 521-531		556
1489	The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. <b>2020</b> , 214, 108393		787
1488	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 854-887	4.5	1011
1487	Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. <b>2020</b> , 40, 825-826		28
1486	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <b>2020</b> , 382, 1653-1659		1316
1485	A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. <b>2020</b> , 51, 337-342		79
1484	The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. <b>2020</b> , 19, 102537		938

1483	Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum. <b>2020</b> , 49, 255-258	64
1482	COVID-19: consider cytokine storm syndromes and immunosuppression. <b>2020</b> , 395, 1033-1034	5500
1481	COVID-19, ECMO, and lymphopenia: a word of caution. <b>2020</b> , 8, e24	158
1480	Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. <b>2020</b> , 506, 145-148	913
1479	Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. <b>2020</b> , 11, 1626	74
1478	Aging and Coronavirus: Exploring Complementary Therapies to Avoid Inflammatory Overload. <b>2020</b> , 7, 354	3
1477	Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. <b>2020</b> , 156, 107-112	76
1476	Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. <b>2020</b> , 23, 101215	8
1475	Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy. <b>2020</b> , 11, 1576	20
1474	The neurological significance of COVID-19: Lesson learn from the pandemic. <b>2020</b> , 22, 100809	1
1473	Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. <b>2020</b> , 291, 113254	75
1472	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. <b>2020</b> , 8, 822-830	72
1471	Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. <b>2020</b> , 10, 277-287	37
1470	Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. <b>2020</b> , 11, 1359	32
1469	Gut-lung axis and dysbiosis in COVID-19. <b>2020</b> , 44, 265-272	64
1468	The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. <b>2020</b> , 5, e444-e451	287
1467	Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. <b>2020</b> , 148, e130	75
1466	The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation. <b>2020</b> , 477, 349-357	89

1465	Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. <b>2020</b> , 26, 1395-1399	269
1464	Immune modulation in COVID-19: Strategic considerations for personalized therapeutic intervention. <b>2020</b> ,	19
1463	Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study. <b>2020</b> , 15, 41	35
1462	Hypercytokinemia and Pathogen-Host Interaction in COVID-19. <b>2020</b> , 13, 255-261	8
1461	The Association of Obesity, Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients. <b>2020</b> , 28, 1826-1832	43
1460	Cerebrovascular disease is associated with the risk of mortality in coronavirus disease 2019. <b>2020</b> , 41, 2017-2019	3
1459	Giant Retroperitoneal Hematoma During Extracorporeal Membrane Oxygenation in a Patient With Coronavirus Disease-2019 Pneumonia. <b>2020</b> , 34, 2839-2840	10
1458	Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns. <b>2020</b> , 22, 1752-1754	3
1457	Albumin and total bilirubin for severity and mortality in coronavirus disease 2019 patients. <b>2020</b> , 34, e23412	3
1456	Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada. <b>2020</b> , 28, 5031-5036	2
1455	COVID-19 Sepsis and Microcirculation Dysfunction. <b>2020</b> , 11, 747	49
1454	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. <b>2020</b> , 9,	46
1453	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. <b>2020</b> , 9,	29
1452	Comparison of clinical and microbiological diagnoses for older adults with COVID-19 in Wuhan: a retrospective study. <b>2020</b> , 32, 1889-1895	1
1451	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. <b>2020</b> , 883, 173348	45
1450	The characteristics and outcomes of 681 severe cases with COVID-19 in China. <b>2020</b> , 60, 32-37	39
1449	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. <b>2020</b> , 319, L325-L336	40
1448	Alternative management of Covid-19 infection. <b>2020</b> , 65, 72-75	4

1447	Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. <b>2020</b> , 11, 2040622320935765	90
1446	Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review. <b>2020</b> , 5,	21
1445	Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure. <b>2020</b> , 5, 1170-1175	33
1444	The COVID-19 pandemic. <b>2020</b> , 57, 365-388	165
1443	Role of inflammatory markers in corona virus disease (COVID-19) patients: A review. <b>2020</b> , 245, 1368-1375	16
1442	Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. <b>2020</b> , 30, e2123	48
1441	Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. <b>2020</b> , 6, 52-60	25
1440	Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU. <b>2020</b> , 510, 47-53	13
1439	Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. <b>2020</b> , 76, 1244-1258	174
1438	Machine-Learning Approaches in COVID-19 Survival Analysis and Discharge-Time Likelihood Prediction Using Clinical Data. <b>2020</b> , 1, 100074	50
1437	Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease. <b>2020</b> , 19, 4219-4232	48
1436	Extracorporeal membrane oxygenation for acute respiratory distress syndrome in patients with coronavirus disease 2019: what do we know so far?. <b>2020</b> , 35, 558-561	
1435	IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. <b>2020</b> , 99, 2953-2956	2
1434	Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. <b>2020</b> , 218, 108517	44
1433	Progression of CXR features on a COVID-19 survivor. <b>2020</b> , 21, e00834	1
1432	Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer. <b>2020</b> , 190, 525-528	11
1431	Endocrine changes in SARS-CoV-2 patients and lessons from SARS-CoV. <b>2020</b> , 96, 412-416	15
1430	The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. <b>2020</b> , 8, 2050313X20933473	23

1429	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline. <b>2020</b> , 11, 1294	15
1428	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <b>2020</b> , 9,	24
1427	Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019. <b>2020</b> , 2, e0138	3
1426	Novel Use of Home Pulse Oximetry Monitoring in COVID-19 Patients Discharged From the Emergency Department Identifies Need for Hospitalization. <b>2020</b> , 27, 681-692	65
1425	The COVID-19 Cytokine Storm; What We Know So Far. <b>2020</b> , 11, 1446	615
1424	COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. <b>2020</b> , 17, 1984-1990	130
1423	Transforming laparoendoscopic surgical protocols during the COVID-19 pandemic; big data analytics, resource allocation and operational considerations. <b>2020</b> , 80, 21-25	12
1422	Extrapulmonary manifestations of COVID-19. <b>2020</b> , 26, 1017-1032	1253
1421	In the eye of the storm: the right ventricle in COVID-19. <b>2020</b> , 10, 2045894020936660	36
1420	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <b>2020</b> , 40, 1353-1360	19
1419	Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas. <b>2020</b> , 7, 817-821	6
1418	Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: A case report and literature review. <b>2020</b> , 49, 858-863	15
1417	A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis. <b>2020</b> , 81, e18-e25	73
1416	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <b>2020</b> , 68, 111-118	24
1415	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <b>2020</b> , 79, 1277-1285	164
1414	Coronavirus disease 2019 induces multi-lineage, morphologic changes in peripheral blood cells. <b>2020</b> , 1, 376	17
1413	C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. <b>2020</b> , 14, 1753466620937175	202
1412	COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?. <b>2020</b> , 50, 567-579	29

1411	A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes. <b>2020</b> , 166, 108294	6
1410	The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond. <b>2020</b> , 69, 237-240	22
1409	The trinity of COVID-19: immunity, inflammation and intervention. <b>2020</b> , 20, 363-374	2173
1408	Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. <b>2020</b> , 42, 393-397	72
1407	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <b>2020</b> , 26, 880-894	23
1406	Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence. <b>2020</b> , 77, 121-122	16
1405	Myocardial injury and COVID-19: Possible mechanisms. <b>2020</b> , 253, 117723	210
1404	The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients. <b>2020</b> , 14, 835-838	19
1403	COVID-19 diagnosis and management: a comprehensive review. <b>2020</b> , 288, 192-206	532
1402	Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic. <b>2020</b> , 22, 26	37
1401	Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. <b>2020</b> , 28, 1200-1204	227
1400	Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. <b>2020</b> , 22, 34	37
1399	Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. <b>2020</b> , 7, 658-663	136
1398	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <b>2020</b> , 116, 1666-1687	714
1397	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the Editors. <b>2020</b> , 9, e017013	38
1396	COVID-19: Therapeutics and Their Toxicities. <b>2020</b> , 16, 284-294	57
1395	[Low dose lung radiotherapy for COVID-19-related cytokine storm syndrome: Why not?]. 2020, 24, 179-181	8
1394	SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. <b>2020</b> , 144, 47-53	86

1393	Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. <b>2020</b> , 382, e102	643
1392	Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. <b>2020</b> , 11, 1049	65
1391	Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work. <b>2020</b> , 21,	89
1390	CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA. <b>2020</b> , 26, 668-674	74
1389	Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. <b>2020</b> , 125, 461-464	88
1388	Platelets in Coronavirus Disease 2019. <b>2020</b> , 46, 823-825	35
1387	SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. <b>2020</b> , 39, 553-561	136
1386	COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. <b>2020</b> , 5, 518-536	162
1385	Morphological anomalies of circulating blood cells in COVID-19. <b>2020</b> , 95, 870-872	80
1384	C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. <b>2020</b> , 92, 856-862	255
1383	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. <b>2020</b> , 40, 416-437	124
1382	Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1117-1/129	53
1381	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. <b>2020</b> , 8, 506-517	812
1380	Understanding pathways to death in patients with COVID-19. <b>2020</b> , 8, 430-432	150
1379	[COVID-19 pandemia: Impact on the cariovascular system. Data of 1 April 2020]. 2020, 69, 107-114	3
1378	Testing for COVID-19 in lung cancer patients. <b>2020</b> , 31, 832-834	49
1377	Rapid surveillance of COVID-19 in the United States using a prospective space-time scan statistic: Detecting and evaluating emerging clusters. <b>2020</b> , 118, 102202	176
1376	Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. <b>2020</b> , 132, 11-16	112

1375	The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. <b>2020</b> , 61, 42-45	90
1374	The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. <b>2020</b> , 309, 70-77	160
1373	Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. <b>2020</b> , 58, 27-28	134
1372	Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. <b>2020</b> , 127, 104354	207
1371	The association between international and domestic air traffic and the coronavirus (COVID-19) outbreak. <b>2020</b> , 53, 467-472	84
1370	[Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients]. <b>2020</b> , 40, 265-271	35
1369	[Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology]. <b>2020</b> , 73, 569-576	39
1368	Ethical considerations in the allocation of critical care resources when capacity is overwhelmed. <b>2020</b> , 22, 404-406	5
1367	Potential impact of contaminated bronchoscopes on novel coronavirus disease (COVID-19) patients. <b>2020</b> , 41, 862-864	4
1366	Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China. <b>2020</b> , 41, 982-983	56
1365	[SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy]. <b>2020</b> , 55, 257-265	24
1364	Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report. <b>2020</b> , 20, 1922-1924	47
1363	Paradigm Shift for COVID-19 Response: Identifying High-risk Individuals and Treating Inflammation. <b>2020</b> , 21, 473-476	8
1362	Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. <b>2020</b> , 30, 101063	86
1361	[Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society]. <b>2020</b> , 74, 337-357	25
1360	Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. <b>2020</b> , 20, 1885-1890	68
1359	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <b>2020</b> , 20, 1800-1808	474
1358	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. <b>2020</b> , 75, 1546-1554	57

1357	Novel coronavirus SARS-CoV-2 and COVID-19. Practice recommendations for obstetric anaesthesia: what we have learned thus far. <b>2020</b> , 43, 1-8	32
1356	Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. <b>2020</b> , 26, e147-e160	22
1355	COVID-19: Immunology and treatment options. <b>2020</b> , 215, 108448	321
1354	Mild versus severe COVID-19: Laboratory markers. <b>2020</b> , 95, 304-307	250
1353	Patient blood management during the COVID-19 pandemic: a narrative review. <b>2020</b> , 75, 1105-1113	56
1352	Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. <b>2020</b> , 45, 100617	85
1351	COVID-19 and Multiorgan Response. <b>2020</b> , 45, 100618	434
1350	Industry 4.0 technologies and their applications in fighting COVID-19 pandemic. <b>2020</b> , 14, 419-422	312
1349	QTY Code-designed Water-soluble Fc-fusion Cytokine Receptors Bind to their Respective Ligands. <b>2020</b> , 1, e4	4
1348	Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. <b>2020</b> , 14, 395-403	446
1347	Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. <b>2020</b> , 55, 105982	160
1346	The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis. <b>2020</b> , 63, 518-524	110
1345	Considerations for Obstetric Care during the COVID-19 Pandemic. <b>2020</b> , 37, 773-779	27
1344	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. <b>2020</b> , 141, 1903-1914	302
1343	Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). <b>2020</b> , 96, 336-345	67
1342	Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?. <b>2020</b> , 28, 1191-1194	163
1341	Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1121-1123	66
1340	Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. <b>2020</b> , 22, 32	111

1339	Cardiovascular complications in COVID-19. <b>2020</b> , 38, 1504-1507	440
1338	Current status of potential therapeutic candidates for the COVID-19 crisis. <b>2020</b> , 87, 59-73	163
1337	Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. <b>2020</b> , 26, 470-475	170
1336	Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. <b>2020</b> , 158, 97-105	340
1335	Current data on the cardiovascular effects of COVID-19. <b>2020</b> , 61, 46-48	14
1334	Coronavirus disease 2019 and the cardiovascular system: Impacts and implications. <b>2020</b> , 72, 1-6	9
1333	Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). <b>2020</b> , 76, 1375-1384	170
1332	The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review. <b>2020</b> , 5, 100033	24
1331	[COVID-19: Clinical, biological and radiological characteristics in adults, infants and pregnant women. An up-to-date review at the heart of the pandemic]. <b>2020</b> , 41, 308-318	19
1330	Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. <b>2020</b> , 191, 9-14	1179
1329	Could COVID-19 represent a negative prognostic factor in patients with stroke?. 2020, 41, 1115-1116	9
1328	SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill. <b>2020</b> , 1-6	24
1327	COVID-19 and psoriasis: Should we fear for patients treated with biologics?. <b>2020</b> , 33, e13434	30
1326	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. <b>2020</b> , 18, 35	26
1325	Clinical utility of cardiac troponin measurement in COVID-19 infection. <b>2020</b> , 57, 202-205	25
1324	Epidemiology and clinical features of COVID-19: A review of current literature. <b>2020</b> , 127, 104357	198
1323	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. <b>2020</b> , 41, 363-382	243
1322	Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. <b>2021</b> , 9, 88-98	158

1321	Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic. <b>2021</b> , 14, 48-70	86
1320	An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients. <b>2021</b> , 40, 208-209	9
1319	A review of pathophysiology and neuropsychiatric manifestations of COVID-19. <b>2021</b> , 268, 2007-2012	46
1318	The Anesthetic Management of the First Lung Transplant for a Patient with COVID-19 Respiratory Failure. <b>2021</b> , 35, 917-920	2
1317	Selective C-reactive protein apheresis for Covid-19 patients suffering from organ damage. <b>2021</b> , 25, 251-252	7
1316	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. <b>2021</b> , 109, 49-53	12
1315	Extrapulmonary complications of COVID-19: A multisystem disease?. <b>2021</b> , 93, 323-335	63
1314	Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. <b>2021</b> , 72, 1247-1250	72
1313	Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. <b>2021</b> , 35, 932-943	1
1312	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. <b>2021</b> , 72, 1067-1073	2
1311	Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness. <b>2021</b> , 45, 100731	5
1310	Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19. <b>2021</b> , 49, 158-165	18
1309	Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. <b>2021</b> , 48, 454-462	9
1308	Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. <b>2021</b> , 184, 460-475.e21	84
1307	A review on how to do hematology consults during COVID-19 pandemic. <b>2021</b> , 47, 100777	9
1306	Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. <b>2021</b> , 143, 21-32	115
1305	Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19: A pilot study. <b>2021</b> , 93, 2243-2251	4
1304	[Travelling to High Altitude Destinations after Recovery from COVID-19-infection: New Aspects of Medical Advice in Altitude Medicine]. <b>2021</b> , 75, 214-220	1

1303	Model-based Prediction of Critical Illness in Hospitalized Patients with COVID-19. <b>2021</b> , 298, E46-E54	35
1302	Cytokine storm syndrome in coronavirus disease 2019: A narrative review. <b>2021</b> , 289, 147-161	84
1301	HIV/SARS-CoV-2 coinfection: A global perspective. <b>2021</b> , 93, 726-732	29
1300	Risk factors for the COVID-19 severity and its correlation with viral shedding: A retrospective cohort study. <b>2021</b> , 93, 952-961	13
1299	Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression. <b>2021</b> , 93, 1078-1098	29
1298	Selenium and viral infection: are there lessons for COVID-19?. <b>2021</b> , 125, 618-627	40
1297	The SARS-CoV-2 and mental health: From biological mechanisms to social consequences. <b>2021</b> , 104, 110046	51
1296	Heart failure and COVID-19. <b>2021</b> , 26, 1-10	55
1295	Multisystem Assessment of the Imaging Manifestations of Coagulopathy in Hospitalized Patients With Coronavirus Disease (COVID-19). <b>2021</b> , 216, 1088-1098	10
1294	Coagulation dysfunction is associated with severity of COVID-19: A meta-analysis. <b>2021</b> , 93, 962-972	16
1293	Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. <b>2021</b> , 27, 52-66	69
1292	COVID-19 in solid organ transplant recipients: No difference in survival compared to general population. <b>2021</b> , 23, e13421	21
1291	Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. <b>2021</b> , 34, 1062-1071	90
1290	Dexamethasone in Hospitalized Patients with Covid-19. <b>2021</b> , 384, 693-704	4434
1289	Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials. <b>2021</b> , 87, 1584-1586	3
1288	COVID-19 complicated by ST-segment elevation myocardial infarction in a 29-year-old patient. <b>2021</b> , 97, 267-271	2
1287	Prominent Longitudinal Strain Reduction of Basal Left Ventricular Segments in Patients With Coronavirus Disease-19. <b>2021</b> , 27, 100-104	16
1286	IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. <b>2021</b> , 147, 72-80.e8	74

1285	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. <b>2021</b> , 44, 13-34	59
1284	Coagulation and anticoagulation in COVID-19. <b>2021</b> , 47, 100761	48
1283	Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure. <b>2021</b> , 35, 1329-1344	19
1282	The looming storm: Blood and cytokines in COVID-19. <b>2021</b> , 46, 100743	24
1281	National case fatality rates of the COVID-19 pandemic. <b>2021</b> , 27, 118-124	15
1280	Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?. <b>2021</b> , 58, 102-110	46
1279	Prevalence and clinical outcomes of cardiac injury in patients with COVID-19: A systematic review and meta-analysis. <b>2021</b> , 31, 2-13	7
1278	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. <b>2021</b> , 147, 520-531	142
1277	Hallazgos pulmonares en un caso de muerte inesperada por infecci de COVID-19. <b>2021</b> , 47, 41-44	
1276	SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?. <b>2021</b> , 1486, 15-38	35
1275	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. <b>2021</b> , 890, 173620	16
1274	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. <b>2021</b> , 181, 32-40	407
1273	Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study. <b>2021</b> , 40, 2154-2161	35
1272	[Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm: Perimyocarditis and coagulopathy after administration of tocilizumab]. <b>2021</b> , 70, 121-126	4
1271	Patient characteristics and admitting vital signs associated with coronavirus disease 2019 (COVID-19)-related mortality among patients admitted with noncritical illness. <b>2021</b> , 42, 399-405	21
1270	Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. <b>2021</b> , 50, 107300	105
1269	Cardiac Involvement of COVID-19: A Comprehensive Review. <b>2021</b> , 361, 14-22	40
1268	Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension. <b>2021</b> , 64, 836-839	3

1267	Clinical and laboratory data, radiological structured report findings and quantitative evaluation of lung involvement on baseline chest CT in COVID-19 patients to predict prognosis. <b>2021</b> , 126, 29-39	20
1266	Unique immunological profile in patients with COVID-19. <b>2021</b> , 18, 604-612	89
1265	Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans. <b>2021</b> , 46, 1543-1551	3
1264	COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. <b>2021</b> , 147, 99-106.e4	23
1263	Longitudinal Profile of Laboratory Parameters and Their Application in the Prediction for Fatal Outcome Among Patients Infected With SARS-CoV-2: A Retrospective Cohort Study. <b>2021</b> , 72, 626-633	8
1262	SARS-CoV-2 associated COVID-19 in geriatric population: A brief narrative review. <b>2021</b> , 28, 738-743	3
1261	The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. <b>2021</b> , 292, 198246	28
1260	COVID-19 mortality risk factors in older people in a long-term care center. <b>2021</b> , 12, 601-607	27
1259	Combining aptamers and antibodies: Lateral flow quantification for thrombin and interleukin-6 with smartphone readout. <b>2021</b> , 333, 129246	9
1258	Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients. <b>2021</b> , 51, 634-647	11
1257	Hypoxic preconditioning - A nonpharmacological approach in COVID-19 prevention. <b>2021</b> , 103, 415-419	6
1256	Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients. <b>2021</b> , 93, 1873-1874	
1255	Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis. <b>2021</b> , 210, 33-47	10
1254	Air pollution, sociodemographic and health conditions effects on COVID-19 mortality in Colombia: An ecological study. <b>2021</b> , 756, 144020	12
1253	Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms. <b>2021</b> , 22, 100887	8
1252	Modeling and simulations of CoViD-19 molecular mechanism induced by cytokines storm during SARS-CoV2 infection. <b>2021</b> , 327, 114863	28
1251	[COVID-19: Still a place for tocilizumab?]. <b>2021</b> , 42, 73-78	3
1250	COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. <b>2021</b> , 103, 439-446	23

1249	Association between iron status and the risk of adverse outcomes in COVID-19. <b>2021</b> , 40, 3462-3469	10
1248	Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. <b>2021</b> , 193, E10-E18	22
1247	Immunopathogenesis and treatment of cytokine storm in COVID-19. <b>2021</b> , 11, 316-329	118
1246	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. <b>2021</b> , 7,	97
1245	A systematic meta-analysis of immune signatures in patients with COVID-19. <b>2021</b> , 31, e2195	11
1244	Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany. <b>2021</b> , 34, 167-175	27
1243	Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles. <b>2020</b> , 4, 1-13	8
1242	The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19. <b>2021</b> , 41, 315-323	5
1241	Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. <b>2021</b> , 320, L301-L330	11
1240	Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. <b>2021</b> , 292, 198235	48
1239	Role of extracorporeal membrane oxygenation in critically Ill COVID-19 patients and predictors of mortality. <b>2021</b> , 45, E158-E170	18
1238	Risk factors prediction, clinical outcomes, and mortality in COVID-19 patients. <b>2021</b> , 93, 2307-2320	40
1237	COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart. <b>2021</b> , 143, 230-243	64
1236	Meta-analysis Comparing Outcomes in Patients With and Without Cardiac Injury and Coronavirus Disease 2019 (COVID 19). <b>2021</b> , 141, 140-146	12
1235	Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. <b>2021</b> , 21, 49-64	56
1234	COVID-19: A review of therapeutic strategies and vaccine candidates. <b>2021</b> , 222, 108634	109
1233	A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development. <b>2021</b> , 10, 18-29	5
1232	A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. <b>2021</b> , 17, 62-72	26

1231	The hematology laboratory's response to the COVID-19 pandemic: A scoping review. <b>2021</b> , 43, 148-159	4
1230	Increased susceptibility to SARS-CoV-2 infection in patients with reduced left ventricular ejection fraction. <b>2021</b> , 8, 380-389	8
1229	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. <b>2021</b> , 159, 1884-1893	6
1228	Gene expression profiling of corona virus microarray datasets to identify crucial targets in COVID-19 patients. <b>2021</b> , 22, 100980	6
1227	Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. <b>2021</b> , 193, 111413	33
1226	The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response. <b>2021</b> , 222, 107794	9
1225	Wildland firefighter exposure to smoke and COVID-19: A new risk on the fire line. <b>2021</b> , 760, 144296	17
1224	Prognostic value of labs ordered on patients hospitalized with COVID-19. <b>2021</b> , 49, 95-99	1
1223	Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. <b>2021</b> , 80, 550-557	60
1222	Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. <b>2021</b> , 57, 106265	4
1221	Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy. <b>2021</b> , 19, 549-554	9
1220	Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. <b>2021</b> , 3, e98-e114	52
1219	The cardiovascular aspect of COVID-19. <b>2021</b> , 53, 227-236	16
1218	Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. <b>2021</b> , 43, 49-57	14
1217	Absolute Lymphocytes, Ferritin, C-Reactive Protein, and Lactate Dehydrogenase Predict Early Invasive Ventilation in Patients With COVID-19. <b>2021</b> , 52, 141-145	8
1216	The Relation Between Otolaryngology-Specific Symptoms and Computed Tomography Findings in Ambulatory Care COVID-19 Patients. <b>2021</b> , 100, 79-85	2
1215	Causes and Circumstances of Death among Patients Hospitalized with COVID-19: A Retrospective Cohort Study. <b>2021</b> , 18, 1076-1079	7
1214	Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. <b>2021</b> , 18, 29-41	9

Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <b>2021</b> , 8, ofaa588	9
Secondary infection among hospitalized COVID-19 patients: A retrospective cohort study in a tertiary care setting. <b>2021</b> , 26, 277-278	4
Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned. <b>2021</b> , 223, 108652	49
1210 Risk factors related to the severity of COVID-19 in Wuhan. <b>2021</b> , 18, 120-127	15
Clinically Suspected Myocarditis in the Course of Severe Acute Respiratory Syndrome Novel Coronavirus-2 Infection: Fact or Fiction?. <b>2021</b> , 27, 92-96	16
Trends and Geographic Variation in Acute Respiratory Failure and ARDS Mortality in the United States. <b>2021</b> , 159, 1460-1472	7
1207 Compartmental immunophenotyping in COVID-19 ARDS: A´case series. <b>2021</b> , 147, 81-91	33
What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies. <b>2021</b> , 56, 217-221	1
1205 Mortality associated with cardiovascular disease in patients with COVID-19. <b>2021</b> , 56, 30-38	5
Not only intensive care unit workload and activities but also quality indicators are influenced by the COVID-19 epidemic. <b>2021</b> , 63, 103008	1
Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes. <b>2021</b> , 19, 153-160	24
1202 COVID-19 and Solid Organ Transplantation: A Review Article. <b>2021</b> , 105, 37-55	111
1201 The effects of lockdown measures due to COVID-19 pandemic on burn cases. <b>2021</b> , 18, 367-374	3
Association of metabolic-associated fatty liver disease and risk of severe coronavirus disease 2019 illness. <b>2020</b> , 5, 4	6
First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID-19 in an allogeneic stem cell transplant patient. <b>2021</b> , 2, 143-146	
1198 Controversy over smoking in COVID-19-A real world experience in New York city. <b>2021</b> , 93, 4537-4543	3
1197 Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. <b>2021</b> , 384, 20-30	578
Favorable outcome of COVID-19 among African American (AA) renal transplant recipients in Detroit. <b>2021</b> , 35, e14169	2

# (2021-2021)

1195	CoVA: An Acuity Score for Outpatient Screening that Predicts Coronavirus Disease 2019 Prognosis. <b>2021</b> , 223, 38-46	18
1194	Correlating arterial blood gas, acid-base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. <b>2021</b> , 58, 95-101	12
1193	COVID-19 myocarditis and prospective heart failure burden. <b>2021</b> , 19, 5-14	27
1192	Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis. <b>2021</b> , 203, 54-66	106
1191	Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis. <b>2021</b> , 51, e13429	76
1190	Laboratory Biomarkers in the Management of Patients With COVID-19. <b>2021</b> , 155, 333-342	5
1189	Review on 3D printing: Fight against COVID-19. 2021, 258, 123943	37
1188	COVID-19, varying genetic resistance to viral disease and immune tolerance checkpoints. <b>2021</b> , 99, 177-191	5
1187	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. <b>2021</b> , 96, 183-202	30
1186	Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity?. <b>2021</b> , 39, 35-47	16
1185	[Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation]. <b>2021</b> , 116, 138-145	1
1184	Comprehensive Landscape of Heparin Therapy for COVID-19. <b>2021</b> , 254, 117232	14
1183	The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. <b>2021</b> , 81, 103520	9
1182	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <b>2021</b> , 18, 936-944	62
1181	Cardiology and COVID-19: do we have sufficient information?. <b>2021</b> , 17, 705-711	1
1180	Cytotoxic lesions of the corpus callosum (CLOCCs) associated with SARS-CoV-2 infection. <b>2021</b> , 268, 1592-159	9416
1179	Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. <b>2021</b> , 93, 1265-1275	8
1178	Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. <b>2021</b> , 21, e66-e75	7

1177	Coronavirus disease 2019: A tissue engineering and regenerative medicine perspective. <b>2021</b> , 10, 27-38	10
1176	Prolonged persistence of PCR-detectable virus during an outbreak of SARS-CoV-2 in an inpatient geriatric psychiatry unit in King County, Washington. <b>2021</b> , 49, 293-298	14
1175	Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. <b>2021</b> , 88, 56-68	62
1174	Liver Injury as a Surrogate for Inflammation and Predictor of Outcomes in COVID-19. <b>2021</b> , 5, 24-32	9
1173	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. <b>2021</b> , 87, 845-857	3
1172	Use of ECMO in Patients With Coronavirus Disease 2019: Does the Evidence Suffice?. <b>2021</b> , 35, 1256-1262	6
1171	Coronavirus disease-19 and cardiovascular disease: A risk factor or a risk marker?. <b>2021</b> , 31, e2172	5
1170	Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy. <b>2021</b> , 22, e67-e69	4
1169	The pediatric solid organ transplant experience with COVID-19: An initial multi-center, multi-organ case series. <b>2021</b> , 25, e13868	32
1168	Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19. <b>2021</b> , 82, e20-e21	19
1167	T-cell responses and therapies against SARS-CoV-2 infection. <b>2021</b> , 162, 30-43	60
1166	Liver Chemistries in Patients with COVID-19 Who Discharged alive or Died: A Meta-analysis. <b>2020</b> , 5, 12	6
1165	Clinical characteristics and outcomes of immunosuppressed patients hospitalized with COVID-19: experience from London. <b>2021</b> , 289, 385-394	6
1164	Immunopathology of Hyperinflammation in COVID-19. <b>2021</b> , 191, 4-17	143
1163	Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. <b>2021</b> , 35, 411-425	15
1162	Cytokine adsorption in a patient with severe coronavirus disease 2019 related acute respiratory distress syndrome requiring extracorporeal membrane oxygenation therapy: A case report. <b>2021</b> , 45, 191-194	4
1161	The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. <b>2021</b> , 32, 17-22	17
1160	Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. <b>2021</b> , 26, 107-108	125

1159	Cardio-Cerebrovascular Disease is Associated With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 23, 258-269	8
1158	Cytokine release syndrome-associated encephalopathy in patients with COVID-19. <b>2021</b> , 28, 248-258	75
1157	Evaluation of 17 patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia-COVID respiratory severity scale (BCRSS) scoring systems. <b>2021</b> , 93, 1532-1537	6
1156	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. <b>2021</b> , 25, 13-22	5
1155	Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. <b>2021</b> , 99, 192-205	1
1154	Respiratory characteristics and related intraoperative ventilatory management for patients with COVID-19 pneumonia. <b>2021</b> , 35, 356-360	O
1153	Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities. <b>2021</b> , 90, 880-890	4
1152	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. <b>2021</b> , 50, 326-331	7
1151	Arterial thrombotic complications in COVID-19 patients. <b>2021</b> ,	
1150	Late mesenteric ischemia after Sars-Cov-2 infection: case report. <b>2021</b> , 20, e20200105	2
1150 1149		2
1149		
1149	Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic. <b>2021</b> , 10, 1-11	4
1149	Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic. <b>2021</b> , 10, 1-11  COVID-19 Dynamics: A Heterogeneous Model. <b>2020</b> , 8, 558368  Elevated HScore is Associated with Poor Clinical Outcomes in COVID-19, Even in the Absence of	4
1149 1148 1147	Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic. 2021, 10, 1-11  COVID-19 Dynamics: A Heterogeneous Model. 2020, 8, 558368  Elevated HScore is Associated with Poor Clinical Outcomes in COVID-19, Even in the Absence of Secondary Hemophagocytic Lymphohistiocytosis.  Assessment of systemic inflammatory reactions and coagulopathy against the background of hormonal therapy in covid-associated lung damage. 2021, 230-237  Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and	2
1149 1148 1147 1146	Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic. 2021, 10, 1-11  COVID-19 Dynamics: A Heterogeneous Model. 2020, 8, 558368  Elevated HScore is Associated with Poor Clinical Outcomes in COVID-19, Even in the Absence of Secondary Hemophagocytic Lymphohisticocytosis.  Assessment of systemic inflammatory reactions and coagulopathy against the background of hormonal therapy in covid-associated lung damage. 2021, 230-237  Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary	2
1149 1148 1147 1146	Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic. 2021, 10, 1-11  COVID-19 Dynamics: A Heterogeneous Model. 2020, 8, 558368  Elevated HScore is Associated with Poor Clinical Outcomes in COVID-19, Even in the Absence of Secondary Hemophagocytic Lymphohistiocytosis.  Assessment of systemic inflammatory reactions and coagulopathy against the background of hormonal therapy in covid-associated lung damage. 2021, 230-237  Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol.	2

1141	Septic shock in patients admitted to intensive care unit with COVID-19 pneumonia. <b>2021</b> , 23, 95	0
1140	COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. <b>2021</b> , 50, 740-749	5
1139	Successful management of COVID-19 induced acute respiratory distress syndrome by extracorporeal membrane oxygenation with 1-year follow-up: A case report. <b>2021</b> , 26, e01281	
1138	Micronutrient zinc roles in adjunctive therapy for COVID-19 by enhancing patients immunoregulation and tolerance to the pathogen. <b>2021</b> , Publish Ahead of Print,	O
1137	Evaluation of the relationship between COVID-19 pneumonia severity and pulmonary artery diameter measurement. <b>2021</b> , 46, 56-62	4
1136	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. <b>2021</b> , 379, 4	8
1135	COVID19 pandemic is a «pandemic» of antimicrobial therapy. <b>2021</b> , 23, 5-15	2
1134	Conceptions of the pathophysiology of happy hypoxemia in COVID-19. <b>2021</b> , 22, 12	9
1133	Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. <b>2021</b> , 16, 843-852	18
1132	Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. <b>2021</b> , 53, 273-282	9
1131	IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <b>2021</b> , 27,	15
1130	Cardiovascular disease in SARS-CoV-2 infection. <b>2021</b> , 10, e1343	8
1129	Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19. <b>2021</b> , 21, 79	14
1128	Inflammatory pathways and potential therapies for COVID-19: A mini review. <b>2021</b> , 19, 205873922110029	5
1127	COVID-19-Related Pericarditis with Pericardial Clotting as a Hallmark: Two Cases and a Review. <b>2021</b> , 31, 1-5	O
1126	Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study. <b>2021</b> , 53, 770-776	4
1125	Clinical characteristics and predictors of mortality in young adults with severe COVID-19: a retrospective observational study. <b>2021</b> , 20, 3	15
1124	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. <b>2021</b> , 18,	17

1123	The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. <b>2021</b> , 591, 130-130	21
1122	The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19. <b>2021</b> , 11,	10
1121	Hyperosmolarity Deserves More Attention in Critically Ill COVID-19 Patients with Diabetes: A Cohort-Based Study. <b>2021</b> , 14, 47-58	3
<b>112</b> 0	Nitric Oxide Releasing Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening. <b>2020</b> , 8, 579788	3
1119	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. <b>2021</b> , 34,	61
1118	Abdominal gastrointestinal imaging findings on computed tomography in patients with COVID-19 and correlation with clinical outcomes. <b>2021</b> , 8, 100326	10
1117	A model to predict the risk of mortality in severely ill COVID-19 patients. <b>2021</b> , 19, 1694-1700	4
1116	Older adults: panoramic view on the COVID-19 vaccination. <b>2021</b> , 8, 388-415	2
1115	Neuropathogenesis of SARS-CoV-2 Infection. <b>2021</b> , 25-43	1
1114	Cytokines in Innate Immunity. 2021,	
1114	Cytokines in Innate Immunity. 2021,  Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. 2021, 4, 100084	3
·	Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary	3
1113	Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. <b>2021</b> , 4, 100084  Risk factors associated with acute respiratory distress syndrome in COVID-19 patients outside Wuhan: A double-center retrospective cohort study of 197 cases in Hunan, China. <b>2021</b> , 9, 344-356	
1113	Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. <b>2021</b> , 4, 100084  Risk factors associated with acute respiratory distress syndrome in COVID-19 patients outside Wuhan: A double-center retrospective cohort study of 197 cases in Hunan, China. <b>2021</b> , 9, 344-356  Serum cytokines profile of critically ill COVID-19 patients with cardiac dysfunction. <b>2021</b> , 9, 2	2 O
1113 1112 1111	Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. 2021, 4, 100084  Risk factors associated with acute respiratory distress syndrome in COVID-19 patients outside Wuhan: A double-center retrospective cohort study of 197 cases in Hunan, China. 2021, 9, 344-356  Serum cytokines profile of critically ill COVID-19 patients with cardiac dysfunction. 2021, 9, 2  Clinical characteristics and cardiovascular implications of the dead patients for COVID-19. 2021, 19, 2058739  Peripheral Inflammatory Cytokines and Lymphocyte Subset Features of Deceased COVID-19	2 O
1113 1112 1111 1110	Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. 2021, 4, 100084  Risk factors associated with acute respiratory distress syndrome in COVID-19 patients outside Wuhan: A double-center retrospective cohort study of 197 cases in Hunan, China. 2021, 9, 344-356  Serum cytokines profile of critically ill COVID-19 patients with cardiac dysfunction. 2021, 9, 2  Clinical characteristics and cardiovascular implications of the dead patients for COVID-19. 2021, 19, 2058739  Peripheral Inflammatory Cytokines and Lymphocyte Subset Features of Deceased COVID-19 Patients. 2021, 2021, 9101082	2 O 22 <u>0</u> 98625
1113 1112 1111 1110	Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. 2021, 4, 100084  Risk factors associated with acute respiratory distress syndrome in COVID-19 patients outside Wuhan: A double-center retrospective cohort study of 197 cases in Hunan, China. 2021, 9, 344-356  Serum cytokines profile of critically ill COVID-19 patients with cardiac dysfunction. 2021, 9, 2  Clinical characteristics and cardiovascular implications of the dead patients for COVID-19. 2021, 19, 2058739  Peripheral Inflammatory Cytokines and Lymphocyte Subset Features of Deceased COVID-19 Patients. 2021, 2021, 9101082  Are numbers deceptive? Is death auditing a solution for death analysis, among the COVID-19 deceased?: A study from a dedicated COVID-19 hospital in Faridabad, Haryana. 2021, 10, 1347-1352  ACUTE TRANSVERSE MYELITIS AS A NEUROLOGICAL COMPLICATION OF COVID-19: A CASE	2 O 22 <u>0</u> 98625

Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis. 2021, 30, 96368972199621

Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study. <b>2021</b> , 11, 20	14
Immune and cellular damage biomarkers to predict COVID-19 mortality in hospitalized patients. <b>2021</b> , 2, 155-162	2
The relation between serum D-dimer, ferritin and vitamin D levels, and dysgeusia symptoms, in patients with coronavirus disease 2019. <b>2021</b> , 135, 45-49	3
Effectiveness and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.	
1100 A research update: Significance of cytokine storm and diaphragm in COVID-19. <b>2021</b> , 2, 100031	2
A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients. <b>2021</b> , 45, 687-694	14
1098 Myocarditis in COVID-19 patients: current problems. <b>2021</b> , 16, 1123-1129	29
1097 A Systematic Review of 571 Pregnancies Affected by COVID-19. <b>2021</b> , 1321, 287-298	3
1096 Herpes Zoster Co-Infection with COVID-19: A Case Series. <b>2021</b> , 5, 195	
1095 COVID-19 Diagnostic Approaches: An Overview. <b>2021</b> , 892-906	
1094 Cardiovascular Health and Disease in the Context of COVID-19. <b>2021</b> , 12, 67-79	7
Poor maternal-neonatal outcomes in pregnant patients with confirmed SARS-Cov-2 infection: analysis of 145 cases. <b>2021</b> , 303, 1483-1488	6
1092 Ischemic Stroke: An Underestimated Complication of COVID-19. <b>2021</b> , 12, 691-704	2
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial.	7
Prediction Models for COVID-19 Integrating Age Groups, Gender, and Underlying Conditions. <b>2021</b> , 67, 3009-3044	7
Neurological and mental health consequences of COVID-19: potential implications for well-being and labour force. <b>2021</b> , 3, fcab012	6
Feasibility of using alternative swabs and storage solutions for paired SARS-CoV-2 detection and microbiome analysis in the hospital environment. <b>2021</b> , 9, 25	7

1087 THE RADIOLOGICAL FINDINGS OF COVID-19. <b>2021</b> ,	1
The risk factors for severe patients with COVID-19 in China: A systematic review and meta-analysis. <b>2021</b> , 19, 205873922110008	O
1085 Identifying COVID-19 cases in outpatient settings. <b>2021</b> , 149, e92	О
<del>IDIIE</del> ovid-19: <del>IDIIII-</del> 1084 <del>DIIIIII2</del> 021, 185-192	
Fatores associados ao enfrentamento da pandemia da COVID-19 por pessoas idosas com comorbidades. <b>2021</b> , 25,	0
Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. <b>2020</b> , 44, e20200198	1
Things You Should Know in the Performing Echocardiographic Examination in Patients with COVID-19. <b>2021</b> , 29, 20-30	1
Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review. <b>2021</b> , 11, e042008	1
Evaluation and improvement of the National Early Warning Score (NEWS2) for COVID-19: a multi-hospital study. <b>2021</b> , 19, 23	31
1078 Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <b>2021</b> , 12, 5932	23 42
Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <b>2021</b> , 12, 5932  1077 COVID-19 Infection Prediction and Classification. <b>2021</b> , 195-208	23 42
	23 42 7
Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence Profiles Before and After Immune Modulation in Hospitalized Patients With Covidence Profiles Before and After Immune Modulation in Hospitalized Patients With Covidence Profiles Before Before After Immune Modulation	
COVID-19 Infection Prediction and Classification. <b>2021</b> , 195-208  Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. <b>2021</b> , 41, 738-747	7
Covidence Profiles Before and After Immune Modulation in Hospitalized Patients with Covidence 2021, 41, 738-747  SARS-Cov-2 myocarditis: what physicians need to know. 2021,	7
Covident Profiles Before and After Immune Modulation in Hospitalized Patients with Covident Sars-Covident Profiles Before and After Immune Modulation in Hospitalized Patients with Covident Sars-Covident Sars-Covi	7
Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.  2021, 41, 738-747  SARS-CoV-2 myocarditis: what physicians need to know. 2021,  The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. 2021, 48, 1763-1771  COVID-19 with non-obstructive coronary artery disease in a young adult. 2021, 11, 111-114	7 1 2

1069 Diagnosis of COVID-19 and the bariatric surgery population: a single center experience. <b>2021</b> , 1	3
Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients. <b>2021</b> , 12, 634	51
Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis. <b>202</b> 104, 368504211000906	<b>21</b> , 7
Temperature dependence of the SARS-CoV-2 affinity to human ACE2 determines COVID-19 progression and clinical outcome. <b>2021</b> , 19, 161-167	16
1065 Potential of Immune-Related Therapy in COVID-19. <b>2020</b> , 11, 609212	2
The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obes Patients. <b>2020</b> , 11, 612268	<b>e</b> 5
Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Stor <b>2021</b> , 35, 231-247	m. <sub>10</sub>
1062 COVID-19 in Patients with Hypertension. <b>2021</b> , 1318, 243-261	O
Death risk and the importance of clinical features in elderly people with COVID-19 using the Random Forest Algorithm. <b>2021</b> , 21, 445-451	O
Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hube province, China: A retrospective analysis. <b>2021</b> , 16, e0246030	ei 14
Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients. <b>2021</b> , 36, 1-10	5
Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, an Implications for Therapy. <b>2021</b> , 13,	nd 7
1057 Can algae contribute to the war with Covid-19?. <b>2021</b> , 12, 1226-1237	17
Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial. <b>2021</b> , 35, 2616	35
COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. <b>2021</b> , 2021, 8874339	72
Machine learning approaches in COVID-19 diagnosis, mortality, and severity risk prediction: A review. <b>2021</b> , 24, 100564	34
Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection. <b>2021</b> , 18,	21
Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents. <b>2021</b> , 41, 575-583	5

1051	Coronavirus and Nutrition. <b>2021</b> , 56, 19-25	2
1050	Clinical Manifestations of Cytokine Storm and Immune Response to COVID-19: Literature Review. <b>2021</b> , 11, 151-174	
1049	Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients. <b>2021</b> , 21, 89	6
1048	SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage. <b>2021</b> , 41, 515-525	36
1047	Clinical course of patients on maintenance hemodialysis and COVID-19: a retrospective longitudinal study. <b>2021</b> , 18, 2366-2371	О
1046	Modeling the cardiac response to hemodynamic changes associated with COVID-19: a computational study. <b>2021</b> , 18, 3364-3383	1
1045	Predicting Novel CoronaVirus 2019 with Machine Learning Algorithms. <b>2021</b> , 289-300	
1044	SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications. <b>2021</b> , 16, 18	1
1043	Acute myocardial injury in COVID-19 survivors without cardiovascular history. <b>2021</b> , 24, 111	
1042	Assessment of Ventilation and Perfusion in Patients with COVID-19 Discloses Unique Information of Pulmonary Function to a Clinician: Case Reports of V/P SPECT. <b>2021</b> , 15, 11795484211030159	1
1041	SARS-CoV-2 Infection in Pregnant Women: Neuroimmune-Endocrine Changes at the Maternal-Fetal Interface. <b>2021</b> , 28, 1-21	3
1040	Public knowledge, attitudes, and practice about COVID-19 pandemic <b>2021</b> , 12, 1519	1
1039	Position Statement on Post-COVID-19 Cardiovascular Preparticipation Screening: Guidance for Returning to Physical Exercise and Sports - 2020. <b>2021</b> , 116, 1213-1226	1
1038	The Many Faces of Cytokine Release Syndrome-Related Coagulopathy. <b>2021</b> , 3, 3-12	4
1037	Prospective multicentre cohort study of transthoracic echocardiography provision in the South West of the UK during the first wave of SARS-CoV-2 pandemic. <b>2021</b> , 8,	2
1036	Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. <b>2021</b> , 53, 391-401	16
1035	Cytokine Storm in Coronavirus Disease 2019 and Adult-Onset Still's Disease: Similarities and Differences. <b>2020</b> , 11, 603389	14
1034	Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City. <b>2021</b> , 36, e15	7

1033	HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City. <b>2021</b> , 8, ofab029	5
1032	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021</b> ,	28
1031	Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the Trial. <b>2020</b> , 11, 624657	23
1030	Immune response to COVID-19 infection: a double-edged sword. <b>2021</b> , 44, 187-196	7
1029	Worsening of heart failure by coronavirus disease 2019 is associated with high mortality. <b>2021</b> , 8, 943-952	7
1028	Learning from pathophysiological aspects of COVID-19 clinical, laboratory, and high-resolution CT features: a retrospective analysis of 128 cases by disease severity. <b>2021</b> , 28, 453-467	2
1027	COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm. <b>2020</b> , 10, 599502	3
1026	Survival Factors and Metabolic Pathogenesis in Elderly Patients (日5) With COVID-19: A Multi-Center Study. <b>2020</b> , 7, 595503	6
1025	COVID-HEART: Development and Validation of a Multi-Variable Model for Real-Time Prediction of Cardiovascular Complications in Hospitalized Patients with COVID-19.	1
1024	The new coronavirus infection followed by damage to the heart, lungs, skin and kidneys. <b>2021</b> , 14, 104	1
1023	CARDIOVASCULAR DISEASE IN COVID-19 PATIENTS. PART 2 <b>2021</b> , 19, 5-9	1
1022	Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. <b>2021</b> ,	1
1021	The SADDEN DEATH Study: Results from a Pilot Study in Non-ICU COVID-19 Spanish Patients. <b>2021</b> , 10,	O
1020	Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia-a regenerative dogma. <b>2021</b> , 8, 3	4
1019	Microvascular Angiopathic Consequences of COVID-19. <b>2021</b> , 8, 636843	8
1018	Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients. <b>2021</b> , 103, 536-539	13
1017	Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. <b>2021</b> , 10,	19
1016	The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. <b>2021</b> , 25, 85-101	4

1015	Sex Differences on Clinical Characteristics, Severity, and Mortality in Adult Patients With COVID-19: A Multicentre Retrospective Study. <b>2021</b> , 8, 607059	14
1014	The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence. <b>2021</b> , 36, 483-491	7
1013	Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations. <b>2021</b> , 138, 155404	19
1012	Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression. <b>2021</b> , 103, 624-627	7
1011	Right Ventricular Damage in COVID-19: Association Between Myocardial Injury and COVID-19. <b>2021</b> , 8, 606318	13
1010	Cardiovascular sequalae in uncomplicated COVID-19 survivors. <b>2021</b> , 16, e0246732	24
1009	Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. <b>2021</b> , 36, 101051	38
1008	Early Warning Factors of Death in COVID-19 Patients. <b>2021</b> , 41, 69-76	O
1007	Using Automated Machine Learning to Predict the Mortality of Patients With COVID-19: Prediction Model Development Study. <b>2021</b> , 23, e23458	19
1006	Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients. <b>2021</b> , 41, 1-6	3
1005	Impact of coronavirus disease 2019 on diabetic patients: An endocrinological perspective for better management. 2, 85-91	
1004	Recent advances in materials science: a reinforced approach toward challenges against COVID-19. <b>2021</b> , 4, 1-17	4
1003	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <b>2020</b> , 7, 629933	15
1002	Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection. <b>2021</b> , 70, 389-405	3
1001	Photosynthetically Controlled Spirulina, but Not Solar Spirulina, Inhibits TNF-Secretion: Potential Implications for COVID-19-Related Cytokine Storm Therapy. <b>2021</b> , 23, 149-155	5
1000	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. <b>2021</b> , 63, 51-61	11
999	Severity Scores in COVID-19 Pneumonia: a Multicenter, Retrospective, Cohort Study. <b>2021</b> , 36, 1338-1345	12
998	Validity of Clinical Symptoms Score to Discriminate Patients with COVID-19 from Common Cold Out-Patients in General Practitioner Clinics in Japan. <b>2021</b> , 10,	2

997	Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF- <b>B</b> : A Systematic Review. <b>2021</b> , 13,	7
996	Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19. <b>2021</b> , 41, 221-233	23
995	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. <b>2021</b> , 18, 105-118	2
994	Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19. <b>2021</b> , 41, 39-45	4
993	Approaching glioblastoma during COVID-19 pandemic: current recommendations and considerations in Brazil. <b>2021</b> , 79, 167-172	0
992	Prognosis and hematological findings in patients with COVID-19 in an Amazonian population of Peru.	
991	Inflammation-associated factors for predicting in-hospital mortality in patients with COVID-19. <b>2021</b> , 93, 2908-2917	8
990	Early prediction model for progression and prognosis of severe patients with coronavirus disease 2019. <b>2021</b> , 100, e24901	O
989	An easy-to-use nomogram for predicting in-hospital mortality risk in COVID-19: a retrospective cohort study in a university hospital. <b>2021</b> , 21, 148	9
988	Observational study of haloperidol in hospitalized patients with COVID-19. <b>2021</b> , 16, e0247122	24
987	Causes and timing of death in critically ill COVID-19 patients. <b>2021</b> , 25, 79	9
986	Microglia Fighting for Neurological and Mental Health: On the Central Nervous System Frontline of COVID-19 Pandemic. <b>2021</b> , 15, 647378	11
985	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. <b>2021</b> , 26, 515-525	7
984	Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. <b>2021</b> , 8, 627723	9
983	Neurological symptoms in Covid-19 patients in the emergency department. <b>2021</b> , 11, e02058	5
982	Honeysuckle Aqueous Extracts Induced Suppress EV71 Replication and Pathogenesis In Vitro and In Vivo and Is Predicted to Inhibit SARS-CoV-2. <b>2021</b> , 13,	10
981	Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies. <b>2021</b> , 26,	37
980	Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 12, 598249	16

## (2021-2021)

979	Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. <b>2021</b> , 26, 5199-5212	96
978	A Machine Learning Prediction Model of Respiratory Failure Within 48 Hours of Patient Admission for COVID-19: Model Development and Validation. <b>2021</b> , 23, e24246	24
977	Therapeutic Intervention of COVID-19 by Natural Products: A Population-Specific Survey Directed Approach. <b>2021</b> , 26,	2
976	Epidemiological Impact of Myocarditis. <b>2021</b> , 10,	10
975	Association of coagulation dysfunction with cardiac injury among hospitalized patients with COVID-19. <b>2021</b> , 11, 4432	3
974	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. <b>2021</b> ,	1
973	Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China. <b>2020</b> , 11, 615287	4
972	SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis. <b>2021</b> , 21, 503-514	2
971	Air Pollution and COVID-19: A Comparison of Europe and the United States. <b>2021</b> , 5, em0074	O
970	The effect of moderate and severe COVID-19 pneumonia on short-term right ventricular functions: a prospective observational single pandemic center analysis. <b>2021</b> , 37, 1883-1890	6
969	Evaluation of factors which determining survival of SARS COV-2 infected patients in intensive care unit. <b>2021</b> , 3, 36-43	1
968	Rehabilitation after new coronavirus infection (COVID-19): principles and approaches. <b>2020</b> , 11, 6-14	9
967	Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection. <b>2021</b> , 1	8
966	Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19). <b>2021</b> , 13, 4811-4830	10
965	Extracorporeal membrane oxygenation versus mechanical ventilation alone in adults with severe acute respiratory distress syndrome: A systematic review and meta-analysis. <b>2021</b> , 75, e14046	3
964	C-Reactive Protein Triggers Cell Death in Ischemic Cells. <b>2021</b> , 12, 630430	15
963	COVID-19 and the heart: direct and indirect impact. <b>2021</b> , 28, 16-31	4
962	T Cell Phenotyping in Individuals Hospitalized with COVID-19. <b>2021</b> , 206, 1478-1482	5

961	Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. <b>2021</b> , 7,	102
960	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <b>2021</b> , 22, 275-296	56
959	Predicting COVID-19 mortality with electronic medical records. <b>2021</b> , 4, 15	36
958	Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019. <b>2021</b> , 89, 1041-1045	30
957	Association between periodontitis and severity of COVID-19 infection: A case-control study. <b>2021</b> , 48, 483-491	80
956	Chemokine Regulation During Epidemic Coronavirus Infection. <b>2020</b> , 11, 600369	4
955	Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study. <b>2021</b> , 10,	3
954	SARS-CoV-2 pneumonia-receptor binding and lung immunopathology: a narrative review. <b>2021</b> , 25, 53	5
953	The Novel Coronavirus Infection (COVID-19) and Nervous System Involvement: Mechanisms of Neurological Disorders, Clinical Manifestations, and the Organization of Neurological Care. <b>2021</b> , 51, 1-8	2
952	Neurobiology of COVID-19: how can the virus affect the brain?. <b>2021</b> ,	9
951	Factors affecting the recovery of Kurdistan province COVID-19 patients: a cross-sectional study from March to June 2020. <b>2021</b> , 10,	О
950	Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. <b>2021</b> , 147, 110486	16
949	Cardiovascular biomarkers in patients with COVID-19. <b>2021</b> , 10, 310-319	16
948	Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis. <b>2021</b> , 45, 998-1016	33
947	The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis. <b>2021</b> , 22,	10
946	Coronavirus disease 2019 and cardiovascular complications: focused clinical review. <b>2021</b> , 39, 1282-1292	23
945	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <b>2021</b> , 193, 43-51	20
944	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. <b>2021</b> , 12, 574425	13

943	The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study. <b>2021</b> , 32, 100715	5
942	Risk Factors for Mortality of COVID-19 Patient Based on Clinical Course: A Single Center Retrospective Case-Control Study. <b>2021</b> , 12, 581469	4
941	Association between benzodiazepine receptor agonist use and increased mortality among patients hospitalized for COVID-19: results from an observational study.	1
940	Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. <b>2021</b> , 14, 39	O
939	Neurological involvement in the respiratory manifestations of COVID-19 patients. <b>2021</b> , 13, 4713-4730	4
938	Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. <b>2021</b> ,	3
937	Phase angle and standardized phase angle from bioelectrical impedance measurements as a prognostic factor for mortality at 90 days in patients with COVID-19: A longitudinal cohort study. <b>2021</b> ,	13
936	and Models to Study SARS-CoV-2 Infection: Integrating Experimental and Computational Tools to Mimic "COVID-19 Cardiomyocyte". <b>2021</b> , 12, 624185	4
935	Spatiotemporal patterns and trends of community transmission of the pandemic COVID-19 in South Asia: Bangladesh as a case study. <b>2021</b> , 3, 39-49	16
934	COVID-19: The Heart of the Matter-Pathological Changes and a Proposed Mechanism. <b>2021</b> , 26, 217-224	5
933	Increased angiotensin-converting enzyme 2, sRAGE and immune activation, but lowered calcium and magnesium in COVID-19: association with chest CT abnormalities and lowered peripheral oxygen saturation.	1
932	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. <b>2021</b> , 8, 606755	2
931	Koronavir Kardiyovaskler Sistem Øerine Etkileri IBda Sporcularñ Yeniden Sahalara DBBB DeBrlendirilmesi.	
930	NURSING INTERVENTIONS IN THE MANAGEMENT OF COVID-19-RELATED DELIRIUM IN INTENSIVE CARE UNITS: LITERATURE REVIEW.	
929	Pro: Venoarterial ECMO Should Be Considered in Patients With COVID-19. 2021, 35, 703-706	0
929	Pro: Venoarterial ECMO Should Be Considered in Patients With COVID-19. <b>2021</b> , 35, 703-706  Serum \( \textstyle{2}\)-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?. <b>2021</b> , 16, e0247758	2
	Serum 🛭-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of	

925	Survival Analysis and Risk Factors in COVID-19 Patients. <b>2021</b> , 1-6	4
924	Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 2021, 9363569	9
923	The interplay between neutrophils, complement, and microthrombi in COVID-19. 2021, 35, 101661	18
922	Prognostic value of cardiac biomarkers in COVID-19 infection. <b>2021</b> , 11, 4930	8
921	COVID-19 and myocarditis: a systematic review and overview of current challenges. 2021, 1	28
920	Fatality and risk features for prognosis in COVID-19 according to the care approach - a retrospective cohort study. <b>2021</b> , 16, e0248869	3
919	Predicting the outcome of COVID-19 infection in kidney transplant recipients. <b>2021</b> , 22, 100	13
918	Con: Venoarterial ECMO Should Not Be Considered in Patients With COVID-19. <b>2021</b> , 35, 707-710	3
917	[Neuroimmunology of COVID-19]. <b>2021</b> , 92, 521-530	1
916	No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. <b>2021</b> , 104, 34-40	4
915	Impact of Cardiovascular Diseases on COVID-19: A Systematic Review. <b>2021</b> , 27, e930032	2
914	Efficacy of tocilizumab treatment in COVID-19 patients with cytokine release syndrome. <b>2021</b> , 5, 269-275	
913	Endovascular Thrombectomy of COVID-19-Related Large Vessel Occlusion: A Systematic Review and Summary of the Literature. <b>2021</b> , 9, 4	2
912	Survey of laboratory medicine's national response to the Covid-19 pandemic in the Republic of Ireland. <b>2021</b> , 1	
911	COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. <b>2021</b> , 19, 1083-1092	4
910	National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohort. <b>2021</b> , 75, e14121	6
909	Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis. <b>2021</b> , 23, e13595	7
908	Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection. <b>2021</b> ,	1

907	Spatiotemporal Analysis of COVID-19 Spread with Emerging Hotspot Analysis and SpaceIIime Cube Models in East Java, Indonesia. <b>2021</b> , 10, 133	13
906	Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. <b>2021</b> , 25, 111	20
905	Predicting Severity and Intrahospital Mortality in COVID-19: The Place and Role of Oxidative Stress. <b>2021</b> , 2021, 6615787	13
904	Proteomic blood profiling in mild, severe and critical COVID-19 patients. <b>2021</b> , 11, 6357	25
903	Probiotics: A potential immunomodulator in COVID-19 infection management. <b>2021</b> , 87, 1-12	31
902	How the Heart Was Involved in COVID-19 during the First Pandemic Phase: A Review. <b>2021</b> , 2, 124-139	O
901	Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19.	
900	Cellular Therapy as Promising Choice of Treatment for COVID-19.	
899	Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2. <b>2021</b> , 9, 1513-1523	1
898	Evaluation of left ventricular global functions with speckle tracking echocardiography in patients recovered from COVID-19. <b>2021</b> , 37, 2227-2233	12
897	Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. <b>2021</b> , 11, 4863	23
896	Comorbidities and clinical features related to severe outcomes among COVID-19 cases in Selangor, Malaysia. <b>2021</b> , 12, 46-52	1
895	Exercise Training and Cardiac Rehabilitation in COVID-19 Patients with Cardiovascular Complications: State of Art. <b>2021</b> , 11,	7
894	Biomarkers of Cardiac Stress and Cytokine Release Syndrome in COVID-19: A Review. <b>2021</b> , 18, 163-168	3
893	Risk Factors and Prognosis in Patients with COVID-19 and Liver Injury: A Retrospective Analysis. <b>2021</b> , 14, 629-637	4
892	Renal Manifestations of Covid-19: Physiology and Pathophysiology. <b>2021</b> , 10,	9
891	Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19). <b>2021</b> , 18,	23
890	Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China. <b>2021</b> ,	4

889	Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. <b>2021</b> , 11, 5975	10
888	Clinical Impact and Predictors of Troponin Elevation in Patients With COVID-19. <b>2021</b> , 33, 41-44	1
887	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. <b>2021</b> , 17, 1277-1291	1
886	The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy-A Prospective Longitudinal Study. <b>2021</b> , 12, 646095	6
885	SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function. <b>2021</b> , 16, 478-492	29
884	Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis. <b>2021</b> , 11, 5012	8
883	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <b>2021</b> , 6,	82
882	COVID-19 in early 2021: current status and looking forward. <b>2021</b> , 6, 114	74
881	Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. <b>2021</b> , 12, 596518	7
880	Effect of Socioeconomic and Ethnic Characteristics on COVID-19 Infection: the Case of the Ultra-Orthodox and the Arab Communities in Israel. <b>2021</b> , 1	12
879	Coronavirus disease 2019: a comprehensive review and meta-analysis on cardiovascular biomarkers. <b>2021</b> , 36, 367-373	3
878	Multi-Organ System Dysfunction in Covid-19 🖪 Review. <b>2021</b> , 10, 632-637	
877	. <b>2021</b> , 193, E389-E398	О
876	Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection. <b>2021</b> , 34, 305-314	3
875	Position Statement on Indications and the Safe Reintroduction of Cardiovascular Imaging Methods in the COVID-19 Scenario - 2021. <b>2021</b> , 116, 659-678	0
874	Mental Health Predictors After the COVID-19 Outbreak in Korean Adults. <b>2021</b> , 59, 18-27	O
873	Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. <b>2021</b> , 13, 23	31
872	Clinical characteristics and outcomes of patients with COVID-19 pneumonia admitted to an intensive care unit in Faisalabad, Pakistan. <b>2021</b> , 75, e14152	2

871	Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis. <b>2021</b> , 22,	5
870	Severity of SARS-CoV-2 infection as a function of the interferon landscape across the respiratory tract of COVID-19 patients. <b>2021</b> ,	6
869	Comments on Leung. <b>2021</b> , 32, 1130-1131	
868	COVID-19 and inflammatory bowel disease: A pathophysiological assessment. <b>2021</b> , 135, 111233	5
867	Sensors for the detection of ammonia as a potential biomarker for health screening. <b>2021</b> , 11, 7185	7
866	SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. <b>2021</b> , 9,	20
865	SARS-CoV-2/COVID-19 Laktualisierte Empfehlungen zu Diagnostik und Therapie. 2021, 29, 80-89	1
864	A network-informed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes' interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-19. <b>2021</b> , 17, e1008810	7
863	The most important biomarker associated with coagulation and inflammation among COVID-19 patients. <b>2021</b> , 476, 2877-2885	11
862	The Centrality of Obesity in the Course of Severe COVID-19. <b>2021</b> , 12, 620566	5
861	Two Hours of In Vivo Lung Perfusion Improves Lung Function in Sepsis-Induced Acute Respiratory Distress Syndrome. <b>2021</b> ,	1
860	The protective effect of rheumatic disease agents in COVID-19. <b>2021</b> , 35, 101659	3
859	Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19. <b>2021</b> , 320, L331-L338	
858	COVID-19 and healthcare workers: A systematic review and meta-analysis. <b>2021</b> , 104, 335-346	62
857	Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. <b>2021</b> , 21, 138	16
856	Severe Acute Respiratory Syndrome-Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research. <b>2021</b> , 3, e0374	12
855	Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study.	
854	Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease. <b>2021</b> ,	O

Possible Therapeutic Role of Cholinergic Agonists on COVID-19 related inflammatory response. **2021**, 5, 102-108

852	Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review. <b>2021</b> , 29, 213-222	4
851	Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis. <b>2021</b> , 134, 104119	18
850	Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. <b>2021</b> , 21, 100716	11
849	Evaluation of the relation between cardiac biomarkers and thorax computed tomography findings in COVID-19 patients. <b>2021</b> , 15, 285-293	O
848	Faktor Risiko Obesitas pada Guru Sekolah Perempuan serta Relevansi dengan PTM Selama Pandemi Covid-19. <b>2021</b> , 5, 31	
847	Tear gas safety and usage practices. <b>2021</b> , 18,	1
846	Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?. <b>2021</b> , 11, 44	8
845	Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. <b>2021</b> , 16, e0247461	111
844	The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). <b>2021</b> , 93, 4319-4325	10
843	Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients.	1
842	Identification of clinical features associated with mortality in COVID-19 patients.	3
841	Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C. <b>2021</b> , 149, 110537	4
840	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. <b>2021</b> , 12, 589095	32
839	COVID-19-associated secondary hemophagocytic lymphohistiocytosis (cytokine storm syndrome). <b>2021</b> , 76, 51-66	6
838	Effects of Anacardic Acid Monoene on the Respiratory System of Mice Submitted to Acute Respiratory Distress Syndrome. <b>2021</b> , 31, 1-7	1
837	Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19. <b>2021</b> , 2021, 6693895	4
836	Heart damage and the role of ultrasonic research in the COVID-19 pandemic. <b>2021</b> , 36, 38-48	3

835	Heart-lung interactions in COVID-19: prognostic impact and usefulness of bedside echocardiography for monitoring of the right ventricle involvement. <b>2021</b> , 1	4
834	Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases. <b>2021</b> , 9,	10
833	Hyponatremia is associated with poor outcome in COVID-19. <b>2021</b> , 34, 991-998	12
832	Coronavirus infection in hip fractures (CHIP) study. <b>2021</b> , 103-B, 782-787	6
831	Admission High-Sensitive Cardiac Troponin T Level Increase Is Independently Associated with Higher Mortality in Critically Ill Patients with COVID-19: A Multicenter Study. <b>2021</b> , 10,	7
830	Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. <b>2021</b> , 9,	53
829	TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. <b>2021</b> , 25, 491-508	11
828	Is acupuncture effective in the treatment of COVID-19 related symptoms? Based on bioinformatics/network topology strategy. <b>2021</b> , 22,	12
827	Obesity as a Risk Factor for Severe COVID-19 and Complications: A Review. <b>2021</b> , 10,	24
826	Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review. <b>2021</b> , 22,	20
825	Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. <b>2021</b> , 178, 113008	13
824	Dexamethasone and transdehydroandrosterone significantly reduce pulmonary epithelial cell injuries associated with mechanical ventilation. <b>2021</b> , 130, 1143-1151	1
823	Complement C3 identified as a unique risk factor for disease severity among young COVID-19 patients in Wuhan, China. <b>2021</b> , 11, 7857	1
822	Do Certain Biomarkers Predict Adverse Outcomes in Coronavirus Disease 2019?. <b>2021</b> , 13, 195-203	O
821	Excess body weight is an independent risk factor for severe forms of COVID-19. <b>2021</b> , 117, 154703	8
820	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. <b>2021</b> , 86, 34-40	39
819	Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis. <b>2021</b> , 30, 289	4
818	Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcome. <b>2021</b> , 137, 109612	7

817	Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. <b>2021</b> , 133, 983-988	10
816	Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. <b>2021</b> , 8,	8
815	Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients. <b>2021</b> , 2, 100229	25
814	COVID-19 prediction using AI analytics for South Korea. <b>2021</b> , 1-19	6
813	Comparison of Characteristics and Outcomes of Patients With Acute Myocardial Infarction With Versus Without Coronarvirus-19. <b>2021</b> , 144, 8-12	12
812	Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19. <b>2021</b> , 224, 60-69	16
811	Obesity and its impact on COVID-19. <b>2021</b> , 99, 899-915	7
810	Abdominal obesity phenotype is associated with COVID-19 chest X-ray severity score better than BMI-based obesity. <b>2021</b> , 1	2
809	Novel prognostic determinants of COVID-19-related mortality: a pilot study on severely-ill patients in Russia.	
808	Thymosin a1 use is not associated with reduced COVID-19 mortality. <b>2021</b> , 53, 252-252	O
807	Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study.	1
806	Systemic therapy and COVID19: Immunotherapy and chemotherapy. <b>2021</b> , 39, 213-220	2
805	Comparison of the effects of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 requiring intubation. <b>2021</b> , 35, 49	1
804	Interplay of Opposing Effects of the WNT/ECatenin Pathway and PPARIand Implications for SARS-CoV2 Treatment. <b>2021</b> , 12, 666693	14
803	The role of extracorporeal membrane oxygenation in critically ill patients with COVID-19: a narrative review. <b>2021</b> , 21, 116	5
802	Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a randomised, double-blinded, phase 2/3, placebo-controlled trial.	
801	Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study. <b>2021</b> , 42, 1196-1200	19
800	Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1). <b>2021</b> , 12, 593595	8

COVID-19: ambulante oder station Be Betreuung? IRisikoscore zur prospektiven Differenzierung 799 leichter und schwerer Verlüfe. 2021, 37, 209-218 MR-proAdrenomedullin as a predictor of renal replacement therapy in a cohort of critically ill 798 patients with COVID-19. 2021, 26, 417-424 Patients with COVID-19 who experience a myocardial infarction have complex coronary morphology and high in-hospital mortality: Primary results of a nationwide angiographic study. 797 4 2021, 98, E370-E378 Using the Health Belief Model to Understand Age Differences in Perceptions and Responses to the 796 13 COVID-19 Pandemic. 2021, 12, 609893 Hematological Abnormalities in COVID-19: A Narrative Review. 2021, 26 795 Prolonged Intubation in Patients With Prior Cerebrovascular Disease and COVID-19. 2021, 12, 642912 2 794 Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple 6 793 donor-derived lines of human umbilical cord-derived mesenchymal stem cells. 2021, 19, 149 792 Interleukin-6 signalling as a valuable cornerstone for molecular medicine (Review). 2021, 47, 6 Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac 9 791 Dysfunction and Inhibit Proinflammatory Cytokine Production. 2020, 11, 614024 790 SARS-CoV-2/COVID-19 Laktualisierte Empfehlungen zu Diagnostik und Therapie. 2021, 56, 277-287 Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After 789 10 Discharge in Wuhan, China. 2021, 224, 1473-1488 The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the 788 role of gene expression. **2021**, 64, 400-415 A meta-analysis on the role of pre-existing chronic disease in the cardiac complications of 3 SARS-CoV-2 infection. 2021, 24, 102264 Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial 786 17 Culture Findings. 2021, 18, Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance. 785 11 **2021**, 21, 498-503 784 Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. 2021, 34, 1456-1467 59 In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and 783 LCB10-0200/Avibactam, against Carbapenem-Resistant,,, and Strains at a Tertiary Hospital in O Когеа. 2021, 14, Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. 2021, 50, 743-779 782

781	A prospective study on the relationship between COVID-19 disease progress and cardiovascular damage. <b>2021</b> , 5, 322-326	1
780	Antibiotic stewardship algorithm to rationalise antibiotic use among hospitalised COVID-19 patients. <b>2021</b> , 50, 366-368	
779	A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. <b>2021</b> , 11, 8562	57
778	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <b>2021</b> , 3, e253-e261	75
777	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. <b>2021</b> , 2021, 6631721	11
776	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. <b>2021</b> , 384, 1503-1516	374
775	Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. <b>2021</b> , 1	11
774	Cardiovascular Risk Assessment after COVID-19 Infection before Resuming Sports Activities - Practical Flowchart and Meta-Analysis. <b>2021</b> ,	
773	H≩lÆerleyen SARS-CoV-2 Enfeksiyonu: Olgu Sunumu. <b>2021</b> , 5, 106-109	
772	Predictors of critical COVID-19 in an Iranian population: Age and disabilities play a special role <b>2021</b> , 35, 94	1
77 <sup>1</sup>	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). <b>2021</b> , 69, 213-224	9
770	A Mini-Review on Cardiovascular and Hematological Complications of COVID-19. <b>2021</b> , 2, 204-208	
769	Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality. <b>2021</b> , 42, 313-317	11
768	IL-6 modulation for COVID-19: the right patients at the right time?. <b>2021</b> , 9,	12
767	Review: SARS-CoV-2, Cardiovascular Disease, Pathophysiology and Role of ACE2 in Cardiac Injury. 1-20	
766	Expression of Programmed Cell Death 1 (PD-1) as a Marker of T-Cell Exhaustion and Its Correlation with Interleukin-10 Serum Level in Patients with COVID-19. <b>2021</b> , 15, 650-657	1
765	Time-to-Death Longitudinal Characterization of Clinical Variables and Longitudinal Prediction of Mortality in COVID-19 Patients: A Two-Center Study. <b>2021</b> , 8, 661940	5
764	CAPRL Scoring System for Prediction of 30-day Mortality in 949 Patients with Coronavirus Disease 2019 in Wuhan, China: A Retrospective, Observational Study. <b>2021</b> , 1, 28-35	

763	Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field. <b>2021</b> , 9,	1
762	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. <b>2021</b> , 129, 33-46	11
761	Spatial analysis of the impact of urban geometry and socio-demographic characteristics on COVID-19, a study in Hong Kong. <b>2021</b> , 764, 144455	23
760	Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19. <b>2021</b> , 110, 165-171	25
759	The SARS-CoV-2 as an instrumental trigger of autoimmunity. <b>2021</b> , 20, 102792	127
758	Ruptured cerebral aneurysms in COVID-19 patients: A review of literature with case examples. <b>2021</b> , 12, 187	3
757	Evaluating sources of bias in observational studies. <b>2021</b> , 39, 604-606	1
756	Plasma microbiome in COVID-19 subjects: an indicator of gut barrier defects and dysbiosis. <b>2021</b> ,	9
755	SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney.	О
754	Post-infectious inflammatory syndrome associated with SARS-CoV-2 in a paediatric patient with Down syndrome. <b>2021</b> , 14,	
753	Cardiac complications in patients with severe COVID-19 pneumonia. <b>2021</b> , 14-17	
752	Biochemical, molecular genetic and clinical aspects of COVID-2019. <b>2021</b> , 20, 147-157	1
751	Cardiac arrest in COVID-19 myocarditis: a case report. <b>2021</b> , 16, 177-177	
750	COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes. <b>2021</b> , 896, 173930	6
749	Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients. <b>2021</b> , 21, 398	8
748	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). <b>2021</b> , 42, 5-18	1
747	Impact of corticosteroids in hospitalised COVID-19 patients. <b>2021</b> , 8,	13
746	Health and Institutional Risk Factors of COVID-19 Mortality in Mexico, 2020. <b>2021</b> , 60, 471-477	6

745	Genetics Insight for COVID-19 Susceptibility and Severity: A Review. <b>2021</b> , 12, 622176	34
744	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. <b>2021</b> , 42, 312-322	35
743	Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality. <b>2021</b> , 21, 342	11
742	Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. <b>2021</b> , 5, 388-402	26
741	SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. <b>2021</b> , 13,	59
740	Importance of Shared Decision Making for Return to Play After COVID-19. <b>2021</b> , 143, 1733-1734	2
739	Biobehavioral Aspects of the COVID-19 Pandemic: A Review. <b>2021</b> , 83, 309-321	9
738	Projecting COVID-19 disease severity in cancer patients using purposefully-designed machine learning. <b>2021</b> , 21, 391	3
737	The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. <b>2021</b> , 12, 633292	1
736	The Impact of COVID-19 Patients With Troponin Elevation on Renal Impairment and Clinical Outcome. <b>2021</b> , 33, 45-48	O
735	Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. <b>2021</b> , 11, 11234	5
734	SARS-CoV-2, Endothelial Dysfunction, and the Renin-Angiotensin System (RAS): A Potentially Dangerous Triad for the Development of Pre-Eclampsia. <b>2021</b> , 2, 95-106	3
733	Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging. <b>2021</b> , 1, 535-549	4
732	Cardiovascular Impacts on COVID-19 Infected Patients. <b>2021</b> , 8, 670659	4
731	The role of IL-6 and IL-6 blockade in COVID-19. <b>2021</b> , 17, 601-618	10
730	Invasive Fungal Sinusitis in Post COVID-19 Patients: A New Clinical Entity. <b>2021</b> , 131, 2652-2658	33
729	Post-COVID-19 Massive Hemoptysis and Gastrointestinal Bleeding: A Case Report. <b>2021</b> , 8,	
728	A descriptive and validation study of a predictive model of severity of SARS-COV-2 infection. <b>2021</b> , 2, 390-398	

727	Artificial intelligence as a fundamental tool in management of infectious diseases and its current implementation in COVID-19 pandemic. <b>2021</b> , 28, 40515-40532	4
726	Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan. <b>2021</b> , 16, e0249655	
725	COVID-19: breaking down a global health crisis. <b>2021</b> , 20, 35	43
724	Uncurtaining the effect of COVID-19 in diabetes mellitus: a complex clinical management approach. <b>2021</b> , 28, 35429-35436	2
723	Prediction of Mortality, Hospitalization and Mechanical Ventilation Need of Patients with Pneumonia in COVID-19 Outbreak.	
722	Extracorporeal membrane oxygenation in COVID-19 patients and in-hospital mortality: results from the Brazilian Registry using a propensity score matched analysis.	
721	Risk factors associated with the need for oxygen therapy in patients with COVID-19. <b>2021</b> , 100, e25819	О
720	The association between the CT severity index and the pulmonary artery area in COVID-19 pneumonia <b>2022</b> , 2841851211070491	
719	Osteopathische Behandlungsaspekte bei COVID-19. <b>2022</b> , 20, 30-35	
718	Repurposing of Mycobacterium indicus pranii for the severe form of COVID -19 patients in India: A cohort study <b>2021</b> ,	4
717	Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial <b>2022</b> ,	6
716	Inflammation and mortality in COVID-19 hospitalized patients with and without type 2 diabetes <b>2022</b> ,	1
715	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection <b>2022</b> , 29, 1	17
714	Prognostic factors for predicting severity and mortality in hospitalized COVID-19 patients <b>2022</b> , e24216	3
713	Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination.	O
712	Development of severity and mortality prediction models for covid-19 patients at emergency department including the chest x-ray. <b>2022</b> ,	O
711	Arrhythmias in the COVID-19 Patient <b>2022</b> ,	О
710	COVID-19 Outcomes in Patients Hospitalised with Acute Myocardial Infarction (AMI): A Protocol for Systematic Review and Meta-Analysis. <b>2022</b> , 2, 138-147	1

709	Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study <b>2021</b> , 12, 738532	0
708	CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects <b>2021</b> , 12, 755891	1
707	SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report <b>2022</b> , 101, e28722	1
706	COV-ECGNET: COVID-19 detection using ECG trace images with deep convolutional neural network <b>2022</b> , 10, 1	10
705	The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy <b>2022</b> , 13, 791922	0
704	SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics <b>2022</b> ,	1
703	A New Scoring Model to Diagnose COVID-19 Using Lung Ultrasound in the Emergency Department. <b>2022</b> , 16,	
702	Oxigenacifi con membrana extracorpfiea en el paciente COVID-19: resultados del Registro Espa <del>l</del> l ECMO-COVID de la Sociedad Espa <del>l</del> la de Cirugli Cardiovascular y Endovascular. <b>2022</b> , 29, 89-102	
701	Palladium-Catalysed Intermolecular Direct CH Bond Arylation of Heteroarenes with Reagents Alternative to Aryl Halides: Current State of the Art. <b>2022</b> , 26,	
700	Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac Injuries 2022,	1
699	Cardiac complications in a geriatric population hospitalized with COVID-19: The OCTA-COVID cohort <b>2022</b> ,	0
698	Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function <b>2022</b> , 231, 153782	6
697	The Use of Intermittent Non-Invasive Ventilation as an Alveolar Recruitment Method for Patient with Severe COVID-19 Pneumonia. <b>2022</b> , 3, 54-58	
696	Diabetes Mellitus and COVID19. 2022, 305-328	
695	Overview of Cytokines and CoViD19. <b>2022</b> , 113-132	
694	Covid-19 and leptospirosis, pulmonary involvement and response to steroids: A comparative observational study from a rural Tertiary care center in Kerala <b>2022</b> , 11, 294-298	O
693	Indications for imaging studies in SARS-CoV-2 infected patients - recommendations of the Polish Medical Society of Radiology <b>2022</b> , 87, e63-e68	O
692	Myocardial Injury in CoViD19. <b>2022</b> , 217-242	

691	Predictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study <b>2022</b> ,	1
690	Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis <b>2022</b> , 12, 15	1
689	The impact of COVID-19 on the comorbidities: A review of recent updates for combating it 2022,	10
688	The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury: State-of-the-Art Review <b>2022</b> ,	8
687	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations <b>2022</b> , 13, 801522	11
686	Nanotechnology Toolkit for Combating COVID-19 and Beyond <b>2022</b> , 8, e202100505	1
685	Intravenous vitamin C use and risk of severity and mortality in COVID-19: A systematic review and meta-analysis <b>2022</b> ,	5
684	Reduced ADAMTS13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19; A Retrospective Observational Study <b>2022</b> ,	O
683	COVID-19 Infection and Incidence of Myocarditis: A Multi-Site Population-Based Propensity Score-Matched Analysis <b>2022</b> , 14, e21879	О
682	Ectopia cordis in an adult patient with COVID-19: A case report and literature review 2022, 10, e05389	3
681	Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients <b>2022</b> , 8, e1292	2
680	Association of ventilator type with hospital mortality in critically ill patients with SARS-CoV2 infection: a prospective study <b>2022</b> , 12, 10	O
679	Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy <b>2022</b> , 232, 114175	4
678	The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19 <b>2022</b> , 294, 120392	O
677	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit <b>2021</b> , 40, 923-928	O
676	Biventricular myocardial function in Covid-19 recovered patients assessed by speckle tracking echocardiography: a prospective cohort echocardiography study <b>2021</b> , 1	2
675	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <b>2021</b> ,	3
674	Increased Use of Antibiotics in the Intensive Care Unit During Coronavirus Disease (COVID-19) Pandemic in a Brazilian Hospital <b>2021</b> , 12, 778386	6

673	Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis. <b>2021</b> , 11, 4994-500	5
672	Mucormycosis of the bones of the facial skull, nasal cavity and par anasal sinuses in patients with COVID19. <b>2021</b> , 23, 347-358	3
671	COVID-19 and Extracorporeal Membrane Oxygenation <b>2021</b> , 1353, 173-195	3
670	Cytokine Storm and Failed Resolution in COVID-19: Taking a Cue from Multiple Sclerosis <b>2021</b> , 1352, 211-222	
669	The Antioxidant Arsenal Against COVID-19. <b>2021</b> , 327-357	
668	Use of corticosteroid hormones in patients with moderate COVID-19: what goals can be achieved. <b>2021</b> , 26, 23-36	
667	A Review on CRP Analysis and Obesity Influence in the Disparity of COVID-19 Pandemic. <b>2022</b> , 13, 48-55	
666	COVID-19 INFECTION AND AUTOIMMUNE REACTIONS. <b>2022</b> , 68, 87-92	О
665	Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study <b>2022</b> , 31, e18	О
664	Effect of COVID-19 on cardiorenal axis: known or unknown universe?. <b>2022</b> , 55, e11932	
663	Prognostic value of HFPEF score in COVID-19 2022, 13, 100111	
662	EFFICACY AND SAFETY OF REMDESIVIR IN INDIAN PATIENTS WITH MODERATE TO SEVERE COVID-19: RESULTS FROM THE OPEN LABEL PERIOD OF A PHASE II, RANDOMIZED CONTROLLED TRIAL. <b>2022</b> , 64-70	
661	Clinical and hematological characteristics of 300 COVID-19 patients in Erbil, Kurdistan Region, Iraq <b>2022</b> , 36, 3946320221085465	
660	RT- PCR Testing of Nasopharyngeal Samples for Diagnosis of SARS-CoV-2: Between Justification and Overestimation, a Multi-Center International Study.	
659	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants <b>2022</b> , 11,	4
658	COVID-19 and cancer: start the resolution!. <b>2022</b> , 41, 1	1
657	Microalgae pigments as a promising immunomodulating food ingredient: In silico study. <b>2022</b> , 998, 012056	1
656	Postoperative mortality in the COVID-positive hip fracture patient, a systematic review and meta-analysis <b>2022</b> , 1	1

655	Can help control cytokine storm in COVID-19?. <b>2022</b> ,	1
654	[Clinical characteristics and risk factors for mortality on admission in patients with heart failure hospitalized due to COVID-19 in Spain] <b>2022</b> , 222, 299-299	
653	Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects <b>2022</b> , 13, 856327	1
652	Factors Possibly Associated with Mortality in Intubated COVID-19 Patients: A Retrospective Study <b>2022</b> , 11,	
651	Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study <b>2022</b> , 22, 184	2
650	Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP) <b>2022</b> , 14,	2
649	Using a Systems Approach to Explore the Mechanisms of Interaction Between Severe Covid-19 and Its Coronary Heart Disease Complications <b>2022</b> , 9, 737592	
648	Increased Circulating Cytokines Have a Role in COVID-19 Severity and Death With a More Pronounced Effect in Males: A Systematic Review and Meta-Analysis <b>2022</b> , 13, 802228	3
647	Prevalence Estimates and Risk Factors of Anxiety among Healthcare Workers in Jordan over One Year of the COVID-19 Pandemic: A Cross-Sectional Study <b>2022</b> , 19,	2
646	Maternal Immune Activation and Interleukin 17A in the Pathogenesis of Autistic Spectrum Disorder and Why It Matters in the COVID-19 Era <b>2022</b> , 13, 823096	1
645	Case Report: Myocarditis After COVID-19 Vaccination - Case Series and Literature Review <b>2022</b> , 9, 836620	2
644	Tocilizumab and COVID-19: Timing of Administration and Efficacy <b>2022</b> , 13, 825749	2
643	Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease 2022,	
642	Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults <b>2022</b> , 9, ofac027	O
641	COVID-19 pathophysiology and ultrasound imaging: A multiorgan review 2022,	1
640	Significance of Cardiac Troponins as an Identification Tool in COVID-19 Patients Using Biosensors: An Update <b>2022</b> , 9, 821155	1
639	Assessment of the clinical and laboratorial profile of patients with obesity and asymptomatic COVID-19 undergoing bariatric surgery in Brazil <b>2022</b> , 32, 1064	
638	Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection <b>2022</b> , 13, 833310	Ο

637	Cardiovascular drugs and analysis of potential risk factors associated with mortality in severe coronavirus disease 2019 patients <b>2022</b> , 68, 176-182	
636	Multivariable analysis of clinical and laboratory data manifestations predicting severity and mortality risk in patients with Coronavirus disease 2019 in the mountainous west of Iran: a retrospective single-center study. <b>2022</b> , 16, 31-42	
635	Specialized interferon action in COVID-19 <b>2022</b> , 119,	7
634	Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection <b>2022</b> , 13, 1018	5
633	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. <b>2022</b> ,	2
632	Comparison of the clinical parameters of patients with COVID-19 and influenza using blood test data: a retrospective cross-sectional survey <b>2022</b> , 50, 3000605221083751	2
631	Novel prognostic determinants of COVID-19-related mortality: A pilot study on severely-ill patients in Russia <b>2022</b> , 17, e0264072	1
630	A Review of the Role of Imaging Modalities in the Evaluation of Viral Myocarditis with a Special Focus on COVID-19-Related Myocarditis <b>2022</b> , 12,	5
629	Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial <b>2022</b> , 9, 819621	Ο
628	Presentation and Outcomes of Patients With End-Stage Kidney Disease Hospitalized With COVID-19 at a Tertiary Center in Riyadh, Kingdom of Saudi Arabia <b>2022</b> , 14, e23575	
627	One-Year Cognitive Follow-Up of COVID-19 Hospitalized Patients 2022,	4
626	Comparison of the Characteristics, Management, and Outcomes of STEMI Patients Presenting With vs. Those of Patients Presenting Without COVID-19 Infection: A Systematic Review and Meta-Analysis <b>2022</b> , 9, 831143	2
625	Increased ACE2, sRAGE, and immune activation, but lowered calcium and magnesium in COVID-19 <b>2022</b> ,	0
624	High serum nitrates levels in non-survivor COVID-19 patients <b>2022</b> , 46, 132-139	O
623	Characteristics of a COVID-19 Cohort With Large Vessel Occlusion: A Multicenter International Study <b>2022</b> , 90,	0
622	Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers <b>2022</b> , 13, 848886	6
621	RAGE has potential pathogenetic and prognostic value in non-intubated hospitalized patients with COVID-19 <b>2022</b> ,	0
620	ASSESSMENT OF DEPENDENCY-ASSOCIATED FINANCIAL BURDEN OF COVID-19 MORTALITIES. 130-133	

619	Comparison of machine learning models for coronavirus prediction. <b>2022</b> , 22, 67-75	1
618	Viruses, periodontitis, and comorbidities 2022,	2
617	Biomarkers Associated with Cardiovascular Disease in COVID-19 <b>2022</b> , 11,	1
616	Dietary factors and low grade inflammation in relation to overweight and obesity revisted 2022, 1-9	Ο
615	Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications <b>2022</b> , 1-8	0
614	[CRP apheresis in acute myocardial infarction and COVID-19] <b>2022</b> , 117, 191	O
613	COVID-19 hastalarāda k <del>r̃mžīh</del> dre da <del>lī</del> m genillīl/ albīhin oranīve laktat dehidrogenaz dīdeyinin prognostik rollī38-43	
612	COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities <b>2022</b> , 101186	1
611	WHO prequalified tocilizumab and vaccine boosters against COVID-19 - Correspondence <b>2022</b> , 106593	
610	Pericardial Effusion in COVID-19 Patients <b>2022</b> ,	O
609	Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required <b>2022</b> , 11, 107-110	
609		0
	and therapeutic strategy is required <b>2022</b> , 11, 107-110  Neutrophil-to-Lymphocyte Ratio as a Predictor of Disease Severity and Mortality in Coronavirus	
608	and therapeutic strategy is required <b>2022</b> , 11, 107-110  Neutrophil-to-Lymphocyte Ratio as a Predictor of Disease Severity and Mortality in Coronavirus Disease 2019: Prospective Study From Central India <b>2022</b> , 14, e23696	O
608	and therapeutic strategy is required 2022, 11, 107-110  Neutrophil-to-Lymphocyte Ratio as a Predictor of Disease Severity and Mortality in Coronavirus Disease 2019: Prospective Study From Central India 2022, 14, e23696  Linking genomic and epidemiologic information to advance the study of COVID-19 2022, 9, 121  Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with	0
608 607 606	Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19 2022, 13, 1589  When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation	0 0 3
608 607 606	Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19 2022, 13, 1589  When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA 2022, 1	o o 3

601	Hydro-ethanol extract of Holarrhena floribunda stem bark exhibits anti-anaphylactic and anti-oedematogenic effects in murine models of acute inflammation <b>2022</b> , 22, 80	
600	COVID-19 associated EBV reactivation and effects of ganciclovir treatment <b>2022</b> , 10, e597	5
599	Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm <b>2022</b> , 13, 853496	О
598	Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19 <b>2022</b> , 5, e223890	4
597	Mortality in patients with COVID-19 requiring extracorporeal membrane oxygenation: A meta-analysis <b>2022</b> , 10, 2457-2467	
596	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: A Phase 2/3, Multicenter, Randomized, Open-label, Controlled Trial <b>2022</b> , AAC0204521	1
595	Transcriptome Analysis of Lungs in a Mouse Model of Severe COVID-19. <b>2022</b> , 2,	0
594	Poverty, noncommunicable diseases, and perceived health risks among older adults during the COVID -19 pandemic in urban Thailand.	O
593	Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine <b>2022</b> ,	
592	Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial <b>2022</b> , 30, 477	3
591	Epidemiological, Radiographical, and Laboratorial Characteristics of Chinese Asymptomatic Cases With COVID-19: A Systematic Review and Meta-Analysis <b>2022</b> , 10, 808471	0
590	Cytokine Adsorption in Critically Ill COVID-19 Patients, a Case-Control Study <b>2022</b> , 8850666221085185	O
589	Extracorporeal haemoadsorption: does the evidence support its routine use in critical care?. 2021,	3
588	Retrospective Observational Analysis of Inflammatory Markers in COVID-19 Patients Admitted to Intensive Care Unit: As Early Predictors of Disease Severity. <b>2022</b> , 26, 482-486	1
587	The role of serum lipoprotein levels in predicting independent short-term mortality In COVID-19 patients. <b>2022</b> , 4, 162-166	2
586	CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses <b>2022</b> ,	2
585	More severe pneumonitis in children predicts the need for admission and elevation of some but not all markers of severe Covid-19.	
584	Factors for success of awake prone positioning in patients with COVID-19-induced acute hypoxemic respiratory failure: analysis of a randomized controlled trial <b>2022</b> , 26, 84	2

583	Data Analysis of COVID-19 Hospital Records Using Contextual Patient Classification System. 1	0
582	Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19 <b>2022</b> , 13, 830715	o
581	Therapeutic Potential of the Purinergic System in Major Depressive Disorder Associated with COVID-19 <b>2022</b> , 1	О
580	Cytokine and chemokine profile in patients hospitalized with COVID-19: A comparative study.	O
579	COVID-19 and myocarditis: a review of literature <b>2022</b> , 74, 23	4
578	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. <b>2022</b> , 1,	О
577	Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach 2022,	4
576	Decoding clinical biomarker space of COVID-19: Exploring matrix factorization-based feature selection methods <b>2022</b> , 146, 105426	5
575	Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19?. <b>2021</b> , 79,	
574	Changes in hematological and other laboratory parameters in COVID-19 infection. 1-8	
573	Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Management of COVID19-Associated Lung Injury: A Review on Publications, Clinical Trials and Patent Landscape <b>2022</b> , 1	1
572	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections <b>2022</b> , 13, 832394	4
571	Therapeutic Potential Of Induced Iron Depletion Using Iron Chelators In Covid-19 2021,	2
570	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression <b>2022</b> , 8, e09230	1
569	Role of Cardiac Imaging Modalities in the Evaluation of COVID-19-Related Cardiomyopathy <b>2022</b> , 12,	1
568	Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial <b>2022</b> , 26, 101	1
567	The relationship of laboratory parameters and rates with prognosis and mortality in COVID-19 infection.	О
566	Mutational Analysis of Interleukin-11 and its Consequences on Cancer and COVID-19 Related Cytokine Storm -An Extensive Molecular Dynamics Study <b>2022</b> ,	

565	COVID-19 Risk Prediction for Diabetic Patients Using Fuzzy Inference System and Machine Learning Approaches <b>2022</b> , 2022, 4096950	3
564	Measurement of Tracheobronchial Angles of COVID-19 Patients on Computed Tomography and Correlation with Pneumonia Severity in Turkish Population.	
563	Differential transcriptomic landscapes of multiple organs from SARS-CoV-2 early infected rhesus macaques <b>2022</b> , 1	1
562	Electrocardiographic findings and mortality in covid-19 patients hospitalized in different clinical settings <b>2022</b> , 53, 99-103	O
561	Leukoerythroblastosis - An unsusal presentation of COVID 19 infection 2022, 101026	0
560	Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms <b>2022</b> , 20, 61-71	1
559	Fungal and bacterial co-infections of the respiratory tract among patients with COVID-19 hospitalized in intensive care units <b>2022</b> , 27, 101588	О
558	Genetic and non-genetic risk factors associated with atrial fibrillation <b>2022</b> , 299, 120529	O
557	Brief psychotic disorder occurring after Covid-19 in a patient with no history of psychiatric diseases - a case report. <b>2021</b> , 22, 187-192	
556	ELEVATED INTERLEUKIN® AND FERRITIN LEVELS EXACERBATE SEVERITY OF 2019 NOVEL CORONAVIRUS DISEASE (COVID-19): A PILOT STUDY. <b>2021</b> , 16-19	
555	[Acute myocardial infarction and cardiogenic shock in patient with COVID-19]. 2021, 61, 104-107	
554	Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA 2021,	O
553	COVID-19 and thrombotic microangiopathy. <b>2022</b> , 15, 639-657	1
552	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <b>2021</b> , 1, 216-234	O
551	COVID-19 and RAAS inhibitors: is there a final conclusion?. <b>2021</b> , 13, 728-736	1
550	Coronavirus Disease 2019 (COVID-19): Emerging detection technologies and auxiliary analysis. <b>2021</b> , e24152	3
549	Periodontal Disease: The Good, The Bad, and The Unknown <b>2021</b> , 11, 766944	13
548	Comparison of IL-6 measurement methods with a special emphasis on COVID-19 patients according to equipment and sample type <b>2021</b> , e24182	1

547	Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease <b>2021</b> , 11, 23874	2
546	Role of neutrophil to lymphocyte ratio as a prognostic indicator for COVID-19 2021, 4, e442	O
545	Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects <b>2021</b> , 8, 785738	4
544	Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. <b>2021</b> , 61, 155	4
543	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19 <b>2021</b> , 10,	0
542	Correlation between nongenomic action of C19-steroids and COVID-19 severity <b>2021</b> , 70, S135-S144	1
541	National Early Warning Score 2 (NEWS2) to predict poor outcome in hospitalised COVID-19 patients in India <b>2021</b> , 16, e0261376	О
540	Safety and Efficacy of Tocilizumab 4 or 8´mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial <b>2022</b> , 9, ofab608	2
539	Predictors of mortality in COVID-19 patients at Kinshasa Medical Center and a survival analysis: a retrospective cohort study <b>2021</b> , 21, 1272	О
538	Soluble immune checkpoints are dysregulated in COVID-19 and heavy alcohol users with HIV infection.	
537	New onset of generalized myasthenia gravis developed after a new coronavirus infection (COVID-19). <b>2021</b> , 13, 127-132	1
536	Ferritina como biomarcador en pacientes hospitalizados con sospecha de COVID-19. <b>2021</b> , 71, e97180	
535	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021</b> ,	3
534	COVID-19 and the differences in physiological background between children and adults and their clinical consequences <b>2021</b> , 70, S209-S225	1
533	Can the immune system be targeted to treat COVID-19?. <b>2021</b> , 69-85	Ο
532	The outcomes of patients with diabetes mellitus in The Philippine CORONA Study <b>2021</b> , 11, 24436	2
531	Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study <b>2021</b> , 12, 791348	2
530	Characteristics of Elderly Patients Who Require Oxygen Therapy. <b>2021</b> , 22, 75-85	

529 Standard Coagulation Tests in COVID-19. **2022**, 13-29

528	Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment <b>2022</b> , 28, 3-11	O
527	Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study <b>2021</b> , 29, 538-549	1
526	Shock Index in COVID Era. <b>2021</b> , 05, 268-272	O
525	Frequency and antimicrobial resistance pattern of bacterial isolates from patients with COVID-19 in two hospitals of Zanjan <b>2021</b> , 13, 769-778	0
524	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19 <b>2021</b> ,	2
523	Myocardial damage in new coronavirus infection (review). <b>2021</b> , 129-145	0
522	Extracorporeal membrane oxygenation outcomes in COVID-19 patients: Case series from the Brazilian COVID-19 Registry <b>2021</b> ,	
521	Concomitant diseases in COVID-19 and their impact on the risks of adverse outcomes. <b>2021</b> , 102, 843-854	
520	EFFECT OF COVID-19 ON CARDIOVASCULAR DISEASES ACCORDING TO LITERATURE. <b>2021</b> ,	
519	Does the initial chest radiograph severity in COVID-19 impact the short- and long-term outcome? - a perspective from India <b>2021</b> , 1-10	0
518	The early start of hemoperfusion decreases the mortality rate among severe COVID-19 patients: A preliminary study <b>2021</b> ,	2
517	COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy <b>2021</b> , 8, 737257	10
516	Effect of Underlying Cardiovascular Disease on the Prognosis of COVID-19 Patients; a Sex and Age-Dependent Analysis. <b>2021</b> , 9, e65	1
515	Miocarditis por COVID-19. <b>2022</b> , 35, 22-25	
514	Impact of the Kidney Transplantation Moratorium in France Because of the COVID-19 Pandemic: A Cohort-Based Study.	
513	Factores de riesgo para lesili renal aguda y terapia de reemplazo renal en pacientes con ventilacili meclica invasiva y COVID-19. <b>2022</b> , 36, 22-30	
512	Impact of lymphopenia on COVID-19 infection severity. <b>2022</b> , 19, 99	

# (2020-2022)

511	Prognostic implications of serial high-sensitivity cardiac troponin testing among patients with COVID-19: A Danish nationwide registry-based cohort study <b>2022</b> , 14, 100131	O
510	Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons 2022, 11,	O
509	Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients <b>2022</b> , 13, 842232	Ο
508	Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS COV-2 Delta variant dominant period and their clinical characteristics <b>2022</b> ,	3
507	Renal tubular dysfunction in COVID-19 patients <b>2022</b> ,	1
506	Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19 <b>2022</b> , 22, 366	O
505	Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients <b>2022</b> , 14,	О
504	Epidemiological and clinical and laboratory features of COVID-19 in pediatric patients. <b>2022</b> , 12, 63-76	
503	Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction <b>2022</b> , 10,	O
502	Herpes Zoster in the era of COVID 19: A prospective observational study to probe the association of herpes zoster with COVID 19 infection and vaccination <b>2022</b> , e15521	2
501	Pre-Pandemic Dietary Assessment of Elderly Persons Residing in Nursing HomesBilesia (Poland). <b>2022</b> , 10, 765	
500	A Comprehensive Review on the Management of COVID-19-Associated Mucormycosis (CAM): The New Basics. <b>2022</b> , 2, 181-198	1
499	The effectiveness of dexamethasone as a combination therapy for COVID-19. <b>2022</b> , 72, 345-358	1
498	A Comparison of XGBoost, Random Forest, and Nomograph for the Prediction of Disease Severity in Patients With COVID-19 Pneumonia: Implications of Cytokine and Immune Cell Profile <b>2022</b> , 12, 819267	O
497	Patterns of presentation, prevalence and associated factors of mortality in ICU among adult patients during the pandemic of COVID 19: A retrospective cross-sectional study <b>2022</b> , 77, 103618	O
496	Table_1.pdf. <b>2020</b> ,	
495	Table_1.DOCX. <b>2020</b> ,	
494	Table_2.DOCX. <b>2020</b> ,	

Table\_3.DOCX. 2020, 493 Table\_4.DOCX. 2020, 492 Data\_Sheet\_1.PDF. 2020, 491 1 Data\_Sheet\_1.docx. 2021, 490 Data\_Sheet\_1.pdf. 2020, 489 488 Data\_Sheet\_1.docx. 2020, 487 Table\_1.docx. 2020, Table\_1.DOCX. **2020**, 486 Data\_Sheet\_1.PDF. 2021, 485 484 Data\_Sheet\_2.PDF. 2021, Data\_Sheet\_3.PDF. 2021, 483 Table\_1.docx. 2020, 482 481 Table\_2.DOCX. 2020, 480 Table\_3.DOCX. 2020, Table\_1.docx. 2020, 479 478 Image\_1.pdf. **2021**, Table\_1.docx. 2021, 477 DataSheet\_1.pdf. 2020, 476

475	DataSheet_1.docx. <b>2020</b> ,	
474	DataSheet_1.pdf. <b>2020</b> ,	
473	Data_Sheet_1.PDF. <b>2020</b> ,	
472	RT- PCR testing of upper respiratory tract samples for diagnosis of SARS-CoV-2: Between justification and overestimation, a multi-center international study <b>2022</b> , 102334	O
471	The immune response to COVID-19: Does sex matter?. <b>2022</b> ,	2
470	External validation of the 4C Mortality Score for hospitalised patients with COVID-19 in the RECOVER network <b>2022</b> , 12, e054700	1
469	JAK inhibitors and COVID-19 <b>2022</b> , 10,	4
468	Potential relationships between COVID-19 and the thyroid gland: an update <b>2022</b> , 50, 3000605221082898	2
467	Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review <b>2022</b> , 13, 813358	3
466	Cardiovascular Complications and its Impact on outcomes in COVID-19: An Original Research <b>2021</b> , 13, S1333-S1337	
465	An analysis of hematological, coagulation and biochemical markers in COVID-19 disease and their association with clinical severity and mortality: an Indian outlook <b>2021</b> , 11, 580-591	
464	Therapeutic Potential of Flavonoids and Zinc in COVID-19 <b>2022</b> , 1,	
463	Cytokine storm and stem cell activation in unveiling potential targets for diagnosis and therapy. <b>2022</b> , 59-70	
462	OUP accepted manuscript.	O
461	Methylene blue treatment for moderate-to-severe cases of acute respiratory syndrome due to COVID-19 infection: clinical outcomes prospective study. <b>2022</b> , 9, 25	
460	Spectrum of herpetic eye disease during COVID-19 pandemic. <b>2022</b> , 34, 47	
459	Homocysteinemia and Viral Infection with Special Emphasis on COVID-19. 2022, 241-256	
458	Does being infected with SARS-CoV-2 in the first-trimester increase the risk of miscarriage?. <b>2022</b> , 94, e20211283	

Therapeutic scale stem cell-derived exosomes for COVID-19: Models Validation, management, 457 and strategies. 2022, 153-168 Associations and Disease Disease Interactions of COVID-19 with Congenital and Genetic Disorders: 456 A Comprehensive Review. 2022, 14, 910 Biomarker based biosensors: An opportunity for diagnosis of COVID-19.. 2022, e2356 455 1 Association of Septic Shock with Mortality in Hospitalized COVID-19 Patients in Wuhan, China.. **2022**, 2022, 3178283 Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian 453 0 hamsters.. 2022. 7. 49 Comparative Analysis of Long Non-Coding RNA Expression and Immune Response in Mild and 452 Severe COVID-19.. 2022, 9, 835590 SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach O 451 with Valproic Acid: A Review. 2022, 10, 962 Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: where we 450 stand and challenges ahead. 2022, COVID-19 Clinical Profiles and Fatality Rates in Hospitalized Patients Reveal Case Aggravation and 1 449 Selective Co-Infection by Limited Gram-Negative Bacteria.. 2022, 19, 448 Clinical challenges of SARS-CoV-2 variants (Review). 2022, 23, 1 Cardiac complications in patients with COVID-19: a systematic review. 2022, 2, 447 1 Can Selenium Reduce the Susceptibility and Severity of SARS-CoV-2?-A Comprehensive Review.. 2022, 23, Extensive Study on Hematological, Immunological, Inflammatory Markers, and Biochemical Profile 445 1 to Identify the Risk Factors in COVID-19 Patients. 2022, 2022, 1-11 Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 444 pandemic.. 2022, 13, 84-100 Association between hypertension and prognosis of patients with COVID-19: A systematic review  $\circ$ 443 and meta-analysis.. 2022, 1-8 Real-Time Prediction of Mortality, Cardiac Arrest and Thromboembolic Complications in 442 Hospitalized Patients with COVID-19. 2022, 100043 Longer length of stay, days between discharge/first readmission, and pulmonary involvement 80% increase prevalence of admissions in ICU in unplanned readmissions after COVID-19 441 O hospitalizations.. 2022, The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy.. 2022, 29, 27

439	The Impact of a Post-Prescription Review and Feedback Antimicrobial Stewardship Program in Lebanon. <b>2022</b> , 11, 642	1
438	EVALUATION OF SERUM LEVELS OF IL-6 AND ADIPONECTIN IN COVID-19 PATIENTS AND THEIR RELATIONSHIP WITH DISEASE SEVERITY.	
437	COVID-19: Main findings after a year and half of unease and the proper scientific progress (Review). <b>2022</b> , 23,	Ο
436	COVID-19 and the role of cytokines in this disease <b>2022</b> , 1	4
435	COVID-19 outcomes among rheumatic disease patients in Kuwait: Data from the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry <b>2022</b> ,	
434	Clinical characteristics and risk factors for mortality on admission in patients with heart failure hospitalized due to COVID-19 in Spain <b>2022</b> , 222, 299-300	
433	A cytokine panel and procalcitonin in COVID-19, a comparison between intensive care and non-intensive care patients <b>2022</b> , 17, e0266652	2
432	The Pathophysiology of Long COVID throughout the Renin-Angiotensin System <b>2022</b> , 27,	3
431	Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19. <b>2022</b> , 13,	0
430	Cardiovascular manifestations secondary to COVID-19: A narrative review <b>2022</b> , 81, 100904	O
429	Correlation of Serum Ferritin, Vitamin D Levels, and Severity of Clinical Symptoms in Patients with COVID-19. <b>2022</b> , 8,	
428	Prognostic performance of shock index, diastolic shock index, age shock index and modified shock index in COVID 19 pneumonia <b>2022</b> , 1-19	O
427	Socioeconomic status and COVID-19-related cases and fatalities in the world: A cross-sectional ecological study <b>2022</b> , 5, e628	0
426	Low dose whole lung irradiation for treatment of COVID-19 pneumonia: A systematic review and meta-analysis <b>2022</b> ,	1
425	Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak - 2021 <b>2022</b> , 32, 100420	
424	Artificial intelligence approach toward analysis of COVID-19 development <b>P</b> ersonalized and epidemiological model. <b>2022</b> , 237-269	
423	Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination <b>2022</b> ,	0
422	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial <b>2022</b> , 23, 401	1

421	Low Oxygen Saturation of COVID-19 in Patient Case Fatalities, Limpopo Province, South Africa. <b>2022</b> , 2, 77-86	О
420	The Role of Zinc and Copper in Platelet Activation and Pathophysiological Thrombus Formation in Patients with Pulmonary Embolism in the Course of SARS-CoV-2 Infection. <b>2022</b> , 11, 752	1
419	Outcome and Complications of Hemoperfusion in Patients with COVID-19 in Intensive Care Unit: A Cross-Sectional Study <b>2022</b> ,	0
418	Comparison of Pneumonia Severity Indices, qCSI, 4C-Mortality Score and qSOFA in Predicting Mortality in Hospitalized Patients with COVID-19 Pneumonia. <b>2022</b> , 12, 801	1
417	How do people get information for COVID-19 according to age groups?. <b>2022</b> ,	
416	Clinical features, laboratory characteristics and risk factors for mortality of COVID-19 patients in a secondary hospital in Oman during the first wave of the SARS-CoV-2 pandemic. <b>2022</b> , 46,	1
415	Endothelialitis, Microischemia, and Intussusceptive Angiogenesis in COVID-19 2022,	2
414	Docosahexaenoic acid ester of phloridzin reduces inflammation and insulin resistance via AMPK <b>2022</b> ,	O
413	The Relationship Between Hepcidin-Mediated Iron Dysmetabolism and COVID-19 Severity: A Meta-Analysis <b>2022</b> , 10, 881412	1
412	Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. <b>2022</b> , 103114	1
411	Immunopathogenesis and immunogenetic variants in COVID-19. <b>2022</b> , 28,	0
410	High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2. 1-8	O
409	Forecasting the recovery period of air passenger transportation by using vector error correction model.	1
408	Anxiolytic Effect of Anthemis Nobilis L. (Roman Chamomile) and Citrus Reticulata Blanco (Tangerine) Essential Oils Using the Light-Dark Test in Zebrafish (Danio Rerio).	O
407	Infections and spinal cord injury: Covid-19 and beyond. <b>2022</b> , 131-146	
406	The Effectiveness of Rehabilitation in a Day Hospital for Patients Previously Suffered from Covid Pneumonia. <b>2022</b> , 21, 6-16	1
405	Brain Biomarkers in Patients with COVID-19 and Neurological Manifestations: A Narrative Review. <b>2022</b> , 09, 010-015	
404	Cardiac Imaging on COVID-19 Pandemic Era: the Stand, The Lost, and Found.	

403	Suboptimal Consumption of Relevant Immune System Micronutrients Is Associated with a Worse Impact of COVID-19 in Spanish Populations. <b>2022</b> , 14, 2254	Ο
402	Efficacy and Safety of Extracorporeal Membrane Oxygenation in Patients under Mechanical Ventilation with COVID-19 and Severe Acute Respiratory Distress Syndrome: A Health Technology Assessment. <b>2022</b> , 19, 6080	
401	Clinical characteristics of COVID-19 patients admitted to Intensive Care Unit in Panama during the first pandemic wave admissions in 2020.	
400	Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19. <b>2022</b> , 13,	
399	Early Prediction Model for Critical Illness of Hospitalized COVID-19 Patients Based on Machine Learning Techniques. <b>2022</b> , 10,	0
398	Network pharmacology and experimental validation identify the potential mechanism of sophocarpine for COVID-19. <b>2022</b> , 71,	O
397	Myeloid-Derived Suppressor Cells and Clinical Outcomes in Children With COVID-19. 2022, 10,	0
396	Cerebral venous sinus thrombosis in COVID 19 patients: report of 2 cases. <b>2022</b> , 101599	
395	Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation.	1
394	Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.	
393	Rapid surveillance of COVID-19 by timely detection of geographically robust, alive and emerging hotspots using Particle Swarm Optimizer. <b>2022</b> , 144, 102719	1
392	Molecular signaling pathways, pathophysiological features in various organs, and treatment strategies in SARS-CoV2 infection. <b>2022</b> , 124, 151908	
391	Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies. <b>2022</b> , 17, 117727192211066	5
390	Dexamethasone. <b>2022</b> , 169-179	
389	Identification of Hub Genes and Key Pathways in TNF-Band IFN-Induced Cytokine Storms via Bioinformatics. <b>2022</b> ,	O
388	Emergency room imaging findings in patients presenting after COVID-19 vaccination. 12, 33	O
387	Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson Disease Affected by COVID-19: A Narrative Review. <b>2022</b> , 12, 1543	O
386	The impact of COVID-19 on some aspects of laboratory activities.	O

385	Da <del>li</del> mioclidico como factor pronlitico en neumonii grave por SARS-CoV-2. <b>2022</b> ,	
384	Calibration and Validation of a Mechanistic COVID -19 Model for Translational Quantitative Systems Pharmacology (A Proof-of-Concept Model Development for Remdesivir.	О
383	Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes. <b>2022</b> , 27, 3651	0
382	Saliva as a Potential Specimen to Monitor IL-6, TNF-Hand IL-10 in COVID-19 Patients.	
381	Exploratory Data Analysis Recognizing Geometrical Patterns in Meta-analysis.	
<b>3</b> 80	AlveolarArterial Gradient Is an Early Marker to Predict Severe Pneumonia in COVID-19 Patients. <b>2022</b> , 14, 470-478	1
379	Post-Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention.	
378	Detection of abnormal lymphocytes in the peripheral blood of COVID-19 cancer patients: diagnostic and prognostic possibility. <b>2022</b> , 27, 745-756	Ο
377	Paraclinical Characteristics of Fatal and Recovered COVID-19 Cases: a Retrospective Study. <b>2022</b> , 10, 80-86	
376	COVID-19 pandemic in Southern Brazil: Hospitalizations, intensive care unit admissions, lethality rates, and length of stay between March 2020 and April 2022.	1
375	Bioinformatics Approach Predicts Candidate Targets for SARS-CoV-2 Infections to COPD Patients. <b>2022</b> , 2022, 1-12	
374	CRRT with Oxiris hemofilter as a new potential therapy in COVID-19: a case series. <b>2022</b> , 47, 908-909	
373	Special Issue 🗓-Reactive Protein and Cardiovascular Disease: Clinical Aspects 🗓 2022, 11, 3610	
372	Strategies to fight COVID-19: Beyond the difference between SARS-CoV-2 and Influenza virus. <b>2022</b> , 5, 016-029	
371	Can natural products modulate cytokine storm in SARS-CoV2 patients?. <b>2022</b> , 35, e00749	0
370	Laboratory predictors for COVID-19 Intensive Care Unit admissions in Trinidad and Tobago. <b>2022</b> , 1, 100022	
369	Anesthesia management in a post Covid-19 obstetric patient-What we need to know. <b>2022</b> , 38, 13	
368	A case of COVID-19 STEMI complicated by second: Degree heart block without pulmonary involvement. <b>2022</b> , 4, 33	

367	Lymphocyte count and A-DROP score in COVID-19 patients: A retrospective observational study. <b>2022</b> , 11, 115	
366	SURGICAL ISCHEMIC ASPECTS OF COVID-19: MANAGEMENT OF PATIENTS WITH COVID TOES AND FINGERS. <b>2022</b> , 75, 1439-1445	
365	Coronavirus Disease 2019 Risk Factors in Karun, Iran: A Case-Control Study. <b>2022</b> , 13, 66-68	
364	Currently available drugs for the treatment of Coronavirus-2. <b>2022</b> , 77-95	
363	Coronary Heart Disease and Coronavirus Disease 2019: Pathogenesis, Epidemiology, Association with Myocardial Revascularization. <b>2022</b> , 10, 319-325	
362	Experience with the use of combination antithrombotic therapy in a patient with acute coronary syndrome and underlying severe coronavirus infection. <b>2022</b> , 12, 60-68	
361	The prevalence and course of COVID-19 and the Cardiovascular Diseases.	
360	THE EFFECT OF COVID-19 ON MYOCARDIAL DAMAGE: A CLINICAL CASE. <b>2022</b> , 31-39	
359	Novel extreme regression-voting classifier to predict death risk in vaccinated people using VAERS data. <b>2022</b> , 17, e0270327	0
358	Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. <b>2022</b> , 100680	1
357	Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. <b>2022</b> , 13,	1
356	Dynamic of Serum TWEAK Levels in Critically Ill COVID-19 Male Patients. <b>2022</b> , 11, 3699	1
355	The Effect of Renin-Angiotensin Blockers on COVID-19 Related Mortality: A Tertiary Center's Experience. <b>2022</b> , 64, 277-281	
354	The Effect of Long Coronavirus Disease on Obesity and the Role of Korean Medicine. 2022, 22, 77-85	
353	Risk assessment in COVID-19: Prognostic importance of cardiovascular parameters.	Ο
352	COVID-19, Mucormycosis and Cancer: The Triple ThreatHypothesis or Reality?. <b>2022</b> , 12, 1119	Ο
351	Serum Ferritin as a Predictor of Outcomes in Hospitalized Patients with Covid-19 Pneumonia. 0885066622	1113 <u>/</u> 2
350	Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections. 13,	

349	Association of blood group A with hospital comorbidity in patients infected by SARS-CoV-2. <b>2022</b> , 159, 27-30	
348	Early Experience With Interleukin-6 Receptor Antagonists in Patients With COVID-19 Admitted to a Community Hospital. 875512252211043	
347	Patterns of development of cardiovascular disorders in patients with COVID-19 (brief review). <b>2022</b> , 1, 127-136	
346	Correlations between Kidney and Heart Function Bioindicators and the Expressions of Toll-Like, ACE2, and NRP-1 Receptors in COVID-19. <b>2022</b> , 10, 1106	Ο
345	International Controlled Study of Revascularization and Outcomes Following COVID-Positive Mechanical Thrombectomy.	0
344	Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study.	O
343	Associations Between 25-Hydroxyvitamin D and Total and 🛭 Fibrinogen and Plasma Clot Properties and Gene Interactions in a Group of Healthy Black South African Women. 9,	
342	Heart failure in general and cardiac transplant patients with COVID-19. <b>2022</b> , 14, 392-402	
341	Hypertension as an Independent Risk Factor for In-Patient Mortality in Hospitalized COVID-19 Patients: A Multicenter Study. <b>2022</b> ,	Ο
340	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <b>2022</b> , 11, 269-297	Ο
339	Complications of invasive mechanical ventilation in critically Ill Covid-19 patients - A narrative review. <b>2022</b> , 104201	
338	The future Landscape of macrophage research in cardiovascular disease: a bibliometric analysis. <b>2022</b> , 101311	Ο
337	Assessment of a Comparative Bayesian-Enhanced Population-Based Decision Model for COVID-19 Critical Care Prediction in the Dominican Republic Social Security Affiliates. <b>2022</b> ,	
336	In-hospital mortality prediction using frailty scale and severity score in elderly patients with severe COVID-19.	Ο
335	Obesity and COVID-19: insights from two pandemics. <b>2022</b> , 14, 27-38	1
334	Clinical progress in MSC-based therapies for the management of severe COVID-19. <b>2022</b> ,	1
333	Immunochemotherapy of refractory classical Hodgkin's lymphoma with high-dose consolidation and autologous hematopoietic stem cell transplantation complicated by a new coronavirus infection. <b>2022</b> , 17, 114-118	
332	Epidemiological and Clinical Characteristics of COVID-19 Patients in Northern Ethiopia: A Retrospective Cohort Study. Volume 15, 3579-3588	1

331	Can Iron, Zinc, Copper and Selenium status be a prognostic determinant in COVID-19 patients?. <b>2022</b> , 103937	2
330	Delayed COVID-19-induced cytokine storm after root canal therapy with favorable response to plasmapheresis, tocilizumab, and methylprednisolone pulses therapy: A case report. <b>2022</b> , 10,	
329	Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination.	O
328	An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. <b>2022</b> , 21, 123-129	
327	Macrophage Membrane-Derived Biomimetic Nanoparticles for Treatment of Cytokine Release Syndrome. <b>2022</b> , 18, 1064-1074	O
326	Biochemical laboratory findings in adult patients with coronavirus disease 2019 (COVID-19) at a university hospital in Cape Town, South Africa. <b>2022</b> , 4, 10-15	
325	Bibliometric Analysis of Health Technology Research: 1990~2020. <b>2022</b> , 19, 9044	
324	Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections. <b>2022</b> , 12, 1852	
323	Loss of smell in COVID-19 patients: is it related to clinical-radiological disease severity?. <b>2022</b> , 4, 228-233	
322	SARS-CoV-2 infection threatening intestinal health: A review of potential mechanisms and treatment strategies. 1-19	1
321	Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study. 13,	O
320	The relationship of laboratory parameters and mortality of patients followed in intensive care units with COVID-19. <b>2022</b> , 5, 1015-1022	
319	Proteomic analysis of cardiometabolic biomarkers and predictive modeling of severe outcomes in patients hospitalized with COVID-19. <b>2022</b> , 21,	
318	Machine learning approach for automated predicting of COVID-19 severity based on clinical and paraclinical characteristics: Serum levels of zinc, calcium, and vitamin D. <b>2022</b> ,	O
317	Antibiotic-Induced Primary Biles Inhibit SARS-CoV-2 Endoribonuclease Nsp15 Activity in Mouse Gut. 12,	1
316	Effects of acylhydrazone derivatives on experimental pulmonary inflammation by chemical sensitization. <b>2022</b> , 21,	
315	Risk factors for mortality among hospitalized COVID-19 patients in Northern Ethiopia: A retrospective analysis. <b>2022</b> , 17, e0271124	O
314	The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. 1-16	O

313	Dysregulation of immunity in COVID-19 and SLE.	1
312	ARDS in the Time of Corona: Context and Perspective.	
311	Humoral and cellular response in convalescent COVID-19 lupus patients. <b>2022</b> , 12,	
310	Respiratory indications for ECMO: focus on COVID-19.	4
309	Care of the Seriously Ill Patient with SARS CoV-2. <b>2022</b> ,	
308	Time to Recovery of Severely Ill COVID-19 Patients and its Predictors: A Retrospective Cohort Study in Tigray, Ethiopia. Volume 15, 1709-1718	
307	Long-Term Effects of COVID-19: A Systemic Review. <b>2022</b> , 4, 8-12	
306	Fibrinojen/Albīhin Oran <del>ññ</del> COVID-19 Hastalar <del>ññ</del> Prognozundaki De <b>ë</b> ri.	O
305	Extensive Nonsegmental Pulmonary Perfusion Defects on SPECT/CT as an Early Sign of COVID-19 Infection.	
304	Severity Predictors of COVID-19 in SARS-CoV-2 Variant, Delta and Omicron Period; Single Center Study.	
303	Two Years into the COVID-19 Pandemic: Lessons Learned.	4
302	Honey as an Adjuvant in the Treatment of COVID-19 Infection: A Review. <b>2022</b> , 12, 7800	1
301	Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study. <b>2022</b> , 11, 4903	1
300	Multisystem involvement in COVID-19: what have we learnt?. 1-5	
299	Stroke-induced changes to immune function and their relevance to increased risk of severe COVID-19 disease.	
298	Impact of high-dose vitamin C on the mortality, severity, and duration of hospital stay in COVID-19 patients: A meta-analysis. <b>2022</b> , 5,	2
297	Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise. 2022,	1
296	Network meta-analysis of deaths from various underlying diseases after COVID-19 infection. 10,	

295 Potential of ATR-FTIR© hemometrics in Covid-19: Disease Recognition.

294	Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study. <b>2022</b> ,	
293	Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.	2
292	Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis. <b>2022</b> , 23, 9141	4
291	Association between the Use of Antibiotics and the Development of Acute Renal Injury in Patients Hospitalized for COVID-19 in a Hospital in the Peruvian Amazon. <b>2022</b> , 11, 4493	
290	Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial. <b>2022</b> , 17, e0269065	Ο
289	An Update on the Mutual Impact between SARS-CoV-2 Infection and Gut Microbiota. <b>2022</b> , 14, 1774	1
288	Assessment of hypertension and other factors associated with the severity of disease in COVID-19 pneumonia, Addis Ababa, Ethiopia: A case-control study. <b>2022</b> , 17, e0273012	
287	Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study. <b>2022</b> , 11, 1078	0
286	Cardiovascular complications and predictors of mortality in hospitalized patients with COVID-19: a cross-sectional study from the Indian subcontinent. <b>2022</b> , 50,	О
285	Effects of coronavirus disease 19 on the gastrointestinal tract and the potential impact on gastrointestinal toxicities during cancer treatment. <b>2022</b> , 16, 168-173	
284	IL-6 drives T cell death to participate in lymphopenia in COVID-19. <b>2022</b> , 111, 109132	1
283	Anxiolytic effect of Anthemis nobilis L. (roman chamomile) and Citrus reticulata Blanco (tangerine) essential oils using the light-dark test in zebrafish (Danio rerio). <b>2022</b> , 298, 115580	О
282	COVID-19 is associated with the risk of cardiovascular disease death: A two-sample Mendelian randomization study. 9,	Ο
281	SARS-CoV-2 Omicron and centaurus variants induced lymphocytopenia: A multicenter clinical investigation on 118,561 cases across Pakistan during 2021-2022. <b>2022</b> , 6, 034-037	О
280	Oral Lesions Associated with COVID-19 and the Participation of the Buccal Cavity as a Key Player for Establishment of Immunity against SARS-CoV-2. <b>2022</b> , 19, 11383	Ο
279	Potential role of biochemical markers in the prognosis of COVID-19 patients. <b>2022</b> , 10, 205031212211086	О
278	Impact of Disruptive Technologies on Society to Combat Pandemics. <b>2022</b> , 195-209	O

277	Are Older People Really More Susceptible to SARS-CoV-2?. <b>2022</b> , 13, 1336	О
276	Incidence of psychiatric illness among COVID-19-positive individuals with and without loss of smell or taste symptoms in a Tertiary Care Hospital in South India [A prospective cohort study. <b>2022</b> , 6, 169	О
275	The prognostic importance of the angiotensin II/angiotensin-(1½) ratio in patients with SARS-CoV-2 infection. <b>2022</b> , 16, 175346662211225	O
274	Role of Herritin COVID-19 pneumonia: Sensitive marker of inflammation, predictor of mechanical ventilation, and early marker of post-COVID-lung fibrosis A prospective, observational, and interventional study in a tertiary care setting in India. 2022, 13, 28	O
273	Severe progression of autoimmune hepatitis in a young COVID-19 adult patient: A case report. <b>2022</b> , 11, 161	1
272	Pulmonary artery diameter on chest CT predicts in-hospital mortality in patients with COVID-19 pneumonia. <b>2022</b> , 3-3	О
271	Identification of high death risk coronavirus disease-19 patients using blood tests. <b>2022</b> , 11, 58	О
270	Cardiovascular manifestations in COVID-19 patients. <b>2022</b> , 19, 168	О
269	Forecasting the COVID-19 Space-Time Dynamics in Brazil With Convolutional Graph Neural Networks and Transport Modals. <b>2022</b> , 10, 85064-85079	О
268	Comorbilidades y caracterEticas clāicas asociadas a la mortalidad hospitalaria por COVID-19 en el estado de Hidalgo, M¤ico. <b>2022</b> , 36, 286-290	О
267	Immunological characteristics of CoVID-19 and its implications. <b>2022</b> , 15, 204	О
266	Predicting death risk analysis in fully vaccinated people using novel extreme regression-voting classifier. <b>2022</b> , 8, 205520762211095	2
265	Clinical and Epidemiological Features of COVID-19 Patients in Rafsanjan County, Iran: A Secondary Data based Study. <b>2022</b> , 11, 99-105	О
264	Clinical Characteristics, Outcomes and Prognostic Factors for Critical Illness in Hospitalized COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study. Volume 15, 6945-6963	O
263	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. 9,	O
262	Antecedents of Patient Satisfaction in Private Clinical Laboratories toward Patient Loyalty with Switching Cost and Location as Moderating Factors (An Empirical Study from Indonesia). <b>2022</b> , 10, 1463-1471	1
261	COVID-19 and Cardiovascular Manifestations. <b>2022</b> , 102-136	О
260	The effect of nutritional scores on mortality in COVID-19 patients. <b>2022</b> , 68, 1096-1102	1

259	Effect of Remdesivir Administration on Occurrence of Major Adverse Cardiac Events in Critically Ill COVID-19 Pneumonia: A Retrospective Observational Study. <b>2022</b> , 26, 993-999	O
258	Makine Eenimi Teknikleri kullantarak COVID-19 Pandemisinin Eth oran <del>ñ sñfl</del> and <del>ftmas.</del> 2022, 15, 566-581	O
257	Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. 13,	0
256	Risk Factors for Hypertension in Hospitalised Patient Mortality with Laboratory-Confirmed SARS-CoV-2: A Population-Based Study in Limpopo Province, South Africa. <b>2022</b> , 2, 147-156	O
255	The biocompatibility and antifungal effect of Rosmarinus officinalis against Candida albicans in Galleria mellonella model. <b>2022</b> , 12,	1
254	A case of Klebsiella pneumoniae pneumonia with a cavitary lesion in the lung with COVID-19 pneumonia. <b>2022</b> , 3, 288-291	O
253	Title: BEYOND COVID-19 AND SARS-CoV-2, CARDIOVASCULAR OUTCOMES OF LONG COVIDE FROM A PATHOLOGICAL PERSPECTIVE LA LOOK BACK AND ROAD AHEAD. <b>2022</b> , 154144	1
252	Lymphocyte <b>II</b> -reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission. 13,	1
251	Cytokine storm and neuropathological alterations in patients with neurological manifestations of COVID-19. <b>2022</b> , 19,	1
250	New insights into human immune memory from SARS-CoV -2 infection and vaccination.	1
249	Determinants of death in critically ill COVID-19 patients during the first wave of COVID-19: a multicenter study in Brazil. e20220083	1
248	Long COVID-19 and the heart: is cardiac mitochondria the missing link?.	O
247	The Different Clinical Characteristics of COVID-19 Patients Between Pediatric and Adults. <b>2022</b> , 24,	O
246	SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages.	4
245	Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	O
244	Predicting In-Hospital Mortality in Severe COVID-19: A Systematic Review and External Validation of Clinical Prediction Rules. <b>2022</b> , 10, 2414	O
243	A case of COVID -19-associated fulminant myocarditis successfully treated with mechanical circulatory support. <b>2022</b> , 10,	О
242	Cytokine levels as predictors of mortality in critically ill patients with severe COVID-19 pneumonia: Case-control study nested within a cohort in Colombia. 9,	O

241	A Systematic Review and Meta-Analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis. <b>2022</b> ,	4
240	The Effects of COVID-19 on Skeletal Muscles, Muscle Fatigue and Rehabilitation Programs Outcomes. <b>2022</b> , 58, 1199	O
239	Obesity and coronavirus disease 2019. <b>2022</b> , 10, 207-218	О
238	3DTR of SARS-CoV-2 spike gene hijack host miR-296 or miR-520h to disturb cell proliferation and cytokine signaling. 13,	O
237	Hospital Outcomes Among COVID-19 Hospitalizations With Myocarditis from the California State Inpatient Database. <b>2022</b> ,	1
236	Hemostatic system and COVID-19 crosstalk: A review of the available evidence. <b>2022</b> , 12, 331-349	O
235	Yoün Bakm Bitesine Kabul Edilen COVID-19 Hastalarnda Tocilizumab Kullanmnn Mortalite Berine Etkisi.	O
234	An algorithm to predict the need for invasive mechanical ventilation in hospitalized COVID-19 patients: the experience in Sao Paulo.	O
233	Effects of COVID-19 on Arrhythmia. <b>2022</b> , 9, 292	O
232	Negative impact of SARS-CoV-2 infection in acute coronary syndrome mortality in a Latin American cohort study. 9,	O
231	Identifying shared genetic loci between coronavirus disease 2019 and cardiovascular diseases based on cross-trait meta-analysis. 13,	1
230	Bayesian Prediction of Severe Outcomes in the LabMarCS: Laboratory Markers of COVID-19 Severity - Bristol Cohort.	O
229	IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA. 13,	1
228	Impact of the Kidney Transplantation Moratorium in France Because of the COVID-19 Pandemic: A Cohort-based Study. Publish Ahead of Print,	O
227	Covid-19 Transmission, Risks Factors and Disease Characteristics in Asthmatics Patients. <b>2022</b> , 61, 125-132	O
226	The importance of biomarkers in determining the prognosis of patients requiring intensive care hospitalization due to COVID-19 infection. <b>2022</b> , 9, 537-547	O
225	Extracorporeal membrane oxygenation in COVID-19 associated acute respiratory distress syndrome: A narrative review. <b>2022</b> ,	О
224	Current understanding on long non-coding RNAs in immune response to COVID-19. <b>2022</b> , 198956	O

223	The relationship between plasminogen activator Inhibitor-1 levels and the course of disease in COVID-19 patients. <b>2022</b> ,	О
222	Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease. 13,	1
221	Coronavirus disease 2019 ( COVID -19): Focus on peripheral blood cell morphology.	0
220	COVID-19 and the antiphospholipid syndrome. <b>2022</b> , 103206	O
219	Managing Covid-19 in patients with heart failure: current status and future prospects.	0
218	Clinical Investigation of Lymphocyte DNA Damage in COVID-19 Patients.	O
217	Gravedad de COVID-19 atribuible a obesidad segli IMC y CUN-BAE. <b>2022</b> , 48, 101840	0
216	Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. <b>2022</b> , 1868, 166559	3
215	Significance of Hematological Parameters and Biochemical Markers in Severe Forms of Covid-19. <b>2020</b> , 9, 88-99	О
214	Effect of vitamin D (25-OH D3) concentration on the course and outcomes of COVID-19 in intensive care patients. <b>2022</b> , 30	O
213	Elevated Natriuretic Peptides in Patients With Severe or Critical COVID-19: A Meta-Analysis. <b>2022</b> , 49,	Ο
212	The importance of laboratory parameters in predicting the severity of coronavirus disease-19 cases. <b>2022</b> , 3, 156-165	O
211	PREDICTORS OF UNFAVOURABLE OUTCOME IN PATIENTS ON MAINTENANCE HEMODIALYSIS WITH SARS COV 2 INFECTION. <b>2022</b> , 43-45	Ο
210	Modeling Cardiac SARS-CoV-2 Infection with Human Pluripotent Stem Cells.	Ο
209	Role of cardiovascular computed tomography parameters and lungs findings in predicting severe COVID-19 patients: a single-centre retrospective study. <b>2022</b> , 53,	Ο
208	Clinical Features Related to Severity and Mortality among COVID-19 Patients in a Pre-Vaccine Period in Luanda, Angola. <b>2022,</b> 7, 338	1
207	A Review of Routine Laboratory Biomarkers for the Detection of Severe COVID-19 Disease. <b>2022</b> , 2022, 1-14	1
206	HEART DAMAGE AS ONE OF THE SYNDROM OF COVID-19 INFECTION. <b>2022</b> , 23, 105-112	O

205	The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.	О
204	Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data. 9,	O
203	Prior SARS-CoV-2 Infection Is Associated With Coronary Vasomotor Dysfunction as Assessed by Coronary Flow Reserve From Cardiac Positron Emission Tomography. <b>2022</b> , 11,	0
202	Berial ferritin titerImonitoring in COVID-19 pneumonia: valuable inflammatory marker in assessment of severity and predicting early lung fibrosis [prospective, multicentric, observational, and interventional study in tertiary care setting in India. 2022, 34,	O
201	Retrospective Analysis of the SARS-CoV-2 Infection Profile in COVID-19 Positive Patients in Vitoria da Conquista, Northeast Brazil. <b>2022</b> , 14, 2424	1
<b>2</b> 00	Paraoxonase Activity an Independent Contributor in SARS-CoV-2 Infection.	O
199	Exploring NFkB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality. <b>2022</b> , 13,	0
198	Association of Human Leucocyte Antigen Polymorphism with Coronavirus Disease 19 in Renal Transplant Recipients. <b>2022</b> , 10, 1840	Ο
197	Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients. <b>2022</b> , 11, 6286	1
196	MIF is a Common Genetic Determinant of COVID-19 Symptomatic Infection and Severity.	O
195	Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic.	0
194	Advances in Biosensing Technologies for Diagnosis of COVID-19. <b>2022</b> , 12, 898	2
193	COVID-19 as a Risk Factor for Alzheimer Disease. <b>2022</b> , 1-24	O
192	Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study. <b>2022</b> , 17, e0273134	O
191	Construction and Validation of Mortality Risk Nomograph Model for Severe/Critical Patients with COVID-19. <b>2022</b> , 12, 2562	O
190	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. 13,	O
189	Pathogenetic therapy in patients with COVID-19. <b>2022</b> , 14, 30-36	0
188	Clinical Factors Associated with Maternal Death in Pregnant Women Infected by COVID-19 in Indonesia: A Multicenter Prospective Study.	O

187	Pharmacological therapies and drug development targeting SARS-CoV-2 infection. 2022,	О
186	The derived neutrophil to lymphocyte ratio can be the predictor of prognosis for COVID-19 Omicron BA.2 infected patients. 13,	2
185	Apheresis and COVID-19 in intensive care unit (ICU). 2022, 103593	О
184	Post-COVID-19 respiratory problems: burden and management. Publish Ahead of Print,	O
183	Cardiovascular Complications in Community-Acquired Pneumonia. 2022, 10, 2177	0
182	Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis.	1
181	Association between prehospital medication and fatal outcomes in a cohort of hospitalized patients due to coronavirus disease-2019 in a referral hospital in Peru. <b>2022</b> , 50, 102472	1
180	A survival analysis approach for identifying the risk factors in time to recovery of COVID-19 patients using Cox proportional hazard model. <b>2022</b> , 5, 100137	1
179	Coagulation Abnormalities in Patients with COVID-19. <b>2022</b> , 141-156	О
178	Peripheral oxygen measurements in suspected elderly COVID-19 patients can be an effective tool for alerting physicians. <b>2021</b> , 10, 40-42	O
177	Effect of Antioxidants on the Production of MCP-1 Chemokine by EA.hy926 Cells in Response to IL-6. <b>2022</b> , 77, 184-191	О
176	Intelligent COVID-19 screening platform based on breath analysis.	O
175	Recovery Period of Air Transportation: Vector Error Correction Model.	O
174	Myocardial injury as a prognostic factor in critically ill patients with severe SARS-Cov-2 pneumonia. <b>2022</b> ,	O
173	COVID-19: From Pathophysiology to Treatment.	О
172	Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial. <b>2022</b> , 28,	1
171	Using Random Effect Models to Produce Robust Estimates of Death Rates in COVID-19 Data. <b>2022</b> , 19, 14960	О
170	A Comparison of the Prognosis of SARS-CoV-2 Viral Infection in Patients with and Without Underlying Heart Disease. <b>2022</b> , 6,	O

169	Higher Risk of Acute Respiratory Distress Syndrome and Risk Factors among Patients with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression. <b>2022</b> , 19, 15125	O
168	The Mortality Predictors in Patients with COVID-19 referred to the Emergency Department of Shahid Mohammadi Hospital in Bandar Abbas city in 2019.	O
167	Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune. <b>2022</b> , 23, 13681	О
166	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. 13,	O
165	Analysis of C-Reactive Protein as a predictor of coronavirus disease 2019. <b>2022</b> , 181,	О
164	COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system: A hypothesis. <b>2022</b> , 154, 103763	O
163	Application regularity of medicinal and dietary substances for patients during COVID-19 rehabilitation. <b>2022</b> , 5, 242-252	0
162	Increasing cardiac troponin-I level as a cardiac injury index correlates with in-hospital mortality and biofactors in severe hospitalised COVID-19 patients. <b>2022</b> ,	O
161	Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery.	2
160	Inflammation in COVID-19: A Risk for Superinfections. <b>2022</b> , 2, 1609-1624	Ο
159	Characteristics of Patients with Severe COVID-19 Pneumonia Who Could Walk Independently at the Time of Discharge. <b>2022</b> , 37, 537-542	0
158	The Evolving Impact of Myocardial Injury in Patients With COVID-19 Amid the Omicron Wave of the Pandemic. <b>2023</b> , 190, 54-60	1
157	Associations between muscle strength, dyspnea and quality of life in post-COVID-19 patients. <b>2022</b> , 68, 1753-1758	1
	00, 1735 1730	
156	Cytokine Profiling in COVID-19 Patients in a Tertiary Hospital in Saudi Arabia; the Pre-Storm Phase. <b>2021</b> , 3, 19-31	O
156 155	Cytokine Profiling in COVID-19 Patients in a Tertiary Hospital in Saudi Arabia; the Pre-Storm Phase.	
	Cytokine Profiling in COVID-19 Patients in a Tertiary Hospital in Saudi Arabia; the Pre-Storm Phase. <b>2021</b> , 3, 19-31	O
155	Cytokine Profiling in COVID-19 Patients in a Tertiary Hospital in Saudi Arabia; the Pre-Storm Phase. 2021, 3, 19-31  SARS-COV-2 enfeksiyonu olan hastalarda laboratuvar parametrelerin prognoz deliri.  A 71-Year-Old Man From Ecuador With a History of Type 2 Diabetes Mellitus and Severe COVID-19 Pneumonia and Lung Cavitation Associated With Triple Infection With Trichosporon Asahii,	0

151	Utility of the HScore for Predicting COVID-19 Severity. <b>2022</b> ,	O
150	Targeting the ComplementBphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. <b>2022</b> , 23, 14340	O
149	Prolonged T-cell activation and long COVID symptoms independently associate with severe disease at 3 months in a UK cohort of hospitalized COVID-19 patients.	1
148	The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients. <b>2022</b> , 46, 1555-1562	o
147	Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study. <b>2022</b> , 5, 95	0
146	SARS-CoV-2 infection and cardiovascular disease. <b>2022</b> , 181,	O
145	Predictors of In-hospital Mortality Among COVID-19-infected Chronic Kidney Disease Patients on Maintenance Hemodialysis: A Retrospective Cohort Study. <b>2022</b> , 9,	O
144	LEVELS OF INTERLEUKIN-6, FERRITIN, C-REACTIVE PROTEIN, LACTATE DEHYDROGENASE, D-DIMER, FIBRINOGEN AND PROCALCITONIN IN BLOOD OF COVID-19 PATIENTS: ITS CORRELATION TO THE DISEASE SEVERITY IN PATIENTS IN A TERTIARY MEDICAL COLLEGE IN	1
143	Platelets[morphology, metabolic profile, exocytosis, and heterotypic aggregation with leukocytes in relation to severity and mortality of COVID-19-patients. 13,	0
142	The Development of Leukemia after a Sustained COVID-19 Infection. <b>2022</b> , 7, 134-139	O
141	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. 10,	O
140	Case report: Disseminated herpes simplex virus 1 infection and hemophagocytic lymphohistiocytosis after immunomodulatory therapy in a patient with coronavirus disease 2019. 9,	O
139	Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors. <b>2022</b> , 20,	1
138	Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study. <b>2022</b> , 3,	6
137	Additional value of chest CT AI-based quantification of lung involvement in predicting death and ICU admission for COVID-19 patients. <b>2022</b> , 4, 100018	0
136	T-cell cellular stress and reticulocyte signatures, but not loss of nafile T lymphocytes, characterize severe COVID-19 in older adults.	O
135	Association of Vitamin C Treatment with Clinical Outcomes for COVID-19 Patients: A Systematic Review and Meta-Analysis. <b>2022</b> , 10, 2456	1
134	Marcadores serolgicos asociados a mal pron¤tico en pacientes Covid-19 positivos. 2, 141	О

133	Mechanism and Experimental Verification of the Use of Rhodiola crenulata to Cytokine Storm Based on Network Pharmacology and Molecular Docking. <b>2022</b> , 17, 1934578X2211427	O
132	Clinical-epidemiological characteristics and maternal-foetal outcomes in pregnant women hospitalised with COVID-19 in Venezuela: a retrospective study. <b>2022</b> , 22,	O
131	Tracking peripheral vascular function for six months in young adults following SARS-CoV -2 infection. <b>2022</b> , 10,	O
130	An NLP tool for data extraction from electronic health records: COVID-19 mortalities and comorbidities. 10,	O
129	The onset of late severe lung impairment in COVID-19 is associated with high inflammation markers at admission and metabolic syndrome markers.	O
128	Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia. <b>2022</b> , 22,	1
127	Angiotensin-converting enzyme 2 in human plasma and lung tissue. 2023, 32, 6-15	0
126	Immune and non-immune mechanisms that determine vasculitis and coronary artery aneurysm topography in Kawasaki disease and MIS-C. <b>2022</b> , 103240	1
125	Utility of lung ultrasound in selecting older patients with hyperinflammatory phase in COVID-19 pneumonia. A monocentric, cross-sectional pilot study. 1-7	O
124	The Relationship Between Chest Computed Tomography Severity Scores and Demographic Features, Laboratory Parameters and Mortality in Patients with COVID-19. <b>2022</b> , 10, 335-343	O
123	Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. <b>2022</b> ,	O
122	Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms. 2,	O
121	COVID-19 inhibits spermatogenesis in the testes by inducing cellular senescence. 13,	O
120	Cardiomyopathy in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). <b>2022</b> , 181-191	O
119	Colchicine in COVID-19 (Mechanism of Action, Effect on Prognosis). <b>2022</b> , 317-329	0
118	Acute Vascular Injury in COVID-19. <b>2022</b> , 151-170	O
117	Evolving pharmaceutical therapies for confronting COVID-19: An overview. 2022,	O
116	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. <b>2023</b> , 28, 795	O

115	Identification of genes and signaling pathways associated with severe COVID-19: high-throughput data analysis with a system virology approach.	O
114	Effect of troponin I and coagulation parameters on mortality in COVID-19 patients.	O
113	Association among lifestyle and risk factors with SARS-CoV-2 infection.	1
112	Correlation of ferritin with the duration of illness, disease severity, oxygenation status, ventilatory requirement, and lung fibrosis in COVID-19 pneumonia: A single-center experience of 1000 cases in tertiary care setting in India. 1-8	O
111	Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas. <b>2023</b> , 12, 262	2
110	New coronavirus infection in patients with chronic non-communicable diseases in primary care. <b>2023</b> , 26, 25-33	O
109	COVID-19日 immuno-pathology and cardiovascular diseases. 108155892211418	1
108	Interleukin-1 receptor antagonist gene (IL1RN) variants modulate the cytokine release syndrome and mortality of SARS-CoV-2.	O
107	Is Nuclear Factor Erythroid 2-Related Factor 2 a Target for the Intervention of Cytokine Storms?. <b>2023</b> , 12, 172	1
106	Analysis of compliance of ambulatory cardiologists and patients to rehabilitation programs after coronary artery bypass grafting. <b>2023</b> , 24-27	O
105	Asymptomatic Esophageal Necrosis in a Patient with Recent COVID-19: The First Case Diagnosed through Autopsy. <b>2023</b> , 59, 154	0
104	Molecular typing and antimicrobial sensitivity of MDR-Pseudomonas aeruginosa isolated from Coronavirus disease-2019 patients.	O
103	T-cell cellular stress and reticulocyte signatures, but not loss of nafile T lymphocytes, characterize severe COVID-19 in older adults.	О
102	Venous Thromboembolism in COVID-19 Patients: A Single-Center Case Series. <b>2023</b> , In Press,	O
101	Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies. <b>2022</b> , 22, 446-459	0
100	Hemoadsorption (CytoSorb[]) in Management of Cytokine Storm and Implication in COVID-19 Pandemic. <b>2022</b> , 1, 61-67	o
99	Inflammatory and coagulation marker profiles in severe pediatric COVID-19 patients: a systematic review. <b>2022</b> , 62, 411-21	0
98	The Implications of COVID-19 Infection on Hematologic Parameters and Coagulation Activity: A Review. <b>2022</b> , 15, 1837-1851	O

97	COVID-19: Pathology Perspective. <b>2023</b> , 101-111	O
96	Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence. <b>2023</b> , 13, 40	O
95	COVID-19: Inpatient Management. <b>2023</b> , 182-232	O
94	Impact of Antibiotic Consumption on the Acquisition of Extended-Spectrum Lactamase Producing Enterobacterales Carriage during the COVID-19 Crisis in French Guiana. <b>2023</b> , 12, 58	O
93	Primary adrenal insufficiency and myocarditis in COVID-19 disease: a case report. <b>2022</b> , 22,	O
92	Interpretable generalized neural additive models for mortality prediction of COVID-19 hospitalized patients in Hamadan, Iran. <b>2022</b> , 22,	O
91	Diagnosis and treatment of gastrointestinal involvement in the late post-COVID. 2023, 234-241	O
90	Electrocardiographic changes in hospitalised children with COVID-19. 1-7	О
89	Sociodemographic and clinical characteristics of SARS-CoV-2 infected population during the second and third epidemiological waves in Sri Lanka. <b>2023</b> , 16, 33	О
88	Innate immune responses in COVID-19. <b>2023</b> , 63-128	O
87		
	COVID-19 phenomics. <b>2023</b> , 191-218	O
86	COVID-19 phenomics. <b>2023</b> , 191-218  The effect of CT-based cardiothoracic ratio on survival of COVID-19 patients. 1-11	0
,		
86	The effect of CT-based cardiothoracic ratio on survival of COVID-19 patients. 1-11	O
86 85	The effect of CT-based cardiothoracic ratio on survival of COVID-19 patients. 1-11  Links between COVID-19 and Alzheimer Disease What Do We Already Know?. 2023, 20, 2146  Consenso de expertos sobre el diagn Etico y el tratamiento de la miocarditis asociada con infeccib	0
86 85 84	The effect of CT-based cardiothoracic ratio on survival of COVID-19 patients. 1-11  Links between COVID-19 and Alzheimer Disease What Do We Already Know?. 2023, 20, 2146  Consenso de expertos sobre el diagn Stico y el tratamiento de la miocarditis asociada con infeccib o vacunaci contra el SARS-CoV-2. 2023,  Applications of digital and smart technologies to control SARS-CoV-2 transmission, rapid diagnosis,	0 0
86 85 84 83	The effect of CT-based cardiothoracic ratio on survival of COVID-19 patients. 1-11  Links between COVID-19 and Alzheimer Disease What Do We Already Know?. 2023, 20, 2146  Consenso de expertos sobre el diagn Bico y el tratamiento de la miocarditis asociada con infecci o vacunaci contra el SARS-CoV-2. 2023,  Applications of digital and smart technologies to control SARS-CoV-2 transmission, rapid diagnosis, and monitoring. 2023, 405-425	O O

79	Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics. <b>2023</b> , 51, 030006052311537	0
78	Treatment of patients with pericarditis with anti-inïammatory drugs. 2023, 100, 509-519	1
77	Gender-dependent impact of COVID-19 lockdown on metabolic and psychological aspects.	0
76	COVID-19 and pneumothorax, pneumomediastinum, subcutaneous emphysema: Analysis of risk factors. <b>2023</b> , 31, 69-77	0
75	Survival Analysis and Its Application of Discharge Time Likelihood Prediction Using Clinical Data on COVID-19 Patients-Machine-Learning Approaches. <b>2023</b> , 323-336	0
74	Assessment of interleukin-6 role in detecting coronavirus disease 2019 severity, mortality, and its control: A cohort study. <b>2023</b> , 72, 183	O
73	Immune Factors Drive Expression of SARS-CoV-2 Receptor Genes Amid Sexual Disparity. 2023, 15, 657	Ο
72	Ultrasound imaging assessment of the diaphragm and abdominal muscles in people with a recent history of moderate Covid-19 infection and healthy participants: A cross-sectional pilot study. <b>2023</b> , 18, e0281098	O
71	Risk Factors for Mortality of Hospitalized Adult Patients with COVID-19 Pneumonia: A Two-Year Cohort Study in a Private Tertiary Care Center in Mexico. <b>2023</b> , 20, 4450	О
70	Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. <b>2023</b> , 127, 66-81	O
69	Immunological aspects of coronavirus disease caused by SARS-CoV-2. <b>2020</b> , 15, 14-21	0
68	Reproductive Effects of COVID-19: A Journey through COVID-19 Pathogenesis. <b>2022</b> , 1-7	О
67	Impact of various hematological and biochemical parameters in severe and nonsevere COVID-19 patients: A retrospective single-center study. <b>2022</b> , 21, 178	0
66	Understanding the mechanisms for COVID-19 vaccine protection against infection and severe disease. <b>2023</b> , 22, 186-192	O
65	Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review. <b>2023</b> , 13, e066218	О
64	Food Insecurity amid COVID-19 Lockdowns: Assessing Sociodemographic Indicators of Vulnerability in Harar and Kersa, Ethiopia.	O
63	The Impact of Vaccination on Disease Course and Outcome in Intensive Care Patients With COVID-19. <b>2023</b> , 11, 610-623	0
62	Is the vitamin D status of patients with COVID-19 associated with reduced mortality? A systematic review and meta-analysis. <b>2023</b> ,	O

61	Characteristics and Potential Roles of Natural Killer Cells During SARS-CoV-2 Infection. <b>2023</b> , 3, 29-35	О
60	Short and Long-Term Cardiovascular Sequelae after SARS-CoV-2 Infection: A Narrative Review Focusing on Athletes. <b>2023</b> , 15, 493	O
59	Unfavorable Outcome and Long-Term Sequelae in Cases with Severe COVID-19. 2023, 15, 485	1
58	Neurological Manifestations and Clinical Outcomes of Patients with COVID-19 in the Aseer Region, Saudi Arabia. <b>2023</b> , 20, 3848	O
57	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. <b>2023</b> ,	0
56	Role of the immune system in COVID-19 pathomorphogenesis. <b>2020</b> , 15, 75-87	O
55	Ectopic expression of SARS-CoV-2 S and ORF-9B proteins alters metabolic profiles and impairs contractile function in cardiomyocytes. 11,	О
54	Association Between Metabolic Syndrome Inflammatory Biomarkers and COVID-19 Severity. <b>2023</b> , 7,	O
53	The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. <b>2022</b> , 9, 17-32	О
52	Association of the ACE and AGT gene polymorphisms with global disparities in COVID-19-related deaths. <b>2023</b> , 33, 41-50	O
51	Bioactive omega-3 fatty acids are associated with reduced risk and severity of SARS-CoV-2 infection. <b>2023</b> , 117, 213-215	О
50	COVID-19 and its long-term impact on the cardiovascular system. <b>2023</b> , 21, 211-218	O
49	Selected Predictors of COVID-19 Mortality in the Hospitalised Patient Population in a Single-Centre Study in Poland. <b>2023</b> , 11, 719	0
48	MicroRNAs and cytokines as potential predictive biomarkers for COVID-19 disease progression. <b>2023</b> , 13,	O
47	Identification of Clinical Features Associated with Mortality in COVID-19 Patients. 2023, 4,	О
46	The role of immune activation and antigen persistence in acute and long COVID. 108155892311580	O
45	Predictors of COVID-19 related death in elderly patients hospitalized due to COVID-19 infection: a cross-sectional study in the west of Iran.	О
44	Integrated analyses of single-cell RNA-seq public data reveal the gene regulatory network landscape of respiratory epithelial and peripheral immune cells in COVID-19 patients.	O

43	Role of CRP in COVID-19 pneumonia: A single-center experience of 1000 cases in a tertiary care setting in India. <b>2022</b> , 5, 430	0
42	Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management. <b>2023</b> ,	О
41	Effects of Mediterranean diets and nutrigenomics on cardiovascular health. 1-20	О
40	Low-Dose Radiotherapy for Patients with Pneumonia Due to COVID-19: A Single-Institution Prospective Study. <b>2023</b> , 11, 858	O
39	Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis. <b>2023</b> , 12, 2222	0
38	Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies. <b>2023</b> , 15, 741	o
37	Role of TGF-Isignaling in Coronavirus Disease 2019. <b>2022</b> , 9, 9	O
36	Medication Adherence in Children with Down Syndrome with Autoimmune Thyroid Disease During the COVID-19 Pandemic: Indonesian Study. <b>2023</b> , 14,	О
35	Natural Course of COVID-19 and Independent Predictors of Mortality. <b>2023</b> , 11, 939	O
34	Architecture of the SARS-CoV-2-specific T cell repertoire. 14,	О
33	The Effect of Estimated Glomerular Filtration Rate on Mortality in the Elderly COVID-19 Patients in the Intensive Care Unit. <b>2023</b> , 13, 371-376	O
33		0
	the Intensive Care Unit. <b>2023</b> , 13, 371-376  Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional	
32	the Intensive Care Unit. 2023, 13, 371-376  Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry?. 2023, 91-122  Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected	O
32	the Intensive Care Unit. 2023, 13, 371-376  Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry?. 2023, 91-122  Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients. 2023, 22,  Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and	0
32 31 30	Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry?. 2023, 91-122  Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients. 2023, 22,  Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing. 2023, 13,  Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery	0 0
32 31 30 29	Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry?. 2023, 91-122  Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients. 2023, 22,  Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing. 2023, 13,  Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. 14,  Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe	o o o

25	A machine learning analysis of correlates of mortality among patients hospitalized with COVID-19. <b>2023</b> , 13,	O
24	Association of ACE ID, MTHFR C677T, and MIF-173GC variants with the clinical course of COVID-19 patients. 1-15	O
23	Investigation of antimicrobial resistance patterns and molecular typing of Pseudomonas aeruginosa isolates among Coronavirus disease-19 patients. <b>2023</b> , 23,	0
22	Exploring Potential Biomarkers and Molecular Mechanisms of Ischemic Cardiomyopathy and COVID-19 Comorbidity Based on Bioinformatics and Systems Biology. <b>2023</b> , 24, 6511	O
21	Looking to the Past to Improve the Future: A Narrative Review of Lessons Learned from Inpatient Cardiac Arrest Care During the COVID-19 Pandemic. <b>2023</b> , 2,	O
20	Correlation Between Diabetes and COVID-19 Indices: A Global Level Ecological Study. <b>2023</b> , 9, 23779608231	1654
19	Immunology of COVID-19. <b>2024</b> , 52-71	0
18	Gastrointestinal Manifestations of COVID-19. <b>2024</b> , 191-202	O
17	Investigation of the level of physical activity, coronavirus fear, and quality of life in oncology patients during the COVID-19 pandemic: A cross-sectional study. <b>2023</b> , 7, 00-00	O
16	The potential of Panax notoginseng against COVID-19 infection. <b>2023</b> ,	O
15	Yoün Bakm fiitesinde yatan Covid-19'lu Gebe ve Lohusalarn Mortalite Risk Faktfleri.	0
14	Does prolonged QTc predict pulmonary involvement in COVID-19 patients?. 1-6	О
13	Post COVID-19 AA amyloidosis of the kidneys with rapidly progressive renal failure. <b>2023</b> , 17, 111-115	0
12	Impact of COVID -19 on maintenance peritoneal dialysis patients and providers: A review.	O
11	Unsupervised Machine Learning Unveil Easily Identifiable Subphenotypes of COVID-19 With Differing Disease Trajectories.	O
10	Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study. <b>2023</b> , 23,	O
9	Understanding COVID-19-related myocarditis: pathophysiology, diagnosis, and treatment strategies. Publish Ahead of Print,	0
8	The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). <b>2023</b> , 43, 147-163	O

## CITATION REPORT

7	The role of IL-6, IL-8 and TNF-Hn COVID-19 patients in Karbala Governorate. <b>2023</b> , 381, 01103	O
6	Subclinical Myocardial Injury in Patients Recovered from COVID-19 Pneumonia: Predictors and Longitudinal Assessment. <b>2023</b> , 10, 179	O
5	Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. <b>2023</b> , 13,	O
4	Mixed storm in SARS-CoV-2 infection: A narrative review and new term in the Covid-19 era. <b>2023</b> , 11,	O
3	Diagnosis of Coronavirus Disease 2019 by Potential Laboratory Factors. <b>2022</b> , 3, 149-154	О
2	Prognostic significance of laboratory parameters in assessment the severity of the course and outcome of coronavirus disease (COVID-19). <b>2023</b> , 20, 54-65	O
1	Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations mini review. 10,	О